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Abstract 
 
The purpose of this research was to enhance the targeted radiotherapy of two metastatic 
malignant diseases: neuroblastoma and prostatic carcinoma. 
 
By virtue of its high affinity for the norepinephrine transporter (NET), [131I]meta-
iodobenzylguanidine ([131I]MIBG) has been used for the therapy of tumours of 
neuroectodermal origin for more than 25 years. Although not yet universally adopted, 
[131I]MIBG targeted radiotherapy remains a highly promising means of management of 
neuroblastoma. MIP-1095, a glutamate-urea-lysine dipeptide has high affinity for prostate-
specific membrane antigen (PSMA) and has recently demonstrated exquisite specificity for 
PSMA-expressing, metastatic prostatic carcinoma. Preliminary imaging studies in patients, 
using [123I]MIP-1095, revealed tumour-selective binding and prolonged retention only in 
malignant sites. This indicates the therapeutic potential of this agent when labeled with 
Iodine-131. 
 
Our aim is to make the most effective use of [131I]MIBG and [131I]MIP-1095 for the 
treatment of neuroblastoma and prostatic carcinoma by combining the [131I]-labelled 
radiopharmaceutical with radiosensitiser drugs.  
 
The thiol-containing molecule disulfiram was selected for combination with targeted 
radiotherapy because of its reported inhibition of the 26S proteasome and NF-kB activity, 
its ability to chelate copper and its pro-oxidative effects. The copper-dependence of the 
cytotoxicity and radiosensitising activity of disulfiram was established in neuroblastoma 
cell models. Radiation dose enhancement values at the 50% toxicity level were 4.24 and 
2.00 in SK-N-BE(2c) and UVW/NAT cells, respectively. The radiosensitising mechanism 
of disulfiram-copper was shown to involve the inhibition of cell cycle arrest in G2. The 
enhancement of the cytotoxicity of [131I]mIBG and of [131I]MIP-1095 by disulfiram-copper 
was demonstrated by delay of the growth of multicellular tumour spheroids. 
 
Finally, the screening of the enhancing effect of chemotherapeutic agents on the spheroid 
growth delay induced by [131I]MIP-1095 indicated that combinations with topotecan, 
nutlin-3, bortezomib or olaparib have good prospects for therapy of metastatic prostate 
carcinoma. In conclusion, it is expected that DSF:Cu will enhance the outcome of patients 
undergoing targeted radiotherapy due to its radiosensitising properties. 
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1 Introduction 
1.1 Radiation, radiotherapy and targeted radiotherapy 
1.1.1 Definition of radiation 
Radiation is the emission of electromagnetic waves of a specific wavelength and 
frequency. The electromagnetic spectrum ranges from high frequency γ-rays, X-rays and 
ultraviolet rays to low frequency microwaves and radiowaves. Ionising radiation (IR) has 
sufficient energy to alter the structure of an atom. IR may arise from the radioactive decay 
of atoms (γ, α and β radiations) or they may be produced by electrical devices (X-rays). α 
and β radiations are the particulate manifestations of the radioactive decay of atoms. α 
particles are nuclei of helium and β particles may be positrons (β+) or electrons (β-). Since 
its discovery at the end of the 19th century, IR has become an important tool in medical 
practice. For instance, X-ray imaging is a standard procedure in orthopaedic diagnosis and 
for the local treatment of tumours. Radionuclides have also been used in the clinic, such as 
the β-emitter iodine-131 (131I) for the treatment and diagnosis of thyroid diseases. 
 
1.1.2 Limitations of external beam radiotherapy of cancer 
Radiation treatment may be administered by an external beam directed at malignant tissue. 
The irradiated volume usually encompasses tumour and a proportion of non-malignant 
surrounding tissue. Advances have been made in external beam radiotherapy, resulting in a 
reduction in the exposure of non-malignant tissue. For example intensity-modulated 
radiotherapy (IMRT) conforms the radiation dose more precisely to the three-dimensional 
shape of the tumour thereby minimizing the dose to adjacent normal organs. However, 
external beam radiotherapy is unable to treat disseminated malignant lesions without 
irradiating healthy tissues. 
 
1.1.3 Targeted radiotherapy 
Targeted radiotherapy is the specific delivery of radiation to malignant lesions by the use 
of a tumour-seeking agent linked to a radionuclide. It is the radiotherapeutic treatment of 
choice when the cancer has metastasised, when the malignant lesions are too small to be 
detected or when they are located close to vital structures. Targeted radiotherapy has been 
devised to circumvent the limitations of external beam radiotherapy. 
 
The specificity of the delivery of radiation by targeted radiotherapy may arise from the 
biological properties of the radionuclide itself. For instance, the thyroid accumulates iodine 
for the synthesis of the thyroid hormones. Hence, the treatment of thyroid cancer has 
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employed Na131I for several decades1. Alternatively, the expression of markers specific to 
the tumour cells can be used for the targeting of radionuclides attached to a tumour-seeking 
molecule. For instance, radiolabelled antibodies have been used to treat solid tumours from 
the breast2, prostate2, colon3 and neuroblastoma4 as well as haematopoietic cancers such as 
lymphoma and leukaemia5. However, antibodies are large molecules that may fail to 
penetrate tumours5. Indeed, an inverse relationship has been demonstrated between tumour 
uptake of radiolabelled antibodies and tumour mass6,7. Improved penetrability may be 
obtained by the use of antibody fragments8. Small molecules, such as the noradrenalin 
transporter (NAT)-targeting agent meta-iodobenzylguanidine (mIBG) for the treatment of 
neuroblastoma, may possess even greater tumour penetrability9-11. 
 
The efficacy of targeted radiotherapy depends on the size of the malignant lesion and on 
the physical properties of the radionuclide. The ability of a radionuclide to deliver radiation 
to untargeted neighbouring cells within the tumour is called cross-fire and this is dependent 
on the path length of the radionuclide. Tumour heterogeneity limits binding and uptake of 
the radiopharmaceutical by cells within the tumour mass. This impediment to tumour cure 
may be surmounted by cross-fire irradiation12 obtained through the use of long-range β-
emitters. However, the longer the path length of the radionuclide, the greater the risk of 
irradiating untargeted surrounding healthy tissue which would result in undesirable 
toxicity. The implication is that, due to sub-optimal deposition of radiation energy within 
the malignant lesion, metastases smaller than the path length of the radionuclide could 
escape sterilisation at activity levels sufficient to eradicate metastases of a diameter similar 
to that of the path length. While short-range α-emitters may be better therapeutic tools than 
β-emitters due to their induction of less collateral damage13, the optimal treatment of 
disseminated disease may consist of cocktails of radionuclides with a range of path 
lengths14. 
 
1.1.4 Current use of targeted radiotherapy 
This section will summarise the current use of targeted radiotherapy in medical practice 
with particular emphasis on neuroblastoma and prostate cancer. 
 
1.1.4.1 Na131I for the treatment of thyroid conditions 
The first radionuclide used in modern medical practice was radioiodine in the 1950s for the 
treatment of thyroid cancer15. Iodine is taken up by the differentiated follicular thyroid 
cells for the biosynthesis of the thyroid hormones triiodothyronine (T3) and thyroxine 
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(T4). For the treatment of thyroid cancer, radioiodine does not need to be conjugated to a 
tumour-targeting vehicle because iodine is specifically accumulated by thyroid cells. 
 
The effectiveness of radioiodine has been examined in patients with high risk thyroid 
cancer with locoregional or distant metastases16. The study reported an important 
improvement of cancer-specific survival and disease progression for patients treated with 
radioiodine versus those who were not16. It demonstrates the beneficial use of radioiodine 
for the treatment of metastatic thyroid cancer or the ablation of residual disease following 
thyroidectomy. Radioiodine treatment of thyroid cancer is considered the greatest success 
of targeted radiotherapy15. 
 
1.1.4.2 Radionuclides for the treatment of bone metastasis 
The incidence of bone metastasis observed at post-mortem examination is 73% in breast 
cancer, 68% in prostate cancer, 42% in thyroid cancer, 36% in lung cancer, 35% in renal 
cancer and 5% in cancers of the gastrointestinal tract17. Morbidities associated with bone 
metastasis include pain, fractures and spinal cord compression17. The presence of bone 
metastases is also associated with poor prognosis. The relief of pain from bone metastases 
is achieved by the administration of bone-seeking radionuclides such as radium-223 
(223Ra), strontium-89 (89Sr), samarium-153 (153Sm), renium-186 (186Re) or phosphorous-32 
(32P) which are incorporated into regenerating bone at metastatic sites. A meta-analysis of 
15 studies worldwide demonstrated that these radionuclides relieved bone pain over a 1 to 
6 months period18. 
 
1.1.4.3 Radioimmunotherapy of haematopoietic malignancies 
Radioimmunotherapy is the treatment of cancer by administration of radiolabelled 
antibody. Despite poor tissue penetration and immunogenicity, radiolabelled antibodies 
have improved the outcome of haematopoietic cancers. Recently two radiolabelled 
antibodies have been approved by the Food and Drug Administration (FDA) for the 
treatment of non-Hodgkin’s lymphoma. The two antibodies directed against the B cell-
specific antigen CD20 and radiolabelled with yttrium-90 (90Y) or 131I are 90Y-ibritumomab 
tiuxetan (Zevalin™, Biogen-IDEC Pharmaceuticals, CA, 2002) and 131I-tositumomab 
(Bexxar™, GlaxoSmithKline, 2003). The efficacies of 90Y-ibritumomab and 131I-
tositumomab has been compared with the non-radiolabelled CD20-targeting antibody. 
These clinical trials indicated that patient outcome was improved with relatively low and 
manageable side-effects and that radioimmunotherapy was a successful treatment of non-
Hodgkin’s lymphoma19,20. 
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1.1.4.4 Somatostatin analogues for the treatment of neuroendocrine tumours 
Neuroendocrine tumours (NETs) constitute a heterogeneous group of malignancies that 
originate in neuroendocrine cells. Common primary sites are the stomach, pancreas and 
intestines21. Despite their heterogeneous location, NETs share common features such as 
histology and hormone production. The somatostatin receptor subtype 2 (SSTR2) is 
expressed in more than 80% of all NETs22. A variety of somatostatin analogues, 
radiometalated using chelators such as diethylene triamine penta-acetic acid (DTPA) or 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA), have been developed. 
Clinical trials using somatostatin analogues such as octreotide and octreotate have 
demonstrated good tumour control associated with acceptable side-effects23,24. 
 
1.1.4.5 Neuroblastoma 
Neuroblastoma is the most common extracranial cancer in childhood, representing 28% of 
all cancers in infants25. Neuroblastoma arises in cells of the neural crest during embryonal 
development of the nervous system. Tumours can develop in all parts of the peripheral 
sympathetic nervous system, most commonly in the adrenal glands. 
 
Neuroblastoma is a heterogeneous disease with outcomes ranging from spontaneous 
regression or differentiation to benign ganglioneuroma to a progressive, metastatic and 
fatal disease. The prognosis of neuroblastoma is related to the Shimada classification of 
tumour histology26, the International Neurobastoma Staging System (INSS) stage of the 
tumour and the age at diagnosis. Moreover, predictors of decreased overall survival are the 
myelocytomatosis viral related oncogene neuroblastoma-derived (MYCN) status and 
genetic modifications such as ploidy, 1p and 11q aberrations and 1q gain. According to the 
International Neuroblastoma Risk Group (INRG) risk stratification, and based on the 
prognostic factors described above, the high risk group of neuroblastoma children 
represents 36.1% of all neuroblastoma cases with a 5-year event-free survival (EFS) less 
than 50% despite intensive multimodal treatment27. In contrast, the very low and low risk 
groups represent 26.8% and 28.2% of the neuroblastoma patients with a 5-year EFS greater 
than 85% and 75%, respectively27. Finally, neuroblastoma tumours tend to metastasise, 
especially in the high risk group. The primary sites of metastases are bone marrow 
(70.5%), non-orbital bones (55.7%), lymph nodes (30.9%), the liver (29.6%) and the 
orbital bone (18.2%). Metastases to the bones, the bone marrow, the central nervous 
system, the orbital bone, the lungs and the pleura are associated with a significant decrease 
in the 3-year EFS28. 
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The classical treatment of high risk neuroblastoma is a 3-step regimen including induction, 
consolidation and maintenance 29. The role of induction and consolidation therapy is to 
reduce the tumour burden before chemoresistance develops while maintenance therapy 
aims to eradicate the residual disease after intensive myeloablative therapy. In the 
induction phase, various combinations of chemotherapeutic agents including cisplatin, 
doxorubicin, vincristine, cyclophosphamide, etoposide or topotecan may be administered. 
Surgical resection and external beam radiation treatment of the primary or metastatic sites 
may be performed. Secondly, consolidation therapy consists of intensive myeloablative 
chemotherapy including carboplatin, etoposide, melphalan or busulphan with autologous 
bone marrow transplant. Finally, maintenance therapy aims to rid the body of residual 
disease by, for example, inducing differentiation of the neuroblastoma cells. The 
differentiating agent 13-cis retinoic acid has been shown to improve outcome in children 
with high risk neuroblastoma30. Furthermore, treatment with 13-cis retinoic acid in 
combination with immunotherapy (anti-GD2, IL-2 and GM-CSF) was shown to improve 
the 2-years EFS compared with 13-cis retinoic acid alone. However this regimen was 
highly toxic31. 
 
Catecholamines are small molecules acting upon the central and peripheral nervous 
systems as neurotransmitters or acting systemically as hormones. At the synapse between 
axon and neurone, NAT is responsible for the reuptake of noradrenaline into the 
intracellular space in order to prevent sustained activation of the noradrenergic receptor. 
By virtue of its analogy of structure to noradrenaline (Figure 1), meta-iodobenzylguanidine 
(mIBG) can be taken up by cells that express NAT. Since 90% of neuroblastoma tumours 
express NAT32, mIBG labelled with iodine-131 ([131I]mIBG) or with iodine-123 
([123I]mIBG) has been used for the treatment and imaging of neuroblastoma, respectively. 
To date, the majority of clinical trials investigating the efficacy of [131I]mIBG have been 
carried out in cohorts of high risk neuroblastoma children who were unresponsive to 
classical therapy, described above, or who relapsed shortly after treatment. The studies 
yielded overall response rates between 30% and 58% and the major toxicity observed was 
myelosuppression33-40. On the other hand, it has been shown that [131I]mIBG as a first-line 
treatment prior to chemotherapy and surgery is an effective option for the treatment of high 
risk neuroblastoma41. 
 
Finally, phase I studies have investigated [131I]mIBG in combination with chemotherapy. 
The combinations of [131I]mIBG with the induction regimen cisplatin, cyclophosphamide, 
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etoposide, vincristine and doxorubicin42 or with irinotecan and vincristine43 resulted in the 
reduction of the tumour burden with tolerable toxicities. These studies showed that 
[131I]mIBG can be incorporated safely into the classical chemotherapeutic treatment of 
high risk neuroblastoma. These studies form the rationale for the preclinical determination 
of new radiosensitising drugs which may improve the efficacy of [131I]mIBG44. 
 
Despite intensive treatment regimens, children with high risk neuroblastomas continue to 
have a poor prognosis. The inclusion of [131I]mIBG in the treatment of neuroblastoma has 
shown efficacy and is promising for patients with chemo-refractory tumours. While long-
term remissions have been achieved, cure is rare. Efforts to improve the outcome of the 
treatment of high risk neuroblastoma has focussed on the scheduling of [131I]mIBG therapy 
within the classical regimen41, the simultaneous administration of radiosensitising drugs 
with [131I]mIBG42,43 and the development of new chemotherapeutic agents29. 
 
 
Figure 1 The chemical structures of meta-iodobenzylguanidine (mIBG) and noradrenaline 
 
1.1.4.6 Prostate cancer (PCa) 
PCa was the fourth most common cancer in Europe in 2008 and the second most common 
cancer in men accounting for 89,300 deaths45. About 75% of PCa worldwide occur in men 
65 years old or over46. It is a heterogeneous disease ranging from indolent tumours to 
aggressive, metastatic and fatal disease. 
 
Localised PCa is confined within the prostate. Given the often indolent nature of localised 
PCa, which is associated with a good prognosis, active surveillance may be the preferred 
option for the management of patients. Other treatment options for localised PCa include 
radical prostatectomy, androgen deprivation therapy (ADT) or radiotherapy in the form of 
external beam radiotherapy and brachytherapy. However, even after complete 
prostatectomy, recurrence and metastases constitute an important complication of the 
treatment of localised PCa47. 
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Due to the reliance of PCa tumour growth on androgen stimulation48, the mainstay of PCa 
treatment is ADT. However, the tumour may progress, even under ADT, a state called 
castrate-resistant prostate cancer (CRPC). Furthermore, metastasis is a common 
complication of advanced CRPC17,49. Bone pain due to bone metastasis may be palliated by 
the administration of bone-seeking radionuclides such as 153Sm, 223Ra or 89Sr but, at 
present, there is no curative treatment of metastatic CRPC. 
 
The improvement of the outcome of CRPC patients is the focus of PCa research. Recent 
phase III trials have shown that the median survival of patients with metastatic CRPC is 1 
to 2 years50-52. The main chemotherapeutic agent approved for the treatment of metastatic 
CRPC is docetaxel. Docetaxel in combination with prednisone has improved survival of 
this group of patients by 2 to 3 months compared with the previous standard treatment 
using mitoxantrone plus prednisone52. Furthermore, recent phase III clinical trials have 
confirmed the benefit of blockers of the androgen-mediated stimulation of PCa tumour 
growth, abiraterone53,54 and enzalutamide55, in docetaxel-refractory CRPC patients. 
 
The above studies indicated that innovative chemotherapy increased the survival of 
patients with metastatic CRPC only by several months, demonstrating the need for 
alternative therapeutic approaches in the treatment of this subset of patients. Given the 
survival benefit afforded by targeted radiotherapy of thyroid cancer, neuroblastoma and 
NETs, radiopharmaceuticals targeting PCa markers may hold promise for therapy of 
metastatic PCa. Furthermore, targeted radiotherapy is already in use for the treatment of 
painful bone metastases in PCa using bone-seeking radionuclides. However, this treatment 
is only palliative and does not target all malignant lesions. Therefore, the development of a 
PCa tumour-targeting radiopharmaceutical which could be used with a curative intent to 
target all malignant lesions (bone metastases, non-osseous metastases and residual disease 
after ablative treatment) is an appealing strategy for the treatment of metastatic CRPC. 
 
N-acetylated α-linked acidic dipeptidase (NAALADase) is a neuropeptidase that releases 
glutamate and N-acetylaspartate from its substrate, the neurotransmitter N-
acetylaspartylglutamate (NAAG)56. Prostate specific membrane antigen (PSMA) was 
found to be genetically and functionally homologous to NAALADase57. It has been 
speculated that the role of PSMA in prostate is the cleavage of molecules with paracrine 
and/or autocrine activity involved in prostate homeostasis58. 
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While the role of PSMA in the prostate is not well understood, its potential as a target for 
prostate carcinoma is recognised. Increased expression of PSMA has been demonstrated in 
prostate carcinomas compared with normal prostate or benign prostatic hyperplasia59. 
Secondly, PSMA immunoreactivity was increased after ADT in 55% (11 out of 20) of the 
patients60. Increased PSMA immunoreactivity was also found after ADT in 100% (4 out of 
4) of metastatic specimens60, suggesting that PSMA is upregulated in metastatic PCa. 
Thus, PSMA-targeting agents is a promising therapeutic tools for the management of 
disseminated PCa61. 
 
Antibodies have been developed against the PSMA antigen2. The first commercial 
antibody was Indium-111 (111In)-CYT-356 (Prostascint). However this antibody 
recognised an intracellular epitope of PSMA and initial testing in human showed 
unexpected myelotoxicity62. Four other antibodies with specificity for extracellular 
epitopes of PSMA have also been developed63. For instance, phase I clinical trials 
evaluating the humanised monoclonal antibody huJ591 have demonstrated PSMA 
specificity and successful application as an imaging agent2. 
 
A series of small heterodimeric compounds, which inhibit the NAALADase activity of 
PSMA, were developed by Molecular Insight Pharmaceuticals, Inc., Cambridge, 
Massachusetts64. The structures of the two lead compounds, (S)-2-(3-((S)-1-carboxy-5-((4-
iodobenzyl)amino)pentyl)ureido) pentanedioic acid (MIP-1072) and (S)-2-(3-((S)-1-
carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido) pentanedioic acid (MIP-1095), consist 
of glutamate bound to lysine by a urea bridge (Figure 2). The benzene ring which allows 
iodination is linked to the nitrogen group of lysine in MIP-1072 or attached to lysine via a 
urea bridge in MIP-1095 (Figure 2). Both compounds have demonstrated PSMA-specific 
uptake in tissue distribution studies in mice bearing xenografts derived from the LNCaP 
and PSMA-transfected PC3 cell lines65. The pharmacokinetic characteristics and the 
imaging potential for prostate carcinoma of the 123I-radiolabelled versions of these two 
compounds ([123I]MIP-1072 and [123I]MIP-1095) have been investigated in patients. It was 
shown that both [123I]MIP-1072 and [123I]MIP-1095 were suitable for the detection of 
malignant lesions in soft tissues, bones and in the prostate61. Notably, the retention of 
[123I]MIP-1095 within tissues was greater than that of [123I]MIP-1072 - manifest by a 
greater absorbed radiation dose61. This study forms the rationale for the investigation of 
radiolabelled MIP-1095 as an imaging tool and also as therapeutic modality for the 
treatment of disseminated PCa. 
 
 Figure 2 The chemical structures of PSMA
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group (-SH) in a reducing environment whereas it exists as a disulphide bridge (-S-S-) in 
an oxidative environment. The formation of disulphide bridges between two sulphur atoms 
within a protein under oxidising conditions may change the conformation and the function 
of a protein with potentially detrimental effects for the cell. Therefore, redox homeostasis, 
the mechanisms responsible for the maintenance of the intracellular redox equilibrium, is 
required to sustain cellular metabolism. Another target of radiation is DNA. The oxidation 
of DNA leads to the generation of abnormal DNA bases (such as 8-oxoguanine), single-
strand breaks (SSB) and double-strand breaks (DSB). These alterations to DNA may lead 
to mutations or cell death. Upon radiation-induced oxidative stress, the cell relies on 
various antioxidant defence mechanisms in order to maintain redox homeostasis and the 
integrity of the genome. Microarray studies have indicated that IR alters the level of 
expression of genes involved in DNA repair67-70, cell cycle regulation67,71,72 and antioxidant 
defence70-72. 
 
1.1.5.2.1 Antioxidant responses 
Superoxide dismutase (SOD) is an enzyme that converts O2- into H2O2 (Figure 3). Since 
H2O2 is a potentially harmful oxidising agent, catalase converts H2O2 into water and 
oxygen. SOD requires a metal ion for its enzymatic activity. SOD1, located in the 
cytoplasm, is coupled with zinc or copper, SOD2, located in the mitochondria, is coupled 
with manganese and the extracellular SOD3 is also coupled with zinc or copper. The 
SOD/catalase system protects cells from the indirect oxidative effect of radiation by the 
scavenging of O2-. 
 
 
Figure 3 The chemical reactions of the conversion of superoxide to hydrogen peroxide by SOD 
M, metal. 
 
Glutathione protects cells from oxidation by several mechanisms: direct scavenging ROS, 
the reduction of oxidised entities or by the conjugation of reduced glutathione (GSH) to 
oxidised moieties. Upon radiation treatment, the glutathione peroxidase gene has been 
found to be upregulated in fibroblasts isolated from glioma72. Glutathione peroxidase 
 37
catalyses the transfer of an electron from the reduced form of glutathione (GSH) to an 
oxidised moiety. This process produces the oxidised form of glutathione (GSSG) and the 
reduced moiety. The reverse chemical reaction, the reduction of GSSG into two GSH 
molecules, is catalysed by glutathione reductase, thereby recycling the cellular antioxidant 
pool. This reaction requires the co-factor nicotinamide adenosine dinucleotide phosphate 
(NADPH) for the provision of electrons. 
 
1.1.5.2.2 Cell cycle regulation in response to radiation 
The proliferation of cells is a highly controlled process requiring progression through four 
successive phases of the cell cycle. In every cycle, a parent cell produces two daughter 
cells. Cells which are in the S phase of the cell cycle are in the process of replicating their 
DNA in order to obtain two copies of the genome. After the entirety of the genome has 
been replicated, the cells may undergo mitosis, a process whereby each daughter cell 
inherits one copy of the parent cell’s genome. The intermediate phases of the cell cycle, 
although not involved with DNA metabolism, are responsible for the verification of the 
genome’s integrity. Cells which are in the G1 phase of the cell cycle, which contain N 
amount of DNA, have exited mitosis and are preparing to enter the S phase in order to 
replicate their DNA. Cells in the G2 phase of the cell cycle, which contain 2N amount of 
DNA, have replicated the entirety of their genome and are preparing to enter mitosis. 
 
The presence of DNA damage such as abnormal bases or SSB during DNA replication 
may interfere with the progress of the replication fork leading to the formation of DSB 
which are strong signals for cell death if they are too numerous to be efficiently repaired. 
Alternatively, DSB present during mitosis may cause unequal distribution of the genome to 
the daughter cells resulting in their death. Moreover, the presence of DNA damage may 
result in an impaired alignment of the chromosomes along the spindle equator. Such 
unrepaired damage may prevent mitotic progression or result in cell death by a process 
called mitotic catastrophe73. Consequently, cells have evolved complex checkpoints which 
arrest cell cycle progression in order to check the integrity of the genome at the G1/S and 
G2/M transitions. Cell cycle checkpoints confer radioresistance upon proliferative cells 
because they allow time for the repair of potentially lethal radiation-induced DNA damage. 
 
1.1.5.2.3 DNA damage and DNA repair 
The absorption of radiation energy by DNA leads to the production of abnormal bases, 
SSB and DSB74. DSB are considered the most critical DNA lesions. Moreover, the 
cytotoxicity of IR on cells is known to be more potent in normoxic conditions compared 
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with hypoxic conditions, implicating ROS in the generation of DNA damage75. It is 
considered that 60-70% of radiation-induced DNA damage is caused by ROS76. The main 
ROS considered to react with DNA molecules is HO. The chemical reaction of HO with 
DNA leads to the same DNA lesions as those induced by the direct absorption of radiation 
energy77. 
 
Nucleotide excision repair (NER) is responsible for the recognition and repair of DNA-
distorting base damage, such as thymidine dimers, predominantly after ultraviolet (UV) 
radiation treatment. On the other hand, base excision repair (BER) is responsible for the 
repair of non-DNA-distorting base damage including deamination, depurination, alkylation 
and other oxidative damage leading to abnormal bases. Such defects are recognised by 
DNA glycosylases and removed by apurinic/apyrimidinic endonucleases. The gap is then 
filled by DNA polymerase β and the nick repaired by DNA ligases78. Both NER and BER 
are involved in the repair of ROS-induced oxidative damage of DNA79_ENREF_14. 
 
The repair of DSB of DNA is carried out by two mechanisms. Homologous recombination 
(HR) uses the homologous strand of DNA for the error-free synthesis of missing DNA 
sequences. The requirement of the homologous strand implies that this mechanism 
preferentially occurs in S-phase and G2, when there are two copies of each DNA 
strand80_ENREF_15. DSB sensors and recombinases are members of the RAD51 protein 
family and they are upregulated after radiation treatment81. Alternatively, non-homologous 
end joining (NHEJ) joins the ends of two DNA strands together. Thus, NHEJ does not 
need the homologous DNA strand. This error-prone DNA repair machinery is therefore 
unable to maintain the integrity of the genome80_ENREF_15. The main effectors of NHEJ 
are the heterodimer KU70/KU80, which is responsible for the recognition of the DSB, and 
DNA-dependent protein kinase (DNA-PK), which is responsible for the recruitment of 
ligase IV and artemis. In turn, the NHEJ complex, consisting of KU70/KU80, DNA-PK, 
ligase IV and artemis, joins both ends of the DNA together80_ENREF_15. 
 
1.1.6 Radiosensitisation 
“A true radiosensitiser is a chemical which increases the cell-killing effect of a given dose 
of radiation. This is achieved either by increased formation of longer-lived toxic radiation-
induced radicals or modification of vulnerable, critical targets in cells, or by interference 
with mechanisms of repair of sublethal radiation damage”82. This definition of 
radiosensitisation directly involves the generation of oxidative stress and the inhibition of 
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the pathways leading to efficient DNA repair following irradiation. These pathways are 
described next. 
 
ROS are produced in all aerobic cells via the oxidation of the constituents of the 
mitochondrial electron transport chain83. Therefore, due to the high metabolic rate required 
to sustain proliferation, cancer cells experience greater oxidative stress than normal cells 
proliferating at a lower rate. Degenerative oxidation of membrane phospholipids, DNA 
damage and the depolarisation of the mitochondrial inner membrane are thought to lead to 
oxidation-induced cell death. It was proposed that oxidising agents could be used 
therapeutically to increase the oxidative stress in cancer cells beyond a theoretical 
threshold corresponding to the maximal level of oxidative stress that a cancer cell can 
withstand. Crucially, due to the existence of greater oxidative stress in cancer cells than in 
healthy cells, this threshold would not be reached in healthy cells84. However, as a 
consequence of elevated oxidative levels, it is speculated that cancer cells may also 
harbour increased levels of antioxidant defences. Therefore, their depletion, which would 
increase the susceptibility to oxidising agents, may also be an efficient therapeutic option. 
 
The primary effect of IR is the oxidation of molecules. Therefore, combination treatment 
comprising IR with an oxidising agent, or with a drug decreasing the antioxidant capacity 
of a cell, should result in a greater imbalance of the redox homeostasis, favouring 
oxidation. Oxidising agents should be radiosensitisers since they increase the cytotoxic 
oxidative effect of IR. Indeed, in vitro studies have demonstrated that the combination of 
2-deoxyglucose with 6-aminonicotinamide radiosensitised cancer cells via an increase in 
oxidative stress. Furthermore, the enhancement of radiation cell kill was accompanied by 
an increased NADP+/NADPH ratio and an increased GSSG/GSH ratio85. Further evidence 
for the positive interaction between oxidising agents and radiotherapy has been provided 
by the clinical study which demonstrated the efficacy of combining the glutathione-
depleting agent arsenic trioxide86 with radiotherapy in patients with glioma87. 
 
The inhibition of G1 and G2 arrest shortens the time for irradiated cells to repair DNA 
damage. Consequently, irradiated cells treated with cell cycle checkpoint inhibitors enter 
mitosis or the S phase with DNA damage. Similarly, DNA repair inhibitors increase the 
proportion of irradiated cells entering mitosis or the S phase with DNA damage. 
 
DNA replication during S phase is a dynamic process requiring multiple components. 
Firstly, the DNA strands are separated from each other. Secondly, each strand serves as a 
 40
template for the synthesis of a complementary strand. As the replication fork advances, 
torsional stress in DNA is created ahead of the fork. Topoisomerase I cleaves one strand of 
DNA, allowing the second strand to pass through the cleavage site before re-sealing the 
nick. During this process, an intermediate state occurs through the formation of transient 
covalent bonds between topoisomerase I and the cleaved strand of DNA, the so-called 
“cleavable complex”. 
 
A DNA repair inhibitor or a G1 arrest inhibitor allows the entry of irradiated cells into the 
S phase in the presence of extensive DNA damage. During DNA replication, SSB caused 
by radiation in addition to those created by topoisomerases at the replication fork may lead 
to the formation of DSB which are strong signals for cell death. Evidence for the 
transformation of SSB into DSB during DNA replication was provided recently by two 
separate studies. Olaparib is an inhibitor of poly(ADP-ribose) polymerase 1 (PARP-1). 
PARP-1 is involved in the recognition of SSB and the recruitment of the DNA repair 
machinery. It is also responsible for the relaxation of the chromatin structure allowing 
access of the DNA damage repair machinery to the DNA break site88. Olaparib is therefore 
an inhibitor of SSB repair. It was demonstrated that (i) aphidicolin, an inhibitor of DNA 
replication, prevented olaparib-mediated radiosensitisation and (ii) that the proportion of 
DSB in S-phase cells after 4 Gy irradiation was increased in the presence of olaparib89. 
Similarly, it was demonstrated that cells synchronised in S phase harboured more DSB 
when they were treated with the alkylating agent temozolomide in the presence of a PARP-
1 inhibitor compared with treatment by temozolomide alone90. These results indicated that 
the inhibition of the repair of SSB by olaparib during the replication of DNA resulted in an 
increase in the formation of DSB after radiation treatment or treatment with an alkylating 
agent. They further suggested that the SSB are converted into DSB during DNA replication 
in the presence of a DNA repair inhibitor which leads to increased cell death. 
 
Alternatively, a G2 arrest inhibitor allows the entry of irradiated cells into mitosis in the 
presence of DNA damage. Such cells may die by mitotic catastrophe. 
 
Many drugs used in anti-cancer therapy disrupt mitotic progress or DNA metabolism 
(Table 1). Moreover, many of these drugs have been used successfully in combination with 
target radiotherapy in patients42,43,91. For example, the combination of [131I]mIBG with a 
radiosensitiser, the topoisomerase I inhibitor and S phase disruptor topotecan, has shown to 
be synergistic in vitro and in vivo. In this study, the combination of topotecan with 
[131I]mIBG induces a more efficient clonogenic kill and an enhancement of the delay in 
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DNA repair compared with [131I]mIBG treatment alone. The schedule of administration of 
the two agents was also shown to be crucial for synergy. The simultaneous administration 
of [131I]mIBG and topotecan resulted in greater delay in the growth of human tumour 
xenografts than [131I]mIBG administration prior to topotecan or vice versa92. This mIBG 
and topotecan in neuroblastoma (MATIN) regimen is now undergoing clinical 
evaluation93. 
 
Drugs Target Mechanism of action 
Vinca alkaloids (vinblastine, 
vincristine) 
Taxanes (paclitaxel, docetaxel) 
Microtubules 
Disruption of the 
polymerisation/depolymerisation dynamic of 
mitotic microtubules 
Cyclophosphamide, cisplatin, 
melphalan, busulphan, temozolomide, 
carmustine, anthracyclins 
(doxorubicin, daunorubicin) 
DNA 
DNA crosslinking, alkylating and intercalating 
agents 
Etoposide, mitoxantrone, topotecan, 
irinotecan 
Topoisomerase I and II 
Stabilisation of the cleavable complex and 
creation of double-strand breaks during DNA 
replication 
Table 1 DNA metabolism-targeting drugs used in anti-cancer therapy 
 
1.1.7 A strategy to improve targeted radiotherapy 
Although targeted radiotherapy has produced promising results, the optimal way to use it 
has yet to be determined91,94. Indeed, the clinical trials listed in Section 1.1.4 have 
indicated that, despite overall response rates of 50% associated with little or manageable 
toxicity, cure of neuroblastoma and NETs remains elusive. 
 
The intracellular pathways driving cell proliferation are numerous and cross talks occur 
among them95,96. Redundant mechanisms allow cells to survive treatment-induced 
alteration of a particular pathway. Resistance to therapy also develops even in initially 
responding patients, notably after ADT of prostate cancer97. Thus, treatment with two or 
more agents that act upon different oncogenic pathways or that act upon different 
components of the same oncogenic pathway are likely to achieve better tumour control 
than single agent therapies. Nowadays, cancer management employs multimodal strategies 
involving surgery, chemotherapy and radiotherapy. Moreover, chemotherapy may 
comprise multiple drugs (Section 1.1.4.5). 
 
The limiting factor of all anticancer therapies is the toxicity to the dose limiting organ. In 
targeted radiotherapy, the main dose-limiting organ is the bone marrow although renal 
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toxicity occurs following administration of octreotide and octreotate for the treatment of 
patients with NET. Furthermore, neutropenia and thrombocytopenia are commonly 
observed after targeted radiotherapy. The anti-cancer efficacy of therapy must be balanced 
by toxicity to the patient. Synergistic interaction between two agents in a combination 
results in a supra-additive effect, i.e. a greater kill than that of the single agents. The 
concept of synergy has also been broadened to the therapeutic ratio in which a combination 
treatment is therapeutically synergistic if the side-effects are less than those of the single 
agents98. Theoretically, a synergistic combination kills at lower doses than those required 
for the single agents to achieve the same kill. Moreover, the use of low doses of a 
synergistic combination results in lower levels of toxicity and fewer side-effects, thereby 
improving the therapeutic ratio. This is of great importance in targeted radiotherapy for 
which bone marrow transplants are often required in order to avoid myelosuppression. 
 
The efficacy of targeted radiotherapy may be improved by combination with 
radiosensitisers. One aim of the research described in this thesis was the screening of 
chemotherapeutic agents for synergistic interaction with targeted radiotherapy. Of 
particular interest was disulfiram because of its pro-oxidative properties, its ability to 
inhibit the proteasome/nuclear factor kappa B (NF-κB) pathway, its ability to chelate 
copper and its radiomodifying properties. A literature review of the biological effects of 
DSF is provided in the second part of this introduction. 
 
1.2 Disulfiram (DSF) 
1.2.1 The nomenclature of DSF and its derivatives 
Dithiocarbamates are defined by a carbamate group in which both oxygens are substituted 
by sulphur atoms. A thiuram is a molecule with two dithiocarbamates linked by a 
disulphide bridge. DSF is a thiuram with four ethyl groups; hence DSF is also called 
tetraethylthiuram disulphide. The reduction of the disulphide bridge yields two 
diethyldithiocarbamate (DETC) molecules. One particular derivative has been extensively 
studied: pyrrolidine dithiocarbamate (PDTC). PDTC is a dithiocarbamate in which the 
nitrogen atom is engaged in a pyrrolidine cycle. DSF and its derivatives all chelate copper 
(Cu). The chemical structures of these compounds are shown below (Figure 4). 
 
 Figure 4 The chemical structures of the dithiocarbamate family members
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cocaine intake, and this may be reduced by the DSF-mediated reduction of noradrenaline 
levels. 
 
1.2.3 Alcoholism, DSF and cancer 
It has been reported that the lung cancer related death of alcoholics was significantly lower 
in those taking DSF than in those who were not107. Although alcohol intake should be 
higher in DSF non-takers, the authors argued that since alcohol is not an indicated cause of 
lung cancer, the difference in alcohol intake could not account for the difference in lung 
cancer incidence. However, smoking, a habit linked to alcohol consumption and a known 
risk factor for lung cancer, was not taken in account in this study. The same study also 
found an association between lower incidence of other cancers and DSF intake but the 
difference was not statistically significant107. This observation raised the question whether 
DSF was a potential anti-cancer agent or not. A case of spontaneous remission from breast 
cancer in an alcoholic following DSF therapy was reported108 and, more recently, DSF 
produced a long-term remission in an advanced stage melanoma patient109. 
 
1.2.4 The biological targets of DSF 
1.2.4.1 Increasing oxidative stress 
DSF is a chelator of divalent metal ions - primarily copper (Cu) but also iron (Fe)110, nickel 
(Ni)111 and cadmium (Cd)112. DSF has been described as a Cu ionophore which exerts 
cytotoxic effects via Cu deposition inside cells113, a mode of action called Cu overload114. 
Cu only exists bound to proteins in the cytoplasm, thus, following Cu overload, cellular 
metabolism may be disrupted by inhibition of many proteins. Alternatively, the Cu-bound 
form of DSF may represent an active form of DSF which is toxic in its own right (see 
Section 1.2.4.2). 
 
Due to their higher metabolic activity, tumour cells exist in a state of increased oxidative 
stress compared with normal cells84. According to the Cu overload theory, excess Cu reacts 
with the glutathione system, thus depleting the antioxidant defences of tumour cells. Also, 
Cu ions can cycle between two ionic forms, Cu(II) and Cu(III), in the presence of H2O2 
and form ROS, such as HO, in a Fenton-like reaction (Figure 5)115. Tumour cells can 
produce high levels of H2O2116. Thus, Cu may be capable of raising oxidative stress beyond 
the threshold that the tumour cell can deal with in two ways: interfering with the 
glutathione system and through the intermediacy of a Fenton-like reaction. Raising Cu 
levels within tumour cells, resulting in the disruption of multiple metabolic pathways and 
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elevating oxidative stress, has been suggested to be an effective anti-cancer option84. 
Furthermore, the Cu-mediated increase in oxidative stress could be a radiosensitising 
mechanism by which DSF could enhance the efficacy of radiotherapy. 
 
 
Figure 5 The Fenton reaction using Fe2+ as an electron donor 
 
Tumours accumulate Cu to sustain their higher metabolic demand, which results in greater 
Cu levels than in non-malignant cells84. For instance, Cu is a co-factor for superoxide 
dismutase (involved in the removal of superoxide radicals), lysyl oxidase (involved in the 
cross linking between collagen and elastin) and cytochrome c oxidase (involved in the 
production of ATP in mitochondria)84. Besides the Cu overload mechanism of action, it 
could be argued that Cu chelation by DSF is in itself toxic to cancer cells by interfering 
with tumour cellular metabolism of Cu. 
 
SOD1 requires Cu for the detoxification of O2-. It has been shown that DETC, the product 
of the reduction of the disulphide bridge of DSF, inhibits SOD117. The authors argued that 
DETC-mediated inhibition of SOD enzymatic activity occurred via binding to Cu. Indeed, 
the inhibition of the enzymatic activity was reversed by Cu supplementation. Moreover, 
the authors observed the formation of a yellow colour following treatment of solutions of 
SOD with DETC, which was indicative of the formation of a complex between DETC and 
Cu110,118. The yellow colour was not extractable by organic solvents but extractable by 
treatment with CuSO4117. This observation suggested that DETC probably binds to SOD 
via its interaction with Cu, thereby inhibiting SOD activity. Therefore, DETC inhibits a 
mechanism which counteracts oxidative damage created by ROS. Since DSF is broken 
down into DETC in vivo, DSF should have similar SOD-inhibitory properties to DETC. 
This mechanism may further contribute to the sensitisation of cancer cells to oxidative 
insults such as IR.  
 
The glutathione system is responsible for the redox homeostasis of the cell by cycling 
between its reduced form (GSH) and its oxidised form (GSSG). This multi-step process 
was described previously (Section 1.1.5.2.1). DSF can interact with the glutathione system 
by virtue of its disulphide bridge. It has been shown that the non-enzymatic reaction 
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between DSF and GSH forms two molecules of DETC and one molecule of GSSG (Figure 
6)119. 
 
 
Figure 6 The non-enzymatic conversion of DSF to DETC by glutathione (GSH), adapted from 
Nagendra et al. (1991)119 
 
Furthermore, it was shown that the cytotoxicity of DSF was potentiated by buthionine 
sulfoximine (BSO) and prevented by N-acetyl cysteine (NAC)120. BSO is an inhibitor of γ-
glutamyl-cysteine synthetase, the rate-limiting enzyme in the biosynthesis of glutathione. 
NAC is an antioxidant and a precursor of GSH. Therefore, DSF decreases the antioxidant 
defences of the cells by lowering the levels of reduced glutathione, which may, in turn, 
lead to cell death in response to oxidants. 
 
In summary, DSF has been shown to contribute to increased oxidative stress in cells via the 
increase of intracellular Cu levels and the inhibition of antioxidant defences such as SOD 
and glutathione. Therefore, DSF should sensitise cells to the pro-oxidative effect of 
radiotherapy. 
 
1.2.4.2 The proteasome/NF-κB axis 
The proteasome is an organelle responsible for the controlled enzymatic degradation of 
proteins. Cu alone or the Cu-chelated form of DSF but not DSF itself inhibited purified 
proteasome in a cell-free system. In contrast, in cells, only the Cu-chelated form of DSF 
inhibited the proteasome121. A possible mechanism is that DSF is required to transport Cu 
through the cell membrane. Cu could then have been released in the cytoplasm with 
subsequent inhibition of the proteasome. However, since the Cu-chelated form of DSF was 
also able to inhibit purified proteasome in a cell-free system, it may be that Cu binding 
confers upon DSF the ability to inhibit the proteasome as well. Both mechanisms may be 
responsible for proteasome inhibition. 
 
The proteasome is also a key component of the activation pathway of the transcription 
factor NF-κB. NF-κB is involved in the control of the cell cycle, apoptosis, immune 
responses and responses to many stimuli such as radiation, oxidative stress and exposure to 
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xenobiotics. The inactive form of NF-κB is bound to its inhibitor IκB and remains in the 
cytoplasm. Upon external stimulation (radiation, oxidative stress), IκB is phosphorylated, 
ubiquitinated and broken down by the proteasome. The degradation of IκB releases NF-κB 
which can then be translocated to the nucleus where it binds DNA in order to drive the 
transcription of its target genes. NF-κB is activated as part of the cellular response to 
oxidative stress and has anti-apoptotic properties. 
 
The production of ROS by IR was described previously (Section 1.1.5.1). Elevated levels 
of ROS in the cytoplasm after irradiation create oxidative stress. The oxidation of key 
amino acids (e.g. cysteine) in active sites of proteins may alter the protein structure. 
Proteins capable of being activated in this way are called oxidative stress sensors. Once 
activated, oxidative stress sensors trigger the transcription of genes encoding antioxidant 
defences. Although the NF-κB activation routes are multiple and unclear, NF-κB was 
demonstrated to be an oxidative stress sensor122. NF-κB has been shown to be activated in 
response to radiation123,124 and to confer upon cells radioresistant properties123,125. 
 
NF-κB activation has been shown to increase the antioxidant capacity of 
phaechromocytoma cells by transcription of the genes encoding catalase and γ-glutamyl-
cysteine synthetase, conferring increased protection against oxidative stress which 
translated into prevention of apoptosis126. Similarly, it has been demonstrated in another 
study that the inhibitor of apoptosis (IAP) was up-regulated after stimulation by tumour 
necrosis factor (TNF-α), a known activator of NF-κB127. The mechanism of IAP-induced 
prevention of apoptosis was thought to be binding to and inhibition of caspases. Thus, NF-
κB has antioxidant and anti-apoptotic properties at least through transcription of genes 
encoding antioxidants and IAP. 
 
DSF and its pyrrolidine derivative, PDTC, are inhibitors of NF-κB activation128,129. The 
inhibition of NF-κB activation by DSF or PDTC is a sensitising mechanism to oxidative 
stress and apoptosis. Therefore, the inhibition of the proteasome/NF-κB axis by DSF 
represents another radiosensitising mechanism by which it could improve the efficacy of 
targeted radiotherapy. 
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1.2.4.3 Is DSF an oxidising agent or an antioxidant? 
Despite the pro-oxidative properties of DSF described previously in Section 1.2.4.1, it has 
also been demonstrated that DSF and its derivatives such as PDTC and DETC have anti-
oxidative properties. 
 
In one study, PDTC, the pyrrolidine derivative of DSF with free thiols, decreased the rate 
of generation of ROS by fenretinide and inhibited apoptosis130, suggesting direct 
scavenging of ROS. In a second study, DSF prevented lipid peroxidation in isolated 
hepatocytes exposed to a range of oxidising agents including H2O2131. These studies 
demonstrated the antioxidant properties of DSF and PDTC. 
 
DSF and its derivatives have pro-oxidative properties exemplified by the transport of Cu 
into the cytosol, the inhibition of NF-κB and the depletion of antioxidant defences such as 
SOD and glutathione. Conversely, they also have anti-oxidative properties by virtue of 
their reduction of peroxidised lipids and the direct scavenging of ROS. A summary of 
these mechanisms is shown in Table 2. An attempt has been made to describe the 
chemistry of dithiocarbamates (PDTC, DETC and DSF) that encompasses both pro and 
anti-oxidative properties132. Using a HO-generating cell-free system (H2O2 and CuCl2), 
the authors demonstrated the scavenging of HO by DSF, DETC and PDTC132. Secondly, 
using a different cell-free system comprising DETC, CuCl2, GSH, glutathione reductase 
(GR) and NADPH, the authors monitored the rate of oxidation of GSH into GSSG. It was 
demonstrated that the inclusion of CuCl2 in a solution of DETC produced the oxidised 
compounds DSF and DETC2:Cu that led to the oxidation of GSH into GSSH132. Therefore, 
the authors cautiously concluded that “dithiocarbamates are radical-scavenging compounds 
with pro-oxidant activity; that is, they remove one-electron oxidants (free radicals) but, in 
doing so, induce a state of two-electron oxidative stress (GSH conversion to GSSG; 
NADPH oxidation to NADP+).” This conclusion indicated that dithiocarbamates are 
oxidising agents. The scavenging of ROS, and therefore the reducing power of 
dithiocarbamates, generates oxidised disulphides or oxidised Cu-complexes that are able to 
deplete cells of reduced glutathione. 
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Chemical Chemical structure Oxidising properties 
Antioxidant 
properties 
PDTC 
 
NF-κB inhibition128 
Scavenging of 
ROS132 
DETC 
 
Inhibition of SOD117 
Scavenging of 
ROS132 
DSF 
 
NF-kB inhibition129, 
glutathione 
depletion119,132, Cu 
chelation and Fenton-like 
reaction84 
Scavenging of 
ROS132, reduction 
of lipid 
peroxidation131 
Table 2 The pro- and anti-oxidative properties of DSF and its derivatives 
 
1.2.5 DSF acts as an anti-viral agent and as an immunomodulator  
The effect of DSF and its derivatives on NF-κB activation and oxidative stress is perhaps 
best exemplified by its use in anti-viral therapy. The effectiveness of treatment against 
influenza and human immunodeficiency virus (HIV) infections is impeded by high 
mutation rates of these viruses. Consequently, targeting of viral components is not an 
optimal strategy. Instead, targeting the host cellular metabolism that is misused for the 
benefit of viral replication and that is not subjected to high mutation rates may prove more 
successful. The mechanism whereby the host’s NF-κB is requisitioned for viral replication 
is not well understood. One possibility is that virus-infected cells release pro-inflammatory 
cytokines, which represents an activation trigger for macrophages to produce toxic ROS in 
order to kill infected tissues. The release of ROS is an activation trigger for the 
transcription factor NF-κB which, in turn, promotes transcription of viral genes133. Several 
investigators have studied the potential of NF-κB inhibitors, such as PDTC, to counteract 
viral infections such as influenza and HIV. It has been shown that PDTC increased the 
survival of influenza-infected mice and reduced infiltration of immune cells into influenza-
infected tissues. It also decreased the production of interferon-gamma, thus limiting 
macrophage-mediated release of ROS and reducing secondary tissue damage134. 
 
NF-κB was first recognised to be a transcription factor binding to the κB chain of 
immunoglobulin κ enhancer gene sequence135. NF-κB is involved in many immunological 
processes such as immunoglobulin production, the maturation of macrophages and the 
maturation and proliferation of T and B cells 136. Despite the requirement for NF-κB in T 
 50
and B cell development, DETC-mediated inhibition of NF-κB activation was shown to 
promote T cell maturation to fully immunocompetent cells in athymic mice137. Since the 
immune system may recognise tumour cells and kill them, it is encouraging that DETC did 
not impede immune function but, on the contrary, enhanced T cell activation. 
 
1.2.6 DSF in combination with chemotherapy 
The multi-drug resistance syndrome is responsible for chemoresistance due to the pumping 
of drugs out of the cell. Drug efflux is mediated by the membrane-bound transporter P-
glycoprotein (P-gp) and this mechanism is dependent on the availability of adenosine 
triphosphate (ATP). DSF was shown to inhibit P-gp drug efflux by modifying thiol groups 
in cysteine residues located within the ATP-binding cassette of P-gp138. Another study 
demonstrated that two DSF metabolites, S-methyl N,Ndiethylthiocarbamate sulfoxide and 
S-methyl N,N-diethylthiocarbamate sulfone, also inhibited P-gp drug efflux139. Therefore, 
DSF may enhance chemotherapy by inhibiting P-gp-mediated chemoresistance, 
rationalising its use in combination with existing drug regimens for the treatment of 
neuroblastoma140 or PCa141. 
 
DSF is a highly reactive thiol-containing compound first discovered for its alcohol 
dehydrogenase inhibiting properties. Dehydrogenases represent a class of oxidizing 
enzymes which perform a variety of roles. They are mainly detoxifying enzymes, such as 
alcohol and aldehyde dehydrogenases, or metabolic enzymes, such as pyruvate or glucose-
6-phosphate dehydrogenases. Dehydrogenases oxidise a substrate and transfer an electron 
to an acceptor, usually a molecule of NAD+ or a functionally similar coenzyme. 
Dehydrogenases have various effects on xenobiotics such as chemotherapeutic agents. The 
oxidation can either convert the chemical into an active (e.g. etoposide) or an inactive form 
(e.g. cyclophosphamide). 
 
Etoposide damages DNA through the formation of a cleavable complex with 
topoisomerase II and the formation of DNA-binding metabolites142. It was reported that 
etoposide cytotoxicity was inhibited by DSF in vitro143. Furthermore, other inhibitors of 
ALDH inhibited etoposide-induced cytotoxicity. The authors concluded that ALDH was 
required for the activation of etoposide143. Clearly, the combination of the ALDH-inhibitor 
DSF with etoposide is antagonistic and does not represent an efficient treatment modality 
worth pursuing. 
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On the other hand, cyclophosphamide requires a succession of metabolic transformations 
in order to be activated in vivo144. The active metabolite of cyclophosphamide, 4-
hydroxycyclophosphamide, exists in equilibrium with aldophosphamide. ALDH is 
responsible for a decrease in active 4-hydroxycyclophosphamide by converting 
aldophosphamide into the non-toxic alcophosphamide. Therefore the benefit from ALDH 
inhibition in combination with cyclophosphamide has been suggested145. It has been shown 
that DSF was able to increase the oncolytic activity of cyclophosphamide in mice in a 
schedule-dependent manner146. Moreover, DSF could reduce cyclophosphamide-induced 
urologic toxicity to the bladder. However haematopoietic toxicity induced by 
cyclophosphamide was slightly increased by DSF146. 
 
Furthermore, it has been shown that DSF prevents cisplatin-induced myelosuppression and 
nephrotoxicity without affecting anti-tumour activity147. While still controversial, the 
mechanism of DSF-mediated protection against cisplatin toxicity is thought to be due to 
chelation of platinum148, myeloprotection or through the shift of platinum excretion to the 
bile, thereby sparing the kidneys149. 
 
Cisplatin and cyclophosphamide are used as first line chemotherapy of neuroblastoma. 
This regimen might be improved by the inclusion of DSF. On the other hand, combination 
with etoposide is likely to be antagonistic. Due to the inhibition of P-gp-mediated 
chemoresistance, DSF may still increase the retention of a wide range of chemotherapeutic 
drugs. However, the example of the antagonistic combination of DSF with etoposide 
illustrates the need for pre-clinical evaluation of the combinations of DSF with 
chemotherapeutic agents. 
 
1.2.7 Cancer stem cells and ALDH 
Besides its role in alcohol metabolism, ALDH was also shown to be overexpressed in stem 
cells, both normal and malignant150. The cancer stem cell (CSC) hypothesis implicates 
normal stem cells as the origin of a tumour. CSC are capable of asymmetric division 
producing another CSC and a more differentiated tumour cell. It is thought that CSC are 
responsible for driving metastasis and for tumour relapse after therapy151. CSC escape 
treatment due to their limited number within a tumour, their location in hypoxic niches 
distant from blood vessels, and their chemoresistance and radioresistance. For instance, it 
has been shown that transgenic mice over-expressing ALDH were protected from alcohol-
mediated enhancement of the pro-apoptotic machinery, indicating that aldehydes are pro-
apoptotic and ALDH anti-apoptotic152. It has been suggested that ALDH inhibition by DSF 
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could re-establish CSC sensitivity to apoptosis150. Recently, it has been shown that 
glioblastoma neurospheres have increased ALDH levels compared with their monolayers 
counterparts153. Glioblastoma cells grown as neurospheres are thought to be enriched in 
glioblastoma stem-like cells. Interstingly, it has been found that the ability of the 
glioblastoma cells to form neurospheres could be inhibited by DSF in a Cu-dependent 
manner153. This study suggested that DSF has cytotoxic properties against glioblastoma 
CSC via the inhibition of ALDH. Since metastasis and relapse after treatment are the two 
leading causes of death from cancer, the targeting of CSC via the ALDH-inhibitory 
properties of DSF may be a useful new therapeutic strategy. 
 
1.2.8 Angiogenesis 
Angiogenesis, the formation of blood vessels, is required to provide oxygen and nutrients 
to tumour cells in order to sustain growth. Therefore, anti-angiogenic chemotherapy has 
been devised for the treatment of cancer. Tumour-associated angiogenesis, like normal 
angiogenesis, requires Cu as a co-factor154. Although, there is no consensus mechanism to 
explain Cu requirement in blood vessel formation, angiogenic growth factors, such as 
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), require Cu 
binding for their secretion and activity. Cu chelators, such as penicillamine, have been 
shown to have anti-angiogenic properties155. It has been hypothesised that DSF may have 
similar properties. Indeed, DSF has been shown to inhibit metalloproteinases (MMP-9 and 
MMP-4)156, key enzymes in the angiogenic process that require zinc as a co-factor. DSF 
may inhibit MMPs via zinc chelation. However, it has been reported that DSF-induced 
inhibition of MMPs may be mediated by the activation of “reversion-inducing-cysteine-
rich protein with kazal motifs” (RECK)157_ENREF_116, an inhibitor of metalloproteinases 
associated with favourable prognosis in colorectal cancer158. Therefore, DSF inhibits 
angiogenesis and may disrupt tumour homeostasis at the vascular stage of tumour 
development. 
 
1.2.9 DSF targets cancer cells 
The specific targeting of malignant lesions rather than normal tissue by anti-cancer 
therapies diminishes the occurrence of side-effects. Cancer cells have a higher proliferation 
rate than normal cells, thus cancer cells are more susceptible to therapies targeting dividing 
cells, such as DNA damaging agents and radiotherapy. As a consequence of their higher 
metabolic rate, tumour cells have increased oxidative stress compared with normal cells, 
thus they are more susceptible to therapy designed to elevate oxidative stress beyond a 
threshold that will trigger cell death. It has also been shown that numerous components of 
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the proteasomal degradation pathway are overexpressed in tumour cell lines and in tumour 
biopsies159,160. Finally, cancer cells have a higher Cu content than normal cells. Elevated 
Cu levels, increased oxidative stress, elevated proteasome activity and faster proliferative 
rate of tumour cells compared with non-malignant cells are differences that can be 
exploited for the targeting of cancer cells over non-malignant cells. DSF has emerged as an 
anti-cancer agent due to its ability to interact with multiple components overexpressed in 
tumour cells and necessary for their survival: 
- Inhibition of the proteasome 
- Induction of oxidative stress via Cu deposition and inhibition of antioxidants such 
as glutathione and SOD 
- Inhibition of angiogenesis 
- Inhibition of resistance to therapy by inactivation of ALDH, NF-κB and P-gp 
- Inhibition of ALDH and the targeting of CSC 
 
1.2.10 Pharmacology and toxicity of DSF 
From the pioneering work on the alcohol deterrent properties of DSF and its broader use in 
anti-addictive therapies to its anti-cancer properties, DSF targets a variety of cellular 
pathways which suggest the possibility of an unfavourable toxicity profile. A summary of 
the pharmacology and the toxicity of DSF is provided in the following paragraphs. 
 
DSF is unstable in vivo and is rapidly metabolised. It has been shown that the peak plasma 
concentration of DSF in humans (0.35 µg/ml; 1.18µM) is reached 10 h following a single 
oral dose of 250 mg and that the DSF plasma concentration is zero 72 h after 
administration161. DSF is reduced to DETC by GSH primarily in erythrocytes162. The 
reactivity of the free thiol of DETC confers upon itself the ability to form disulphide 
bridges with cellular thiols. Accordingly, it has been shown that approximately 20% of the 
drug remains bound to tissues in the body for 1 to 2 weeks after ingestion163. Alternatively, 
DETC can be chemically modified by liver enzymes through methylation and 
sulfoxidation or by conjugation to glucuronic acid for rapid excretion in urine164. Non-
enzymatic breakdown of DETC may also occur, yielding carbon disulphide and 
diethylamine165. 
 
Carbon disulphide is thought to be the most toxic metabolite of DSF, particularly to nerve 
cells166. The side-effects of DSF include hepatotoxicity167, optic neuritis168, 
encephalopathies and neuropathies166,169-172, malaise, nausea, diarrhoea, endocrine and 
cardiovascular abnormalities173. However, three case reports have described the reversible 
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nature of the side-effects after cessation of DSF or reduction of the dose109,169,170. The 
typical oral dose of DSF given to patients is 250-500 mg daily. In this regimen, the most 
severe side-effects (neurotoxicity) appear after several months of therapy173. Despite case 
reports of DSF-induced toxicity, millions of alcoholic patients have been treated safely 
with DSF since it was approved by the FDA in 1948174. 
 
1.2.11 Old drugs, new tricks 
It is a long and expensive process to develop new and effective anti-cancer agents. It takes 
on average 13.5 years from discovery to marketing. It usually involves validation of a 
target, validation of targeting compounds, pre-clinical evaluation and Phase I, II and III 
clinical trials. However, the rate of drugs entering clinical trials and failing to demonstrate 
therapeutic efficacy is 70% in Phase II and 59% in Phase III175_ENREF_131. These high 
failure rates are coupled with the high development cost of new compounds176. DSF was 
approved by the FDA in 1948 and has been in clinical use ever since for alcohol aversion 
therapy. Therefore the clinical practice, toxicity and other pharmacological data related to 
DSF, normally determined in lengthy and expensive clinical trials, are already well known. 
 
Moreover, the cost of cancer treatment is escalating for the patient and societies. For 
instance, more than 90% of FDA-approved anti-cancer compounds in the last 4 years cost 
more than $20,000 for a treatment lasting 12 weeks177_ENREF_133. An alternative 
approach has been proposed: the use of non-profit drugs such as DSF178_ENREF_134. 
This involves using off-target effects of cheap and available old drugs. One year’s 
treatment with DSF costs £550 per patient178. DSF has recently been described as an anti-
cancer agent for its Cu-dependent cytotoxicity. This is an off-target effect, i.e. unrelated to 
ALDH inhibition which is responsible for alcohol aversion. In a financial climate where 
investments are at risk, it is not surprising to see many studies and clinical trials 
investigating DSF as an anti-cancer therapy179_ENREF_135. 
 
1.2.12 Clinical trials involving DSF 
There are five clinical trials listed by the US National Institute of Health, which aim to 
determine the feasibility of DSF treatment in cancer patients (Table 3). Several scientific 
approaches have been chosen in these clinical trials. Whereas two clinical trials are 
investigating the effect of DSF alone in prostate cancer and melanoma, three are 
investigating the effect of DSF in combination with Cu, cisplatin or standard radio-
chemotherapy. The Cu-dependency of DSF cytotoxicity is well known; therefore it is 
important to test whether Cu supplementation is required to enhance the tumour control by 
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DSF in humans. Secondly, the clinical trials investigating the combinations of DSF with 
cisplatin in non-small cell lung cancer or with standard radio-chemotherapy of 
glioblastoma multiform are testing the hypothesis that DSF is an effective adjuvant 
therapeutic option. The ability of DSF to enhance chemotherapy with cisplatin via 
inhibition of side-effects or the ability of DSF to inhibit P-gp-mediated chemoresistance 
was discussed previously (Section 1.2.6). 
 
Principal 
investigator 
Cancer Comment Phase Dose ID 
Nechustan H 
Non-small cell 
lung cancer 
Combination 
with cisplatin 
II - III  NCT00312819 
Grossmann K 
Solid tumour 
metastasis to the 
liver 
Combination 
with Cu 
gluconate 
I 
250 mg DSF + 2 
mg Cu gluconate 
daily 
NCT00742911 
Fruehauf JP 
Metastatic 
melanoma 
 I - II 
250 mg twice 
daily 
NCT00256230 
Karamanakos PN 
Glioblastoma 
multiform 
DSF as an 
adjuvant therapy 
prior to standard 
radio-
chemotherapy 
II  NCT01777919 
Carducci MA Prostate cancer   
250 or 500 mg 
daily 
NCT01118741 
Table 3 Clinical trials investigating DSF as an anti-cancer therapeutic 
 
1.2.13 DSF, a radiation modifier 
A consideration of the biological effects of DSF also provides a rationale for  
the investigation of DSF in combination with radiation. The activation of NF-kB results in 
the expression of anti-apoptotic and antioxidant genes which confers upon cells 
radioresistant properties (Section 1.2.4.2). Thus, the inhibition of the proteasome/NF-κB 
pathway by DSF could explain radiosensitising properties of DSF. On the other hand, the 
pro- and anti-oxidative properties of DSF led to the hypotheses that DSF was a 
radiosensitiser and a radioprotector, respectively. The conflicting literature describing the 
radiomodifying properties of DSF is presented in Table 4 and is described below. 
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Author 
In 
vivo 
In 
vitro 
Chemical Schedule Radiomodification Endpoint 
Van Bekkum 
DW (1956)180 
Yes No 
DSF 4800 
mg/kg 
Simultaneous No effect 
30-days 
survival 
Nemavarkar P 
et al. 
(2004)181 
No Yes 
DSF 100-200 
µM 
DSF 20 min post 
IR 
No effect 
Yeast 
survival 
Nemavarkar P 
et al. 
(2004)181 
No Yes 
DSF 100-200 
µM 
DSF 20 min pre IR 
- wash 
No effect 
Yeast 
survival 
Taylor RD et 
al. (1986)182 
No Yes DSF 0.337 µM 
DSF 24 h prior IR 
- no wash 
No effect 
Surviving 
fraction 
Evans RG et 
al. (1982)183 
No Yes DETC 1 mM 
DETC 1 h prior to 
IR - no wash 
Radioprotection 
Surviving 
fraction 
Evans RG et 
al. (1983) 
Yes No 
DETC 1000 
mg/kg 
DETC 0.5 h prior 
to IR 
Radioprotection Survival 
Van Bekkum 
DW (1956)180 
Yes No 
DETC 360 
mg/kg 
Simultaneous Radioprotection 
30-days 
survival 
Rencova J et 
al. (1997)184 
Yes No 
DETC 120 
mg/kg 
Simultaneous Radioprotection Survival 
Nemavarkar P 
et al. 
(2004)181 
No Yes 
DSF 100-200 
µM 
Simultaneous Radioprotection 
Yeast 
survival 
Gandhi NM et 
al. (2003)185 
Yes No DSF 50 mg/kg 
DSF 1 h prior to 
IR 
Radioprotection 
Lipid 
peroxidatio
n and DNA 
damage 
Kent et al. 
(1988)186 
Yes No DETC 50 mg/kg 
DETC 2 to 4 h 
prior to IR 
Radiosensitisation 
Tumour 
growth 
delay 
Lin PS et al. 
(1979)187 
No Yes DETC 0.1 µM 
DETC 1 h prior to 
IR - no wash 
Radiosensitisation 
Surviving 
fraction 
Evans RG et. 
(1982)183 
No Yes DETC 1 mM Simultaneous Radiosensitisation 
Surviving 
fraction 
Stone D et al. 
(1978)188 
No Yes DETC 2.4 mM DETC 1 h after IR Radiosensitisation Haemolysis 
Stone D et al. 
(1978)188 
No Yes DETC 2.4 mM 
DETC 1 h prior to 
IR - no wash 
Radiosensitisation Haemolysis 
Westman G et 
al. (1980)189 
No Yes DETC 3 mM 
DETC 1 h prior to 
IR - wash 
Radiosensitisation 
Surviving 
fraction 
Table 4 The conflicting literature on the modification of the radiation effect by DSF and DETC 
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1.2.13.1 The mixed disulphide theory 
Thiol groups are major constituents of cellular proteins. They are readily oxidised to form 
disulphide bridges. According to the mixed disulphide theory, thiol-containing compounds 
(R1-SH) exist in a mixed disulphide state with the target cellular thiol (R2-SH): 
 
R1-SH + R2-SH  R1-S-S-R2 (mixed disulphide) (1) 
 
Being already oxidised, the mixed disulphide confers radioprotection to the target cellular 
thiol from the oxidising effect of IR190. Many thiol-containing compounds, including DSF 
and its metabolite DETC, have been studied for their radioprotective properties in the 
search for a compound that would protect workers in the radiation industry and the armed 
forces180,191. The mixed disulphide must be a transient and reversible complex in order to 
avoid toxicity in case of the target cellular thiol being involved in vital cellular processes. 
Thus, the timing and scheduling of administration of the thiol-containing compound 
simultaneously with or around the time of irradiation is critical in order to achieve optimal 
radioprotection. 
 
The mixed disulphide theory also offers an explanation for the radiosensitising effect of 
thiol-containing compounds. The glutathione system is responsible for the redox 
homeostasis of the cell by cycling between GSH and GSSG. Therefore, thiol-containing 
compounds may form a mixed disulphide with GSH: 
 
GSH + R2-SH  GS-S-R2  (2) 
 
In this context, the GSH pool would be diminished, making the cell more susceptible to 
oxidative stress from IR. The mixed disulphide theory offers an explanation for both the 
radiosensitisation and radioprotection conferred by DSF and its derivatives (Table 4).  
 
1.2.13.2 Radioprotection 
DSF and its metabolic derivatives, including DETC, were screened for their ability to alter 
the lethal effect of X-rays in mice180. It has been found that all tested compounds, but not 
DSF, had radioprotective properties. This is surprising because DSF is metabolised to two 
DETC molecules and DETC was found to be radioprotective. However, unlike the other 
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compounds, the administration of DSF was intraorally in arachis oil, which, according to 
the author, caused diarrhoea thus limiting absorption of DSF into the body180. 
 
Another study reported that Sprague-Dawley rats died within 14 to 44 days after a tail vein 
injection of 1.45 MBq/kg of 210Po whereas they died within 36 to 93 days after the same 
210Po treatment but co-administered with 120 mg/kg of DETC184. DETC also partially 
restored blood and bone marrow cell count. The radioprotective mechanism of DETC was 
argued to be due to chelation of 210Po to facilitate its excretion184. 
 
Other mechanisms of radioprotection by DSF or its derivatives have been demonstrated in 
two studies. The yeast Saccharomyces cerevisiae was investigated, cultured either in its 
aerobic or anaerobic state. Radioprotective properties of DSF were observed in the aerobic 
cultures but not in the anaerobic ones, suggesting that scavenging of radiation-induced 
ROS is the mechanism by which DSF protects from the lethal effect of radiation181. By 
extrapolation, one can consider anaerobic cultures to resemble hypoxic tumours, which 
rely on glycolysis for energy production, and aerobic cultures to mimic non-malignant 
cells. If oxygen level is lower in the tumour than in normal tissue, radioprotection by DSF 
could only be achieved in healthy non-malignant tissues. 
 
Interestingly, others have reported the reduction of radiation-induced lipid peroxidation 
and DNA damage in vivo by DSF185 and the protection of bone marrow colony forming 
units in vivo following irradiation192.  
 
1.2.13.3 Radiosensitisation 
In a study involving erythrocytes, DETC was shown to enhance radiation-induced 
haemolysis which was likely due to inhibition of SOD and subsequent elevation of ROS 
levels188. This result have been supported by two subsequent reports187,189. These data are 
in striking opposition to radioprotection due to scavenging of ROS by DSF181. 
 
Interestingly, a study reported that, when non-cancerous cells in the plateau phase of 
growth were irradiated and immediately thereafter exposed to 1 mM of DETC, an 
enhanced kill compared with radiation alone was detected183. This effect was not observed 
when the same scheduling and dosing of DETC and radiation were applied to cells 
maintained in Hank’s balanced salt solution (HBSS) as opposed to Eagle’s minimum 
essential medium complemented with foetal calf serum (FCS)183. One may conclude that 
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complemented medium contains an agent that confers upon DETC the ability to enhance 
radiation-induced cell kill. 
 
1.2.13.4 All about scheduling? 
In the study comparing the radiomodifying effect of DETC in cells maintained in 
complemented culture medium compared with cells maintained in HBSS183, DETC was 
shown to have radioprotective properties if the cells were exposed to DETC for 1 hour 
prior to irradiation and a radiosensitising effect if the cells were exposed to DETC at the 
same time as irradiation183, suggesting that scheduling was critical. However, in a separate 
study, it has also been shown that cells exposed to DETC 1 h prior to irradiation or 1 h 
after irradiation were both radiosensitised188. One possible explanation for these 
contradictory results is that non-dividing Chinese Hamster HA-1 fibroblasts were used in 
the first study whereas human erythrocytes were used in the second. Erythrocytes transport 
oxygen and thus rely to a greater extent on ROS detoxifying enzymes, such as SOD, than 
the HA-1 cells to protect themselves from the oxidising effect of radiation. This would 
make erythrocytes more susceptible to SOD inhibition due to DETC and explain the potent 
radiosensitising effect of both schedules. In the first study, the radioprotective effect of 
DETC (the cells were exposed to DETC 1 h prior to irradiation) was in line with the theory 
that constituents of the cells are protected from the oxidative effect of radiation by mixed 
disulphide formation. In the simultaneous treatment, DETC may not have had time to bind 
cellular thiols therefore failing to protect against radiation. Pre-incubation with DETC was 
required for radioprotection whereas radiosensitisation occurred instantly (the 
simultaneous exposure to radiation and DETC was radiosensitising). This implies that the 
radioprotective mechanism of DETC is a slower mechanism than its radiosensitising effect. 
 
Among the in vivo studies listed in Table 4, DETC given 0.5 to 1 h prior to irradiation 
provided radioprotection185,186,193 whereas DETC given 2 to 4 h prior to irradiation 
afforded radiosensitisation186. The longer pre-incubation period before irradiation resulted 
in radiosensitisation whereas the shorter pre-incubation period resulted in radioprotection, 
which was contradictory to the in vitro findings described in the previous paragraph. These 
results demonstrated the added complication of in vivo scheduling of radiosensitisers with 
radiation. For optimal combination therapy, the time taken for the radiosensitiser to 
penetrate the tumour must be taken into account in order to achieve maximal intratumoural 
activation/inhibition of the radiosensitising target at the time of tumour irradiation. 
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Likewise, in the case of targeted radiotherapy, knowledge about the time taken for the 
radiopharmaceutical to reach the tumour must be taken in account. The effect of DETC on 
the survival of rats following injection of the radionuclide 210Po (1.45 MBq/kg) has been 
evaluated184. The schedule for optimal DETC-induced radioprotection is dependent on 
210Po pharmacodynamics. For example, absorbed 210Po remains in the body with a half-
time of over 100 days194. Thus, in the study evaluating the effect of DETC on the survival 
or rat following administration of 210Po, tissues were exposed to 210Po irradiation for over 
100 days. DETC peak plasma concentration occurs 10 h after a single oral dose161. DETC 
was given ten times over 2 weeks after 210Po administration. Therefore, DETC was bound 
to tissues during at least the first two weeks during which tissues were exposed to 
irradiation from 210Po, conferring radioprotection during this period. 
 
1.2.14 Conclusion 
Despite its use as an alcohol deterrent for the past 60 years, the biological effects of DSF 
are still not completely understood. The multiplicity of targets inhibited by DSF and 
overexpressed in cancer cells (Section 1.2.9) makes DSF an attractive anti-cancer option. 
The scavenging of ROS and the reduction of peroxidised lipids were shown to confer upon 
DSF and its derivatives antioxidant properties whereas the reduction of the glutathione 
pool, the inhibition of SOD-mediated removal of ROS, the inhibition of NF-κB activation 
and the deposition of Cu were shown to confer upon DSF and its derivatives oxidising 
properties (Table 2). Of the studies listed in Table 4, DETC was shown to be a 
radioprotector and a radiosensitiser whereas DSF was shown to have no effect or to be 
radioprotective. There was no association between pro-oxidative or anti-oxidative 
properties of DSF or DETC with radiosensitisation or radioprotection, respectively. 
Strikingly, the demonstration of radioprotection by DSF via scavenging of ROS181 was in 
sharp contrast to the radiosensitisation by DETC via inhibition of SOD and subsequent rise 
of ROS188. The studies listed in Table 4 are heterogeneous with respect to the dose range of 
DSF or DETC used (0.1 µM to 2.4 mM), the use of different schedules of combination 
treatment with radiation and the endpoint investigated. There was no trend found between 
these parameters and the observation of radiosensitisation or radioprotection. This 
indicated the existence of other determinants of the radiomodifying property of DSF and 
its derivatives, such as the amount of Cu present, the status of NF-κB, P-gp expression, 
SOD activity or glutathione levels. 
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2 Thesis aims 
 
- to investigate the dependence on Cu of DSF toxicity 
- to investigate alternative determinants of the radiomodifying properties of DSF 
- to quantify the radiomodifying properties of DSF in cellular monolayers following 
external beam irradiation 
- to quantify the radiomodifying properties of DSF in multicellular tumour spheroids 
following exposure to [131I]mIBG or [131I]MIP-1095 
- to determine a mechanism explaining the radiomodifying properties of DSF 
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3 The Cu-dependent toxicity of DSF to tumour cells grown as 
monolayers. 
3.1 Introduction 
3.1.1 The cytotoxic activity of DSF is imperfectly understood 
DSF targets multiple molecular entities that are essential for the survival and the 
proliferation of cancer cells, notably the proteasome and NF-κB121,129,195. The proteasome 
is involved in many biological pathways including antigen presentation196, survival, 
progression through the cell cycle and apoptosis197,198. NF-kB is a stress sensor which, 
upon activation, drives the transcription of antioxidant and of anti-apoptotic genes199,200. 
The inhibition of the proteasome/NF-κB axis was hypothesised to confer upon DSF pro-
oxidative and pro-apoptotic properties201-203. Another cancer-related target of DSF is 
superoxide dismutase (SOD) whose inhibition also results in increased oxidative 
stress117,204. By virtue of its disulphide bridge, DSF interacts with the glutathione system, 
thereby altering the antioxidant defences of the tumour cell120. The pro-oxidative effect of 
DSF is mediated by the inhibition of multiple targets (the glutathione system, SOD, NF-
κB) resulting in the reduction of cell viability and cell death205. However, the 
concentration-dependent cytotoxicity of DSF is not well understood. It has been 
demonstrated that DSF-induced cell kill follows a reverse N-shape relationship with 
increasing concentration in vitro206. Explicitly, DSF induced cell kill at low concentration 
followed by a reversal of cytotoxicity at higher concentration and a further increase in DSF 
concentration resulted in a second phase of cell kill. This biphasic response profile cannot 
be explained by conventional pharmacological laws stipulating that a particular effect 
follows a linear, hyperbolic or sigmoidal relationship with increasing dose. 
 
It has been hypothesised that the biphasic response profile might be due to the multiplicity 
of disulfiram targets but this hypothesis was not tested206. According to this hypothesis, the 
inhibition of one particular molecular target (target 1) by DSF would lead to cell kill at low 
concentrations and the inhibition of a second particular target (target 2) would lead to a 
second cell kill at high concentrations. The IC50 value of mechanism 1 (IC50-1) should be 
lower than the IC50 value of mechanism 2 (IC50-2). Furthermore, in order to explain the 
reversal of cytotoxicity observed at intermediate concentrations of DSF, mechanism 2 and 
mechanism 1 should be antagonistic. As the DSF concentration increases beyond IC50-1 but 
has not yet reached IC50-2, mechanism 2 inhibits mechanism 1 resulting in a reversal of 
cytotoxicity. A further increase in DSF concentration results in cytotoxicity due to 
mechanism 2 only (Figure 7). 
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Finally, the biphasic response profile may represent an artefact of the experimental setup. 
For instance, one property of DSF is chelation of Cu205. Similarly to DSF, the majority of 
Cu-binding proteins in the human body contain thiol-rich domains that form the Cu-
binding site211. DSF chelates Cu through the interaction of its four sulphur atoms and has 
been shown to increase dramatically the cytotoxic205 and the proteasome-inhibitory effects 
of DSF121. Notably, Cu is present in the serum used to complement cell culture medium212. 
It has been demonstrated that the cytotoxicity of PDTC, a member of the dithiocarbamate 
family, increased with the serum content of the culture medium213. Since PDTC-mediated 
cytotoxicity was prevented when dialysed serum was used, the authors concluded that 
cytotoxicity was due to a protein. However, since Cu binds to proteins and is rarely in its 
free ionic form in biological systems, dialysis may also have eliminated Cu from the 
serum. Since Cu increases DSF-induced cytotoxicity, the Cu concentration must be 
carefully monitored in all experiments involving DSF. Accordingly, serum-free culture 
medium was used in the ensuing investigation of the cytotoxicity of DSF in Cu-controlled 
conditions. 
 
3.1.2 The importance of defining the concentration-effect relationship of DSF on the 
basis of pharmacological laws. 
The work in the following chapters will focus on the cytotoxic effect of the combination of 
DSF with γ-radiation. In order to analyse the effect of a combination treatment, one has to 
understand the interaction between the single agents used in the combination. Combination 
analyses are more extensively explained in the next chapters. For now, suffice to say that 
the analysis of a combination treatment depends on the application of a mathematical 
model, the median effect principle, which is built from pharmacological laws that describe 
the concentration-effect relationship of the single agents214. Particularly, the dose-effect 
relationship is described by two parameters: the concentration reducing the effect by 50% 
(IC50) and the coefficient of sigmoidicity m of the concentration-effect relationship. DSF-
induced cytotoxicity does not follow a classical concentration-effect relationship, as 
indicated by the biphasic response profile. Therefore the evaluation of the interaction 
between DSF and radiation is not amenable to combination analyses which require a 
monotonic response to dose escalation. The experimental work of this chapter will 
determine the effect of equimolar concentrations of DSF and Cu (DSF:Cu). It will be also 
be shown that the median effect principle can describe DSF:Cu-induced cytotoxicity. 
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3.2 Aims 
The aims of this chapter are: 
- determination of the involvement of Cu in the biphasic response profile of DSF. 
- determination in vitro of the parameters IC50 and m of the concentration-effect 
relationship of DSF and DSF:Cu in SK-N-BE(2c) and UVW/NAT cells 
 
3.3 Materials and methods 
3.3.1 Cell culture 
The cell lines SK-N-BE(2c) (neuroblastoma) and LNCaP (prostate carcinoma) were 
purchased from the American Tissue Culture Collection (ATCC). SK-N-BE(2c) cells were 
grown in Dulbecco’s modified essential medium (DMEM) media supplemented with 15% 
(v/v) FCS (Autogen Bioclear), 2 mM L-glutamine and 1% (v/v) non-essential amino acids. 
LNCaP cells were grown in Roswell Park Memorial Institute (RPMI) media supplemented 
with 10% (v/v) FCS (Hyclone, Fisher Scientific, UK), 4 mM L-glutamine, 10 mM HEPES, 
2.52 g/l D-glucose and 1 mM sodium pyruvate. The UVW/NAT cell line was derived from 
a human glioblastoma and obtained from the Medical Oncology Department, Beatson 
Laboratories, Glasgow215. It was previously transfected to express the NAT gene 
(UVW/NAT)92. UVW/NAT cells were grown in Modified Essential Medium (MEM) 
supplemented with 10% (v/v) FCS (Autogen Bioclear), 2 mM L-glutamine and 1 mg/ml 
geneticin for the selection of the NAT-expressing cells. All media and supplements were 
obtained from Invitrogen (Paisley, UK). 
 
SK-N-BE(2c), UVW/NAT and LNCaP monolayers were passaged twice weekly at 1:10, 
1:10 and 1:3 dilutions, respectively. Fresh cultures were thawed from liquid nitrogen stock 
at passage 30. The monolayers were incubated at 37°C in a 5% CO2 atmosphere. 
 
3.3.2 Drugs and drugs treatments 
The following nomenclature for DSF and Cu complexes will be adopted in this thesis: 
- DSF refers to the molecule of DSF without addition of copper 
- DETC refers to the molecule of dithiocarbamate obtained by reduction of the 
disulphide bridge of DSF 
- DSF:Cu refers to the Cu-chelated form of DSF obtained by mixing equimolar 
concentrations of DSF and Cu 
- DETC2:Cu refers to the Cu-chelated form of DETC obtained by mixing DETC and 
Cu in a 2 to 1 molar ratio of DETC to Cu 
- Cu[DETC]2 is the commercial form of Cu-chelated DSF. 
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It is important to note that the chemical formulae of DSF:Cu, DETC2:Cu and Cu[DETC]2 
are similar. 
 
All treatments were carried out using cells in exponential growth. DSF and DETC were 
dissolved in 100% dimethyl sulfoxide (DMSO). DSF, DETC and DSF:Cu treatments were 
carried out in culture media for 24 h at 37°C and 5% CO2. The concentration of DMSO 
was kept constant at 0.1% (v/v) in all treatments. When indicated, the Cu chelator 
bathocuproine disulfonate (BCPD) or the radical mop NAC were added along with DSF. 
Cu, in the form of chloride salt, was dissolved in water before addition to the culture 
medium. Serum-free culture medium was used in the cases where the concentration of Cu 
required to be controlled. Untreated controls with serum-free culture medium were always 
included. After 24 h of treatment, the cells were washed three times in phosphate-buffered 
saline (PBS) in order to remove the drugs. DMSO, DSF, DETC, Cu, BCPD and NAC were 
obtained from Sigma-Aldrich (Dorset, UK). The DSF tablets Antabuse were obtained from 
Actavis, Denmark, and Cu[DETC]2 was obtained from Tokyo Chemical Industry. 
 
3.3.3 Viability assay 
The reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) to formazan 
by mitochondrial reductases was assessed as described previously216. Cells were seeded in 
96-well plates (Iwaki, Japan) at 37°C and 5% CO2. Once in exponential growth, 200 µl of 
fresh medium containing drugs was added. After 24 h incubation, the drug-containing 
medium was removed and replaced by fresh, drug-free medium. Then 50 µl of a 5 mg/ml 
MTT solution (Sigma-Aldrich, Dorset, UK) was added for 4 h in the dark and at 37°C. The 
medium containing MTT was then removed and formazan was solubilised with DMSO. 
Cell viability is proportional to the absorbance of formazan at 570 nm. The 
spectrophotometer Emax precision microplate reader (Molecular devices, US) was used to 
measure formazan absorbance at 570 nm. 
 
3.3.4 Clonogenic assay 
After drug treatments, the cells were trypsinised and counted using a haemocytometer. For 
every treatment, cells were seeded in triplicate dishes (Nunclon, Roskilde, Denmark) in 4 
ml fresh medium. Preliminary experiments indicated that the appropriate cell number to 
seed per dish was 250 for UVW/NAT and 600 for SK-N-BE(2c). The number of cells to 
seed per dish was chosen experimentally to yield the maximal number colonies without 
overlapping. The plating efficiencies were 70.55 ± 4.64% and 32.98 ± 2.40% for 
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UVW/NAT and SK-N-BE(2c), respectively. The colonies were allowed to grow for up to 
14 days at 37°C and 5% CO2. The medium was then removed; the colonies were washed in 
PBS and fixed in 50% (v/v) methanol in PBS. Methanol was removed after 10 min and the 
dishes were allowed to dry. The colonies were stained with a 0.1% (v/v) crystal violet 
(Sigma-Aldrich, Dorset, UK) for 10 min and rinsed with tap water. Colonies containing 
more than 50 cells were then counted by eye. The surviving fractions were calculated for 
each treatment by dividing the number of colonies derived from treated cultures by the 
number of colonies of the untreated control. Three independent experiments were 
performed for every cell line. 
 
3.3.5 The median effect principle 
The median effect principle217 is a mathematical model describing the relationship between 
a dose D of an agent and its associated effect fa/fu: 
 
fa/fu = (D / IC50)m  (3) 
 
where fa is the fraction affected by the dose D, fu is the fraction unaffected by a dose D ( 
fu = 1 – fa), IC50 is the dose which inhibits 50% of the effect and m is the coefficient 
describing the shape of the dose-effect relationship, where m = 1, m > 1, and m < 1 
indicate hyperbolic, sigmoidal, and flat sigmoidal dose-effect curves, respectively 214. 
 
The logarithmic form of equation (3) converts it into a linear form “y = mx + b”: 
 
log fa/fu = m log D - m log IC50 (4) 
 
A linear regression using the method of least squares applied to equation (4) allows the 
determination of the slope m and of the y-intercept b (b = - m log IC50). The IC50 can then 
be calculated using: 
 
IC50 = 10 - b/m  (5) 
 
The accuracy of the calculation of the IC50 and m depends on the degree of fitness of the 
linear transformation of the data obtained after the method of least squares has been 
applied to equation (4). The degree of fitness is measured by the coefficient of 
determination R2. R2 values higher than 0.9 were accepted214. 
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3.3.6 Absorbance measurement 
The absorbance profiles of DSF, DETC, Cu, DSF:Cu and Cu[DETC]2 were obtained using 
a UV/VIS spectrophotometer Lambda 25 (Perkin Elmer). Each compound or mixture was 
dissolved in 1 ml DMSO and the absorbance profiles were obtained for wavelengths 
ranging from 200 to 600 nm.  
 
In subsequent experiments, the absorbance at 438 nm was measured in 200 µl DMSO 
using an Emax precision microplate reader (Molecular devices, US). When the absorbance 
of DSF:Cu was measured intracellularly, 100% (v/v) DMSO was added onto the cells in 
order to solubilise DSF:Cu. For the experiments carried out in the presence of a reducing 
agent, ascorbic acid (Asc ac) was also dissolved in DMSO. 
 
3.3.7 Proteasome assay 
Chymotrypsin-like proteasomal activity was measured using Proteasome-Glo™ 
Chymotrypsin-Like, Trypsin-Like and Caspase-Like Cell-based Assay kit (Promega, US). 
Exponentially growing cells were treated in 96-well plates with equimolar concentrations 
of DSF and Cu for 8 h at 37°C and 5% CO2. The known proteasome inhibitor bortezomib 
was used as a positive control. Exponentially growing cells were treated in 96-well plates 
with bortezomib for 2 h at 37°C and 5% CO2. The cells were washed with PBS and 
resuspended in 100 µl of PBS. One hundred µl of the manufacturer’s buffer containing 
luciferase and the proteasome substrate Suc-LLVY-luciferin was then added to the cells. 
Proteasomal cleavage released aminoluciferin which can then be used as a substrate by 
luciferase. Luciferase released a luminescent signal which was a measure of proteasomal 
activity. Luminescence was measured using a Lmax luminometer (Molecular Devices, 
US). 
 
3.3.8 Fluorescence-activated cell sorting (FACS) analysis of the cell cycle 
Proliferating cells can be categorised by virtue of their DNA content. Cells that have 
undergone mitosis but have not yet started to replicate their DNA contain N amount of 
DNA. This is the G0/G1 population. Cells that have replicated their DNA but not yet 
undergone mitosis contain 2N amount of DNA. This is the G2/M population. Cells 
containing between N and 2N amount of DNA are in the DNA replicating phase called S. 
The fluorescent DNA-binding molecule propidium iodide (PI) can be used to determine the 
cell cycle profile of a population of cells based on DNA content218. The cells were treated 
with DSF:Cu and harvested by trypsinisation after 1, 2, 4, 8, 12 and 24 h. The cells were 
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washed and fixed in a dH2O solution containing 70% (v/v) ethanol for at least 24 h at -
20°C. Ethanol was washed off and the cells were suspended in PBS containing 20 µg/ml of 
PI and 200 µg/ml of RNAse A for 2 h at room temperature in the dark. The cell cycle 
profile was obtained by FACS analysis using FACSCalibur (BD Biosciences, Mountain 
View, CA). The data were acquired using BD CellQuest Pro software (BD Biosciences, 
Mountain View, CA). A minimum of 10,000 cells was acquired for each sample. The 
percentage of cells in each phase of the cell cycle (G0/G1, S and G2/M) was obtained 
using the analysis software FlowJo (BD Biosciences, Mountain View, CA). An example of 
the analysis and gating on cell populations of interest using FlowJo is shown in the 
appendix (Figure 80). 
 
3.3.9 Statistical analysis 
The independent samples t-test was used to compare the means of two groups. The 
assumption of equal variance was tested using Levene’s test. All statistical tests were 
carried out using SPSS v.19 (IBM). If the p-value was greater than 0.05, the difference was 
not considered statistically significant. 
 
3.4 Results 
3.4.1 The biphasic response profile of DSF 
The biphasic response profile of DSF was compared with that of Antabuse (clinical version 
of DSF in the form of tablets) in SK-N-BE(2c) cells. Serum-complemented culture 
medium was used. DSF and Antabuse induced similar biphasic response profiles. The first 
clonogenic cell kill, ranging from 55% for DSF and 75% for Antabuse, was observed at 1.7 
µM. The reversal of cytotoxicity peaked at 10 µM. A further increase in DSF or Antabuse 
concentrations yielded a 70% clonogenic cell kill at 16.9 µM (Figure 8a). 
 
The clonogenic cell kill at low and high concentrations of DSF may represent two different 
mechanisms reflecting the multiple targets inhibited by DSF. BCPD, a Cu chelator, and the 
antioxidant NAC were used to assess the involvement of Cu and the involvement of 
oxidative stress in the DSF-induced clonogenic cell kill, respectively. BCPD (300 µM) 
prevented the clonogenic cell kill at DSF concentration less than 3.4 µM, implicating a Cu-
dependent mechanism of cytotoxicity at these low DSF concentrations. On the other hand, 
NAC prevented the clonogenic cell kill at concentrations of DSF higher than 10.1 µM, 
implicating a pro-oxidative mechanism of cytotoxicity at the higher DSF concentrations 
(Figure 8b). These observations are consistent with Cu-dependent, DSF-induced 
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The absorbance profiles of DMSO solutions containing Cu[DETC]2 (a), DETC, Cu and DETC2:Cu (b) were 
analysed at wavelengths ranging from 200 to 600 nm. (c) The relationship between the absorbance and the 
molar concentration of Cu[DETC]2 is shown. 
 
When DETC was mixed with Cu in a 2:1 molar ratio, a single peak appeared at 438 nm. 
DMSO, DETC and Cu alone did not result in a peak absorbance at or near to 438 nm. The 
wavelength (438 nm) of the absorbance peak obtained after mixing 200 µM DETC with 
100 µM Cu (Figure 11b) was similar to that obtained by 100 µM of the commercially 
available Cu-chelated form of DSF Cu[DETC]2 (437 nm) (Figure 11a). This suggested the 
formation of DETC2:Cu after mixing DETC and Cu in DMSO (Figure 11b). Thus, it is 
possible to monitor the formation of the Cu-chelated form of DSF by measuring 
absorbance. The wavelength 438 nm was chosen in all subsequent experiments. 
 
When equimolar concentrations of DSF and Cu were mixed in DMSO (100 µM), there was 
no absorbance measured at 438 nm, indicative of no formation of DSF:Cu. However, 
formation of DSF:Cu was observed in the presence of 10 mM of the reducing agent Asc ac 
(p < 0.001) (Figure 12a). These data indicated that the disulphide bridge in the DSF 
molecule needs to be reduced into two DETC molecules in order to be able to chelate Cu 
and form DSF:Cu. Importantly, commercial Cu[DETC]2 was not affected by Asc ac 
(Figure 12b). 
 
Since the cytotoxicity of DSF and DETC depends on ratios of DSF or DETC to the relative 
concentration of Cu, the stoichiometry of the formation of DSF:Cu and DETC2:Cu was 
investigated. Two molecules of DETC or one molecule of DSF and one molecule of Cu 
were required for the maximal formation of DETC2:Cu and DSF:Cu, respectively (Figure 
13a). No significant increase in the formation of DETC2:Cu was achieved by increasing the 
molar ratio of DETC relative to Cu beyond 2:1 (Figure 13a). In the case of the mixture of 
DSF and Cu, one mole of DSF and one mole of Cu were required for the maximal 
formation of DSF:Cu. The DSF:Cu absorbance was not significantly modified by further 
increase, beyond equimolarity, in the concentration of DSF relative to that of Cu (Figure 
13b). Formation of DSF:Cu was increased by Asc ac (Figure 13b). This experiment 
demonstrated that a molar excess of DSF and DETC relative to Cu did not alter the 
structure of the compound formed. Therefore, the reversal of cytotoxicity observed by 
MTT assay in the presence of an excess molar concentration of DSF or DETC relative to 
Cu (Figure 9 and Figure 10) could not be explained by alteration of the Cu-chelation 
process. 
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is 10 µM (Figure 11c). 
in these experiments. When monolayers were exposed to equimolar concentrations of DSF 
and Cu, DSF:Cu was formed in the cytosol (
significant only in UVW/NAT compared with the untreated control (p < 0.05). If no cell 
was present, there was no formation of DSF:Cu, indica
efficiently washed off from the flasks before solubilising DSF:Cu. 
was used as a negative control.
Due to the low Kd value of BCPD it was 
BCPD would compete with DSF
DSF:Cu in the cytosol, 
concentrations of BCPD and DSF 
into the cytosol. Thus the inhibition of DSF
medium. It further suggest
the chelation of Cu by DSF
chelate Cu and form DSF:Cu
relative to Cu on the formation of DETC
 in the presence or in the absence of 10 m
The independent samples t
ns indicates non-significance (p > 0.05). 
 in the cytosol of UVW/NAT and SK-N-
. It was anticipated that the 
over, the lower detection limit of DSF:Cu absorbance 
Therefore, a high concentration of DSF and Cu
Figure 14a, Figure 14
ting that DSF and Cu 
 The Kd value of BCPD was estimated to be 10
anticipated that equimolar concentrations of 
 for the binding to Cu. BCPD inhibited the formation of 
demonstrating the competition for Cu binding 
(Figure 14a and Figure 14b). BCPD does not penetrate 
:Cu formation by BCPD 
ed that there is a reducing agent in the culture medium allowing 
. Indeed, it was shown that DSF require
 (Figure 12a). 
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b). The formation was 
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The Cu chelator BCPD 
-19.8
 M220. 
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occured in the culture 
d Asc ac in order to 
  
Figure 14 DSF:Cu is present in cells exposed to DSF and Cu
UVW/NAT (a) and SK-N
free culture medium in the presence or in the absence of 1 mM of the Cu chelator 
min, the monolayers were washed to remove DSF, Cu or BCPD remaining in the culture medium. The cell 
pellets were then dissolved in 100 ml of DMSO. The absorbance was measured at 
SEM; n=3. The independent samples t
control unless otherwise indicated. 
0.05 compared to untreated control.
 
3.4.4 The determination of the dose
in the absence of Cu
A decrease in MTT absorbance signal may be due to cell death, lower proliferation rate or 
increased senescence. The MTT assay is 
On the other hand, the clonogenic assay assesses the abi
form a colony comprising more than 50 cells
Since it was shown that equimolar concentrations of DSF and Cu form the cytotoxic 
compound DSF:Cu (Figure 
investigated using the clonogenic assay. UVW/NAT and SK
to measure the parameters m and IC
behaviour of DSF:Cu as indicated in 
were therefore excluded from this analysis. In the presence of equimolar concentrations of 
DSF and Cu, the IC50
UVW/NAT cells (Figure 
DSF:Cu were calculated based on the median effect plots (
the absence of Cu, the IC
23.61 µM in UVW/NAT cells (
 
-BE(2c) (b) monolayers were exposed to 1 mM of DSF with 1 mM of Cu in serum
-test was used to compare the mean absorbance values to that of the 
ns indicates non-significant (p > 0.05) and one symbol
 
-response relationship of 
 
an approximate measurement of 
lity of a single cell
, i.e. the ability to proliferate indefinitely.
12a), the concentration-effect relationship of DSF:Cu was 
-N-BE(2c) cell lines were used 
50 using the median effect principle describing the 
Section 3.3.5. LNCaP cells did not form colonies and 
 was 0.32 µM in SK-N-BE(2c) cells (Figure 
15b). The parameters of the concentration
Figure 15
50 for DSF was 16.50 µM in SK-N-BE(2c) cells (
Figure 16b). The parameters of the concentration
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BCPD for 30 min. After 30 
438 nm. Data are mean ± 
 (*) indicates p < 
DSF in the presence or 
cellular viability. 
, a clonogen, to 
 
15a) and 0.28 µM in 
-effect relationship of 
c and Figure 15d). In 
Figure 16a) and 
-effect 
 relationship of DSF were calculated based on the median effect plots (
Figure 16d). 
 
Figure 15 The effect of equimolar concentrations of DSF and Cu 
of SK-N-BE(2c) and UVW/NAT
SK-N-BE(2c) (a, c) and UVW/NAT (b
24 h in serum-free culture medium. The cells were washed with PBS and clonogenic assay was performed. 
Data are mean ± SEM; n=3. 
log IC50 where fa is the fraction
clonogens, and m is the coefficient of the sigmoidicity of the concentration
was performed to calculate 
 
 
(DSF:Cu) 
 cells 
, d) cells were exposed to equimolar concentrations of DSF and Cu for 
(c, d) The median effect plots were constructed using log 
 of clonogens affected by the treatment, fu is the unaffected fraction
-effect curve. Linear regression 
m (the slope) and IC50 = 10-intercept/m. 
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Figure 16c and 
 
on the clonogenic capacity 
fa/fu = m log D – m 
 of 
 Figure 16 The effect of DSF alone on the clonogenic capacity of SK
SK-N-BE(2c) (a, c) and UVW/NAT cells (b
Cu for 24 h in serum-free culture medium. The cells were washed with PBS and clonogenic assay was 
performed. Data are mean ± SEM; n=3. 
log D – m log IC50 where 
the sigmoidicity of the concentration
and IC50 = 10-intercept/m. 
 
3.4.5 Proteasome activity 
The proteasome inhibitory activity 
1 µM121,221. Since it was s
15), the proteasome inhibitory property of DSF
in LNCaP, SK-N-BE(2c) and UVW/NAT cells
proteasome inhibition to cell 
50% of the proteasome activity of the untreated control were 1.42, 4.99 and 7.48 
LNCaP, SK-N-BE(2c) and UVW/NAT
that 1 µM DSF:Cu induce
inhibited only 0.02-36.1% 
mechanism responsible for cell kill
-N-BE(2c) and UVW/NAT
, d) cells were exposed to various concentrations of DSF without 
(c, d) The median effect plots were constructed using log 
fa is the affected fraction, fu is the unaffected fraction, and 
-effect curve. Linear regression was performed to calculate 
 
of DSF:Cu in vitro requires concentrations in excess of 
hown that DSF:Cu is cytotoxic at concentrations <
:Cu was investigated at 
 to determine the contribution of 
kill (Figure 17a). The concentrations of DSF:Cu inhibiting 
 cells, respectively (Figure 
d 75-90% kill in the three cell lines examined
of the proteasome activity (Figure 17c). This indicate
, at DSF:Cu concentrations lower than 1 
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fa/fu = m 
m is the coefficient of 
m (the slope) 
 1 µM (Figure 
these concentrations 
µM in 
17c). It is noteworthy 
 (Figure 9) but 
d that the 
µM, is unlikely 
 to be proteasome inhibition.
included as a positive control for proteasome inhibition
concentrations inhibiting 
LNCaP, SK-N-BE(2c) and UVW/NAT, respectively (
values are within the range of the average bortezomib concentration 
growth by 50% (7 nM) in a panel of sixty cancer cell lines
induced cytotoxicity may
mechanism of action made no more than a minor contribution to DSF:Cu
cytotoxicity. 
 
 
Figure 17 The effect of DSF:Cu 
LNCaP, SK-N-BE(2c) and 
(a) The cells were exposed to various equimolar concentrations of DSF and Cu for 8 h in serum
medium. After washing, a buffer containing luci
cells and luminescence was measured
to compare the mean absorbance value of the DSF:Cu
every cell line. One symbol indicates p < 0
0.001. (b) The median effect plot of protea
R2 and the y-intercept) and the calculated percentage inhibition of the proteasome based on the median effect 
equation are shown. 
 
 The well-established proteasome inhibitor bortezomib was 
 (Figure 18
50% of the proteasome activity were 10.81, 3.11 and 3.43 
Figure 18c).
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. Ther
 be explained by inhibition of the proteasome whereas 
on the chymotrypsin-like catalytic activity of the proteasome in 
UVW/NAT cells 
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-treated groups with the respective untreat
.05; two symbols indicate p < 0.01 and three symbols indicate p < 
some inhibition. (c) The concentration
80
). The bortezomib 
µM in 
 Significantly, these 
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-free culture 
 samples t-test was used 
ed control for 
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 Figure 18 The effect of bortezomib on the chymotrypsin
LNCaP, SK-N-BE(2c) and 
(a) The cells were exposed to various concentrations of bortezomib for 2 h in serum
After washing, a buffer containing luciferase and the aminoluciferin substrate were applied to the cell
luminescence was measured
compare the mean absorbance value of the bortezomib
for every cell line. One symbol indicates p < 0.05
0.001. (b) The median effect plot of proteasome inhibition is presented. 
parameters (m, IC50, R2 and the y
on the median effect equation are shown
 
3.4.6 Cell cycle 
The effect of 5 µM DSF on the cell cycle has previously been investigated
showed that DSF induced a decrease in the 
population and an increase of the Sub
activity is an important modulator of cell cycle
found not to be the major
(Figure 17), it was hypo
cycle profile. To determine the legitimacy of this conjecture
LNCaP, SK-N-BE(2c) and UVW/NAT were acquired 1, 2, 4, 8, 12 and 24 h following 
treatment with 0.3 and 1 
 
-like catalytic activity of the proteasome in 
UVW/NAT cells 
. Data are mean ± SEM; n=3. The independent samples
-treated groups with their respective untreated control 
; two symbols indicate p < 0.01
(c) The concentration
-intercept) and the calculated percentage inhibition of the proteasome based 
.  
G0/G1 population, an increase in the S 
-G1 population indicative of apoptosis
 progression223. Since the proteasome 
 target for DSF:Cu cytotoxicity at concentrations less than 1 
thesised that concentrations up to 1 µM would not affect the cell 
, the cell cycle profiles of 
µM DSF:Cu. 
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UVW/NAT cells throughout
of DSF:Cu (Figure 19
change in the distribution of LNCaP, SK
phases of the cell cycle up to 24 h (
cells were killed by 12 h of exposure to equimolar concentrations of DSF and Cu.
Therefore the investigation of the cell cycle in LNCaP cells 24 h 
DSF:Cu was impossible becau
 
Figure 19 The effect of DSF:Cu
(a, b and c) The cells were exposed to 
medium for 12 h. (d, e and f)
1, 2, 4, 8, 12 and 24 h in serum
10000 propidium iodide–stained 
the amount of DNA [N (G0/G1
G0/G1, S and G2/M were measured using the software FlowJo (
are mean ± SEM; n=3. 
 
3.5 Discussion and summary of
For most drugs, the relationship between concentration and effect is linear, hyperbolic or 
sigmoidal. In contrast, the response of several cancer cell 
doses of DSF has been 
change in the distribution of LNCaP, SK
 the phases of the cell cycle after 12 h exposure to 0.3 or 1 
a, Figure 19b and Figure 19c). Furthermore, t
-N-BE(2c) or UVW/NAT cells 
Figure 19a, Figure 19b and Figure 
following 
se no adherent cell was recovered. 
 on the distribution of cells throughout the phases of the cell cycle
equimolar concentrations of DSF and Cu (
 The cells were exposed to equimolar concentrations of DSF and Cu (1 
-free culture medium. Cell cycle profiles were obtained by FACS analysis of 
cells. The assignment of a cell into a phase of the cell cycle was based on 
), 2N (G2/M) or more than N but less than 2N (S)]. 
BD Biosciences, Mountain View, CA
 the results 
lines to treatment with a range of 
described by a biphasic response profile206, for which t
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results offer an explanation. Clonogenic cell kill resulting from exposure to DSF 
concentrations less than or equal to 3.4 µM in serum-complemented medium was inhibited 
by the Cu chelator BCPD (Figure 8b), demonstrating the dependency on Cu for DSF-
mediated cytotoxicity at low dosage. The cell culture media DMEM, MEM and RPMI 
contain no Cu supplementation. However, the FCS used to complement the culture media 
contained approximately 15 µM of Cu212,224-226. Therefore, the Cu concentration in the 
medium used for the culture of SK-N-BE(2c) cells, which comprised 15% serum, was 2.25 
µM. This was close to the concentration of DSF (1.6 µM) which induced maximal, Cu-
dependent, clonogenic cell kill. 
 
The investigation of the Cu-dependence of the cytotoxicity of DSF in serum-free culture 
medium revealed that Cu reduced the IC50 concentration of DSF 80-fold and 50-fold in 
UVW/NAT and SK-N-BE(2c) cell lines, respectively (Figure 15 and Figure 16). 
Moreover, DSF-induced cytotoxicity was dependent on the ratio of DSF to Cu. The 
clonogenic survival nadir was observed when DSF and Cu were present in equimolar 
amounts. This was a reflection of the 1:1 ratio of DSF and Cu required for chelation to 
generate DSF:Cu. Similarly, significant cytotoxicity occurred when DETC (two molecules 
of which produce DSF under oxidising conditions) and Cu were mixed in a 2:1 molar ratio. 
Two molecules of DETC plus one molecule of Cu yielded one molecule of DETC2:Cu. 
Therefore it was the Cu-chelated form of DETC and the Cu-chelated form of DSF that 
were cytotoxic at concentrations less than or equal to 3.4 µM in serum-complemented 
culture medium. However, it has to be acknowledged that in the investigation of the 
dependency on the ratio of DETC to Cu for cytotoxicity in LNCaP and UVW/NAT cells, 
the cytotoxicity was greater when equimolar concentrations of DETC and Cu were mixed 
together (Figure 10b). This suggested that DETC:Cu is also formed and is as cytotoxic as 
DETC2:Cu. 
 
A hypothesis that explained the biphasic response profile of DSF in serum-complemented 
culture medium was shown in Figure 7. It was hypothesised that DSF was cytotoxic via 
two independent and antagonistic mechanisms (1 and 2) with two distinct potencies (IC50-1 
and IC50-2) (Figure 7). Since DSF-cytotoxicity at low dosage was inhibited by the Cu 
chelator BCPD and DSF-cytotoxicity at higher dosage was inhibited by the antioxidant 
NAC, the two mechanisms hypothesis seemed plausible. The results presented in this 
chapter suggested that mechanism 1 is mediated by Cu (Figure 8b), which conferred upon 
DSF the ability to inhibit a cellular target more potently than DSF alone. The addition of 
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Cu reduced the IC50 value of DSF 80-fold and 50-fold in UVW/NAT and SK-N-BE(2c) 
cells lines, respectively (Figure 15 and Figure 16). The Cu atom may confer a planar 
structure upon DSF132 thereby facilitating intercalation between planar molecules (such as 
aromatic side-chains of amino acids [phenylalanine, tyrosine and tryptophan]) in a manner 
analogous to the integration of carcinogenic acridine dyes in DNA227. An analogy may be 
drawn with the anti-cancer drug elesclomol that induces apoptosis in cancer cells by 
elevating the levels of intracellular reactive oxygen species (ROS)228. The chelation of Cu 
by elesclomol is necessary for its pro-oxidative and pro-apoptotic effects. It has been 
shown that the target of the elesclomol-Cu complex is the mitochondria, in which the 
redox cycling of Cu(II) to Cu(I) results in ROS production113. Interestingly, the chelation 
of Cu by elesclomol created a compound characterised by tetra-coordinated trapezoid 
planar geometry (Figure 20)229. In the light of the effect of Cu on the structure of 
elesclomol, the results presented in this chapter suggested that Cu may induce similar 
conformational constraints on the DSF molecule resulting in a planar structure. In turn, the 
Cu-dependent planar structure of DSF could confer increased affinity for a particular 
target, thus leading to greater cytotoxic potency of DSF:Cu compared with DSF as 
indicated by the 50- to 80-fold decrease in the IC50 concentration of DSF:Cu compared to 
DSF (Figure 15 and Figure 16). 
 
 
Figure 20 The planar structure of the elesclomol:Cu complex, adapted from Lianming Wu et al. 
(2011)229 
Blue, nitrogen (N) atoms; yellow, sulphur (S) atoms; pink, copper (Cu) atom; red, oxygen atoms; grey, 
carbon atoms; white, hydrogen atoms. 
 
Secondly, the ratios of DSF or DETC to Cu influenced the cytotoxicity. There was a 
progressive reversal of cytotoxicity when DSF or DETC was present in molar excess 
relative to Cu (Figure 9 and Figure 10). This phenomenon suggested competition between 
DSF and DSF:Cu for an intracellular site whose integrity is necessary for cell survival. The 
hypothesis that Cu confers upon DSF a conformational change in its chemical structure 
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thereby leading to higher potency offered an explanation for the competitive nature of the 
reversal of DSF:Cu-mediated cytotoxicity by DSF. The concentration of DSF must be 
greater than the concentration of DSF:Cu in order to displace DSF:Cu from its cellular 
targets because DSF:Cu has more affinity for the target than DSF. Importantly, excess 
concentration of DSF or DETC to Cu did not reduce the chelation of Cu by DSF (Figure 
13b) nor DETC (Figure 13a), discounting the possibility that prevention of kill by excess 
molar ratio of DSF to Cu was due to the reduced formation of DSF:Cu. Thus, the results 
suggested that competition of DSF with DSF:Cu explained the recovery phase of the 
biphasic response profile of DSF shown in Figure 8a.  
 
Finally, in SK-N-BE(2c) cells, the last phase of the biphasic response profile at DSF 
concentrations greater than 10 µM was explained by a second cytotoxic mechanism, for 
which the IC50 was 16.50 µM (Figure 16a). The inhibition of DSF cytotoxicity by the 
antioxidant NAC suggested that DSF was cytotoxic at these doses via the generation of an 
oxidative stress. Therefore, these results are not entirely consistent with the hypothesis 
stated in Figure 7. The more potent mechanism 1 is brought about by the conformational 
change conferred upon DSF by Cu. The mechanism 2 is the generation of oxidative stress 
by DSF alone. However, the hypothesis stated that mechanism 2 (the generation of an 
oxidative stress) must antagonise mechanism 1 (Cu-mediated) resulting in a reversal of 
cytotoxicity. The question whether the generation of an oxidative stress inhibits the Cu-
mediated cytotoxicity of mechanism 1 remains unanswered and constitutes a follow-up 
project. Instead, it was speculated that the reversal of cytotoxicity was triggered by the 
competition between DSF and DSF:Cu for the binding to an intracellular target. 
 
Cu-dependent DSF cytotoxicity, as opposed to the cell kill mediated by oxidative stress 
(Figure 8), is of therapeutic interest for two reasons. Firstly, it has been determined that an 
oral dose of 250 mg of DSF results in a peak plasma concentration of 1 µM (0.3 µg/ml or 1 
µM)161. A daily oral dose of 250 mg is a routine regimen in the treatment of alcoholics. 
The IC50 concentrations of DSF:Cu in SK-N-BE(2c) and UVW/NAT cells are 0.32 and 
0.28 µM (Figure 15and Figure 16), respectively. These values are within the range of the 
low dose kill observed in many other cancer cell lines206 and are lower than the peak 
plasma concentration of DSF in patients161. For the future use of DSF in the treatment of 
cancer, firstly it is important to demonstrate efficacy at plasma concentrations that can be 
achieved in patients. Secondly, DSF has side effects such as vomiting, drowsiness, loss of 
coordination and loss of consciousness. Therefore it is important to use the lowest possible 
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therapeutic dose, especially if administered in combination with other therapeutic 
modalities. 
 
An alternative theory for the mode of action of DSF may be as a Cu ionophore114,205. It has 
been argued that the resulting Cu overload in the cytosol is responsible for the inhibition of 
multiple targets, including the proteasome121. Under appropriate intracellular redox 
conditions, Cu could be released by DSF resulting in various cytotoxic effects. Similarly, 
elesclomol has been shown to chelate Cu in the extracellular space, transport Cu into the 
cytosol as an elesclomol-Cu complex, deposit Cu inside the mitochondria, then efflux from 
the cytosol into the extracellular space in order to chelate more Cu and start another cycle 
of transmembrane Cu transport113. However, the detection of DSF:Cu in lysed cells (Figure 
14) suggests that DSF acts not solely as a Cu ionophore. DSF:Cu may also exist in its 
complexed form in the cytosol and have a cytotoxic effect in its own right. The reversal of 
cytotoxicity observed when DSF is in molar excess relative to DSF:Cu suggests 
competition between the two entities. The competition for the same target implies that 
DSF:Cu has an effect of its own and does not act merely as a Cu ionophore. Therefore both 
Cu on its own and the complex formed with DSF may play a role in DSF:Cu-induced 
cytotoxicity. 
 
The cytotoxicity of DSF:Cu was compared with that of DSF. The coefficient of 
sigmoidicity m was approximately 1 for DSF:Cu (Figure 15) and 4 for DSF (Figure 16), 
indicative of hyperbolic and sigmoidal dose-response relationships, respectively. A 
hyperbolic curve indicates a steeper increase in cytotoxicity at low concentrations whereas 
the increase in the effect slows down at higher concentrations. On the other hand, a 
sigmoidal curve indicates a slow increase in cytotoxicity at low and high concentrations 
(shoulders in the curve) whereas there is a steep increase in cytotoxicity at intermediate 
concentrations. For instance, a 10% kill is achieved at lower concentrations of a drug with 
a hyperbolic concentration-effect relationship than a drug with a sigmoidal concentration-
effect relationship. This is consistent with the hypothesis that Cu stabilises the 3-D 
structure of DSF in a fixed plan, making the DSF molecule less free to rotate around its 
disulphide bridge. Therefore, the stabilised DSF:Cu molecule has more affinity for its 
target and is more cytotoxic, consistent with the observations that Cu lowers the IC50 of 
DSF and switches the shape of the curve from sigmoidal to hyperbolic. 
 
A wide range of DSF concentrations (10-2 to 102 µM) has been shown to inhibit the 
proteasome in several cell lines195,221. However, in SK-N-BE(2c), UVW/NAT and LNCaP 
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cells, DSF:Cu did not inhibit the proteasome at concentrations that are therapeutically 
relevant (0.3 µg/ml – equivalent to 1 µM) (Figure 17). Furthermore, the distribution of 
cells through the different phases of the cell cycle was unaffected by DSF:Cu. In contrast, 
the proteasome inhibitory properties of bortezomib can explain its toxicity in cells (Figure 
18) and it was shown that bortezomib induced a cell cycle arrest at the transition between 
the G2 phase and mitosis230. Therefore, it was concluded that DSF:Cu-induced cytotoxicity 
at concentrations less than 1 µM was not due to inhibition of the proteasome in SK-N-
BE(2c), UVW/NAT and LNCaP cells. The cytotoxic mechanism of DSF:Cu remains not 
well understood. 
 
The fact that DSF competes with DSF:Cu for intracellular targets means that if DSF is in 
molar excess relative to Cu in the tumour, a tumouricidal effect may not be achieved. The 
plasma concentration of Cu is in the range 10 to 20 µM224,226,231,232 and Cu is mostly bound 
to proteins such as ceruloplasmin and albumin. The Kd values characterising the binding of 
Cu to ceruloplasmin and albumin are 10-17 and 10-11 M, respectively233. It has been shown 
that a concentration of 5 µM of DSF alone had little effect on the cell cycle but DSF in 
combination with ceruloplasmin, added as a source of Cu, was able to induce dramatic 
changes in the distribution of cells through the cell cycle109. It has also been shown that 
DSF and DETC bind to albumin in the plasma234. These reports suggest that DSF may bind 
Cu in the plasma through direct binding to albumin and, perhaps, ceruloplasmin. 
Furthermore, Cu is a co-factor of many cellular enzymes. Therefore tumours are enriched 
in Cu due to their high metabolic demand84. The affinity of DSF for Cu may represent a 
tumour-targeting mechanism by which DSF:Cu may form preferentially in the tumour so 
that DSF:Cu may always be in excess compared with DSF in the tumour. 
 
The biphasic response profile of DSF was explained and classical hyperbolic 
concentration-effect curves of DSF:Cu were obtained for SK-N-BE(2c) (Figure 15) and 
UVW/NAT cells (Figure 16). The IC50 and m parameters were determined, allowing the 
analysis of the interaction between DSF:Cu and radiation in the next chapter. 
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4 The radiosensitising effect of DSF:Cu 
4.1 Introduction 
DSF and its metabolite DETC are known radiation modifiers (Table 4). Both 
enhancement183,186-189 of and protection from the effect of radiation180,181,184,185,193 have 
been reported using a variety of endpoints. The demonstration of radiosensitisation by 
DETC in serum-complemented culture medium but not in Hank’s Balanced Salt Solution 
(HBSS)183 (Section 1.2.13.3) is significant because DETC requires Cu for cytotoxicity 
(Figure 10). HBSS contains salts such as magnesium, sodium, potassium and chloride but 
does not contain Cu. Conversely, the serum used to complement culture medium contains 
approximately 15 µM Cu212,224-226. Since the presence of Cu is important for the DETC-
mediated cytotoxicity (Figure 10), it is hypothesized that the lack of Cu in HBSS was the 
reason for the absence of a radiosensitising effect. Therefore, the first aim of this chapter is 
to investigate the effect of Cu on the putative radiosensitising effect DSF. 
 
The IC50 concentrations of DSF:Cu in SK-N-BE(2c) and UVW/NAT cells are 0.32 and 
0.28 µM, respectively (Figure 15). These concentrations are clinically relevant. The peak 
plasma concentration of DSF achieved after ingestion of 250 mg dose is 1 µM161. Among 
the ten studies, listed in Table 4, which have investigated the radiomodifying effect of DSF 
or DETC in vitro, only two have examined clinically relevant concentrations - 0.1 µM 
DETC187 and 0.337 µM DSF182. Therefore, the second aim of this chapter is to investigate 
the putative radiosensitising effect of DSF:Cu in the human neuroblastoma cell line SK-N-
BE(2c) and the human glioma cell line UVW/NAT at clinically applicable levels. The 
concentrations of DSF:Cu or DSF used in combination with γ-radiation are based on the 
results depicted previously showing the dependency of clonogenic cell kill on dose of 
DSF:Cu and DSF administered as single agents (Figure 15 and Figure 16). 
 
4.1.1 Assessing the efficacy of the combination of drugs with radiation 
There are several ways of analysing the effect of a combination of a drug with radiation. 
One method uses the linear-quadratic model to assess the effect of a range of radiation 
doses on cultured cells in the presence of the radiomodifier compared with the effect of 
radiation alone235. Secondly, the nature of the interaction of two agents in combination can 
be assessed by either the isobologram method98 or the combination index method of 
synergy analysis217. 
 
 4.1.2 The linear-quadratic model
A radiosensitiser is defined 
alone82. Radiosensitisation
required for cell survival after irradiation, increased formation of radicals or inhibition of 
DNA repair82. All of these mechanisms result in a leftward shift of the radiation survival 
curve (Figure 21). 
 
Figure 21 The effect of a radiosensitiser on the survival of clonogens following radiation treatment
The surviving fraction is the frac
the number of clonogens forming colonies in the unirradiated control. In this example, 6.8 Gy radiation alone 
induced a 90% clonogenic cell kill whereas only 4.4 Gy was required to induce a similar kill in the presence 
of 10 µM of a radiosensitiser. The leftward shift demonstrating radiosensitisation at the 90% level of 
clonogenic cell kill is indicated by the red arrow. The dose enhancement factor (DEF) was 6.8/4.4 = 1.55.
 
The linear-quadratic model describes the effect of radiation
mathematical relationship between radiation dose and cell survival define
components of cell killing. The linear component, defined by the initial slope 
radiation survival curve
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be lethal than single strand breaks. This is manifest as a greater decrease in clonogenic 
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quantify the leftward shift of the radiation survival curve in the presence of a 
radiomodifier. The dose enhancement factor (DEF) measures the percentage reduction in a 
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radiation dose that can be delivered in the presence of a radiosensitiser that results in the 
same clonogenic kill as radiation alone (Figure 21).  
 
4.1.3 Isobologram and combination index methods of synergy analysis 
The use of the linear-quadratic model enables the designation of a drug as a radiosensitiser 
if it enhances radiation kill compared with that achieved by radiation alone. Therefore, the 
dose enhancement factor, calculated according to the linear-quadratic model, only 
measures the effect of one component (e.g. a radiomodifier) of the combination on the 
other agent (i.e. radiation). However, the effect of a combination treatment results from the 
effect of agent A on the cytotoxicity induced by agent B and from the effect of agent B on 
the cytotoxicity induced by agent A. The dose enhancement factor is not a measure of the 
interaction of two agents in a combination. Several methods have been used to analyse the 
response of cells to combination treatment214. The most widely used are the isobologram98 
and the combination index217 methods of synergy analysis. Both methods define the 
concept of additivity and compare the effect of the combination to a theoretical additive 
interaction between the two agents of the combination. The theoretical additive effect is 
calculated based on the concentration-effect relationships of each single agent. A 
combination treatment may be infra-additive, additive or supra-additive if the combined 
effect is less than, equal to or greater than the expected addition of the effects of each 
agent, respectively. The quantification of radiosensitisation using the dose enhancement 
factor calculated from the leftward shift of the radiation survival curve does not give 
information concerning the nature of the radiosensitising effect (additive versus supra -
additive). There is not a defined threshold value of the dose enhancement factor beyond 
which radiosensitisation no longer results from a simple additive effect but results from a 
supra-additive effect. 
 
A synergistic combination has therapeutic advantages over an additive combination. 
Synergism means that the doses of both components of the combination can be reduced 
and still be as (or more) cytotoxic in combination with each other. Consequently, the 
reduction of the doses of each agent will reduce side-effects, leading to an improvement of 
the patient’s quality of life. A purely additive combination may still be of therapeutic 
interest due to the increase in tumour cell toxicity compared to each agent alone, especially 
if the combination does not increase toxicity in normal tissue98. Therefore, the in vitro 
determination of the additive or the supra-additive nature of the radiosensitising effect 
allows the prediction of a combination treatment which could induce less clinical side-
effects while retaining its efficacy. 
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This chapter is concerned with the determination of the nature of the interaction between 
DSF:Cu or DSF and γ-radiation using the clonogenic assay. It will be shown that DSF:Cu 
and DSF are both radiosensitisers. The interactions between DSF:Cu or DSF and γ-
radiation were synergistic, additive or antagonistic depending on the level of toxicity 
induced by the combined treatments. 
 
4.2 Aims 
- determination of the requirement of Cu for the radiomodifying properties of DSF 
- determination of the radiomodifying effects of DSF:Cu and DSF in the human cell 
lines SK-N-BE(2c) (neuroblastoma) and UVW/NAT (glioma) at clinically relevant 
concentrations 
- analysis of the interaction between DSF:Cu or DSF and γ-radiation 
 
4.3 Materials and methods 
4.3.1 Tissue culture 
See Section 3.3.1. 
 
4.3.2 γ-radiation treatment 
The cells were irradiated using an external beam irradiator containing a 60Co source 
(Alcyon II Teletherapy Unit). The flasks containing the cells were covered using a 0.8 cm 
perspex plate to ensure maximal energy deposition. The dose rate was approximately 1 
Gy/min. 
 
4.3.3 Clonogenic assay 
See section 3.3.4. 
 
4.3.4 The linear-quadratic model 
4.3.4.1 The linear-quadratic equation 
The linear-quadratic model describes the effect of radiation on the survival of cells. The 
cell survival curve follows the mathematical equation: 
 
SF = exp (- αD - βD2)  (4) 
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in which SF is the fraction of clonogens surviving a dose D of radiation. The linear-
quadratic model assumes two components of clonogenic kill, one that is proportional to the 
dose D of γ-radiation with a coefficient α and one that is proportional to the square of D 
with a coefficient β235. GraphdPadPrism version 6.01 was used to fit clonogenic survival 
data to the linear-quadratic model and to calculate α and β values. 
 
4.3.4.2 Calculation of the IC50 
Equations (5) and (6) are two versions of the logarithmic transformation of equation (1): 
 
ln SF = - αD - βD2 (5) 
 
0 = - αD - βD2 - ln SF (6) 
 
The resolution of a quadratic equation is based on the calculation of its determinant ∆236: 
 
∆ = α2 - 4βln SF (7) 
 
If ∆ < 0, there is no solution to equation (6), if ∆ ≥ 0, the two solutions D1 and D2 to 
equation (6) are given by: 
 
D1 = (- α + √∆) / 2β (8) and 
D2 = (- α - √∆) / 2β (9) 
 
As the surviving fraction cannot increase with increasing radiation dose, the values α and β 
are positive values according to equation (4). Furthermore, the surviving fraction is always 
a value between 0 and 1. Therefore ln SF is negative. From these observations, it follows 
that 4βln SF is always a negative value. Therefore, for all possible surviving fraction 
values, ∆ is always greater than 0 according to equation (7). Because ∆ > 0 and a dose 
cannot be negative, the unique solution of equation (6) is given by: 
 
D = [- α + √(α2 - 4βln SF)] / 2β (10) 
 
It follows that: 
 
 IC50 = [- α + √(α2 - 4βln 0.5)] / 2β  (11) 
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4.3.4.3 Calculation of DEF 
DEF is the factor by which the dose of radiation may be reduced in the presence of a drug 
to achieve the same clonogenic cell kill as would radiation treatment alone. Three levels of 
clonogenic cell kill were assessed: 25%, 50% and 75%. IC25, IC50 and IC75 were calculated 
using equation (10), by replacing SF by 0.75, 0.5 and 0.25, respectively. For each level of 
clonogenic cell kill, DEF25, DEF50 and DEF75 were calculated using: 
 
DEFx = ICx radiation alone / ICx of radiation in the presence of a drug (12) 
 
The greater the DEFx value, the smaller the radiation dose needed in the presence of a drug 
in order to induce the same clonogenic cell kill as radiation alone. 
 
4.3.4.4 Drug treatment 
SK-N-BE(2c) and UVW/NAT cells were exposed to various doses of γ-radiation in the 
absence or in the presence of various concentrations of DSF:Cu or DSF in serum-free 
medium. The doses of γ-radiation and the concentrations of DSF:Cu and DSF were chosen 
so that the maximal combination treatment intensity corresponded to a mixture of the IC50 
values of each agent. The cells were exposed to DSF:Cu or DSF and irradiated 
immediately afterward. Clonogenic assays were performed 24 h after treatment of the cells 
with DSF:Cu or DSF. 
 
4.3.5 The median effect principle 
The median effect principle is described in Section 3.3.5. The mathematical equation 
relating the dose of an agent to its effect is: 
 
 fa/fu = (D /IC50)m  (3) 
 
where fa is the fraction of clonogens affected by the dose D; fu is the fraction of clonogens 
unaffected by dose D (hence fu = 1 – fa); IC50 is the dose which inhibits 50% of the effect 
(IC50) and m is the coefficient of sigmoidicity describing the shape of the dose-effect 
relationship, where m = 1, m > 1, and m < 1 indicate hyperbolic, sigmoidal, and flat 
sigmoidal dose-effect curves, respectively214. The parameters m and the IC50 value can be 
calculated as described in Section 3.3.5. Equation (3) can be rearranged in order to 
calculate the concentration producing a given effect: 
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D = IC50 × ( fa/fu)1/m (12) 
 
4.3.6 Isobologram analysis 
Isobologram analysis was performed in order to determine the nature of the interaction 
between DSF:Cu or DSF with γ-radiation according to the method of Steel and Peckham98. 
The concept of additive interaction between two agents in a combination is based on their 
dose-response curves as single agents. There are two ways of defining additivity by the 
isobologram method: mode I and mode II. In the mode I determination of additivity, it is 
considered that there is a linear relationship between concentration of each agent and the 
effect produced, i.e. the clonogenic cell kill for any increment in concentration is constant 
for all parts of the survival curve. In the mode II determination of additivity, it is 
considered that there is a non-linear relationship between the concentration of each agent 
and the effect produced, i.e. the clonogenic cell kill for any increment in concentration 
varies throughout the survival curve98. 
 
4.3.6.1 Mode I isobologram analysis 
In mode I, both agents reduce the surviving fraction in a linear fashion. Therefore, as the 
concentration increases by a constant increment, the reduction of the surviving fraction is 
constant. In order to obtain mode I in an isobologram constructed at the 50% level of 
cytotoxicity, a series of concentrations of agent A that produce an effect up to 50% as a 
single agent are calculated using the median effect principle. The effects were 0%, 10%, 
20%, 30%, 40% and 50%. Then, concentrations of agent B are calculated so that, when 
added to the effect of agent A, they produce an overall 50% reduction in clonogenicity. For 
example, the concentration of agent A producing a 30% effect is 3 AU and the 
concentration of agent B producing a 20% effect is 0.8 AU (Figure 22a). Finally, mode I is 
constructed by plotting the pairs of concentrations of agents A and B whose combined 
effect adds up to 50% (Figure 22d). The circled diamond corresponds to the pair IC30 of 
agent A (3 AU) combined with the IC20 of agent B (0.8 AU) as calculated in Figure 22a. 
 
4.3.6.2 Mode II isobologram analysis 
In mode II, both agents reduce the surviving fraction in a non-linear fashion. Therefore, as 
the concentration increases by a constant increment, the reduction of the surviving fraction 
varies. Modes IIa and IIb assume non-linearity of the effect of agents A and B with 
increasing concentration, respectively. In order to obtain mode IIa in an isobologram 
constructed at the 50% level of effect, a series of concentrations of agent B that produces a 
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series of levels of toxicity up to 50% (0%, 10%, 20%, 30%, 40% and 50%) is calculated. 
This series of effects is then used as the initial level of cytotoxicity from which the 
increment of the concentration of agent A that produces a total level of toxicity of 50% is 
calculated (Figure 22b). For example, the concentration of agent B that produces a 20% 
cell kill is 2.2 AU and the increment concentration of agent A that allows the overall 
toxicity to increase from 20% to 50% is 1.2 AU (8 - 6.8) (Figure 22b). Finally, mode IIa is 
constructed by plotting the concentration of agent B against the increment concentration of 
agent A whose combined effect adds up to 50% (Figure 22e). The circled triangle (Figure 
22e) corresponds to the pair IC50 – IC20 of agent A (1.2 AU) combined with the IC20 of 
agent B (2.2 AU) as calculated in Figure 1b. 
 
In order to obtain mode IIb in an isobologram constructed at the 50% level of effect, a 
series of concentrations of agent A that produces a series of levels of toxicity up to 50% 
(0%, 10%, 20%, 30%, 40% and 50%) is calculated. This series of effects is then used as 
the initial level of cytotoxicity from which the increment of the concentration of agent B 
that produces a 50% effect is calculated (Figure 22c). For example, the concentration of 
agent A that produces a 20% effect is 6.8 AU and the increment concentration of agent B 
that allows the overall toxicity to increase from 20% to 50% is 1.4 AU (3.6 – 2.2) (Figure 
22c). Finally, mode IIb is constructed by plotting the increment concentration of agent B 
against the concentration of agent A whose combined effect adds up to 50% (Figure 22e). 
The circled square (Figure 22e) corresponds to the pair IC20 of agent A (6.8 AU) combined 
with the IC50 - IC20 of agent B (1.4 AU) as calculated in Figure 1c. 
 
 Figure 22 The determination of additivity by mode I, IIa and IIb in the construction of an isobologram 
at the 50% level of cytotoxicity
The example given for the construction of modes I (a), IIa (b) and IIb (c) is a combination of the 
concentration of one agent that pr
30% effect. (d) Mode I defines the line of additivity. (e) Modes IIa and IIb define the envelope of additivity.
 
4.3.6.3 Determination and interpretation of the isoeffect points
The following method describes the determination of the isoeffect points at the 50% level 
of toxicity. Firstly, the surviving fractions are plotted against the concentrations of agent A 
in the absence and in the presence of 4 different concentrations of agent B. The 
concentrations of agent A producing a 50% effect (IC
AU of agent B are calculated using the median effect principle (
example, they are 6.34, 4.85, 3.83 and 2.68 AU, respectively (
AU of agent A in combination with 2 AU
clonogenicity. The pairs of AU values (6.34
coordinates of four isoeffect points at the 50% level of cytotoxicity (
the analogous procedure is performed to determine the effect of agent B on the survival 
fraction in the absence and in the presence of 4 different concentrations of agent A (
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Figure 23 Determination of isoeffect points
(a) The effect of agent A on the survival fraction in the absence and in the presence of 4 concentrations of 
agent B. (b) The effect of agent B on the survival fraction in the absence and in the presence of 4 
concentrations of agent A. The median effect pr
particular effect of agent A in the presence of various concentrations of agent B, and, 
in the presence of various concentrations of agent A. The effect of 50% is chosen in t
isobologram constructed at the 50% level of cytotoxicity.
 
The isoeffect points generated from the combinations of agent A and B are then plotted 
onto the isobologram chart, as shown in 
the envelope of additivity, the response is supra
the envelope of additivity, the response is additive. If t
the envelope of additivity but within the square of the doses of the single agents producing 
the same effect, the response is infra
the response is protectiv
, 12.68), (5, 9.69), (7, 7.66) and (9, 5.36) are the coordinates of four 
Figure 23b). 
 
inciple is used to calculate the concentration producing a 
 
Figure 24. If the isoeffect points lie to the left of 
-additive. If the isoeffect points lie within 
he isoeffect points lie to the right of 
-additive. If the isoeffect points lie outside that square, 
e (Figure 24). 
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Figure 24 The significance of plotted isoeffect points relative to the envelope of additivity
 
4.3.6.4 Drug treatment
Isobologram analysis was performed on the data set obtained for the evaluation of the 
combination of DSF:Cu or DSF with 
Methodology is described in Section 
 
4.3.7 Combination index analysis
4.3.7.1 Combination index analysis
Combination index analysis was performed according to the method of Chou and 
Talalay217. In this method, the doses of each agent with
given level of cytotoxicity
cytotoxicity as single agents. The median effect equation 
parameters m and IC50
3.3.5. Knowing m and IC
dose D corresponding to a given effect using
 
D = IC50 × (fa/fu)1/m 
 
in which fa is the fraction of clonogens affected by a dose 
of clonogens, IC50 is the dose required to reduce the effect by 50% and m is 
of sigmoidicity describing the shape of the dose
and m < 1 indicate hyperbolic, sigmoidal, and flat sigmoidal dose
respectively214. 
 
 
 
γ-radiation using the linear-quadratic model. 
4.3.4.4. 
 
 
in the combination that produce
 are compared with those producing the same level of 
is used to calculate the 
 of the single agents and the combinations as described in 
50, the median effect equation could be rearranged to calculate a 
 equation (12): 
(12) 
D, fu is the unaffected fraction 
-effect relationship, 
-
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For combination treatments, the calculated dose D is the sum of the doses of each agent. 
The contribution of each agent to the combination is calculated using a constant ratio (P/Q) 
of the doses of each agent. For instance, the dose D of the combination is split into the 
concentration of agent A (DA) and the dose of agent B (DB). P is the proportion of the total 
dose D of the combination which corresponds to the concentration of agent 1, whereas Q is 
the proportion of the total dose D of the combination which corresponds to the dose of 
agent B: 
 
DA = D × P/(P+Q) (13) 
 
DB = D × Q/(P+Q) (14) 
 
The dose reduction index (DRI) was then calculated for each agent of the combination by 
dividing the dose within the combination by the dose as a single agent that induced the 
same kill: 
 
DRI = D within the combination / D as single agent (15) 
 
The combination index (CI) was the sum of the DRI of each agent of the combination: 
 
CI = DRIagent1 + DRIagent2 (16) 
 
The interpretation of the CI value for the determination of infra-additivity, additivity or 
supra-additivity is given in Table 5. 
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Table 5 The interpretation of the combination index (CI) according to Chou214 
Supra-additivity (synergy) is defined by CI values lower than 0.90, additivity is defined by CI values 
comprised between 0.90 and 1.10 and infra-additivity (antagonism) is defined by CI values greater than 1.10. 
 
4.3.7.2 Drug treatment 
The combination index method of synergy analysis was applied to a data set different from 
the one used for the analysis of radiosensitisation by the linear-quadratic method and 
analysis of synergy by the isobologram method. SK-N-BE(2c) and UVW/NAT cells were 
treated with DSF:Cu, DSF and γ-radiation as single agents and with combinations of 
DSF:Cu or DSF with γ-radiation. DSF:Cu and DSF treatments were carried out in serum-
free medium for 24 h. DSF:Cu and DSF were combined with γ-radiation in a constant ratio 
based on the IC50 concentrations of each agent. The selected combination treatment of 
highest intensity was a mixture of the 50% inhibitory concentrations of each agent (IC50). 
The altered combination treatments consisted of one-half, one-quarter and one-eighth of 
the maximum combination treatment dose214 (Table 6). 
 
Toxicity level Agent A (M) Agent B (M) 
IC0 0 0 
IC50/8 IC50-A/8 IC50-B/8 
IC50/4 IC50-A/4 IC50-B/4 
IC50/2 IC50-A/2 IC50-B/2 
IC50 IC50-A IC50-B 
Table 6 Experimental design of the combination treatment intensities in combination index analysis 
 
The IC50 values of DSF:Cu and DSF were determined previously (Figure 15 and Figure 
16). The IC50 values of γ-radiation will be described in Figure 25. SK-N-BE(2c) cells were 
treated with a ratio of 3 Gy γ-radiation to 0.3 µM DSF:Cu or 3 Gy γ-radiation to 15 µM 
DSF. UVW/NAT cells were treated with a ratio of 3 Gy γ-radiation to 0.3 µM DSF:Cu or 3 
 Gy γ-radiation to 24 µ
and irradiated immediately afterward. Clonogenic assay was performed immediately after 
the 24 h incubation period in the prese
 
4.4 Results 
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Figure 25 The effect of γ
The clonogenic survival of SK
treatment using a cobalt-60 external beam irradiator. Data are means ± SEM; n=5.
 
4.4.2 Determination of the radiosensitising effect of disulfiram using the linear
quadratic model
The effect of DSF:Cu and DSF on radiation cell kill was assessed using the clonogenic 
assay. SK-N-BE(2c) and UVW/NAT cells were irradiated with various 
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the presence and in the absence of various concentrations of DSF:Cu and DSF. The 
concentrations of DSF:Cu and DSF and the doses of γ-radiation were selected so that the 
maximum treatment intensity corresponded to the IC50 value of each modality. The linear-
quadratic equation was fitted to the data in order to calculate α, β, IC50 and DEF values at 
the 25%, 50% and 75% cytotoxicity levels. These values were then used to characterise the 
radiosensitising potency of DSF:Cu and DSF. 
 
4.4.2.1 The effect of DSF:Cu on the survival of γ-irradiated SK-N-BE(2c) clonogens  
DSF:Cu enhanced the γ-radiation-induced kill of SK-N-BE(2c) cells (Figure 26a). The IC50 
value decreased from 3.22 Gy in the absence of DSF:Cu to 0.76 Gy in the presence of 0.3 
µM DSF:Cu (Figure 26b). The DEF values of 0.3 µM DSF:Cu were 5.42, 4.24 and 3.59 at 
25, 50 and 75% cytotoxicity, respectively (Figure 26b). Moreover, the α value increased 
with increasing concentrations of DSF:Cu (Figure 26b). This indicated that DSF:Cu 
increased the proportion of γ-radiation-induced cytotoxicity caused by breakage of single 
strands of DNA. Finally, the β value increased with increasing DSF:Cu concentrations, 
indicative of the increase by DSF:Cu of the proportion of γ-radiation-induced cytotoxicity 
caused by multi-event DNA damage (Figure 26b). 
 
4.4.2.2 The effect of DSF on the survival of SK-N-BE(2c) clonogens following γ-
radiation treatment  
Similarly, DSF enhanced the γ-radiation-induced kill of SK-N-BE(2c) cells (Figure 26c). 
The IC50 value decreased from 3.04 Gy in the absence of DSF to 0.82 Gy in the presence 
of 15 µM DSF (Figure 26d). The DEF values of 15 µM DSF were 5.03, 3.72 and 3.29 at 
25, 50 and 75% clonogenic kill, respectively (Figure 26d). Moreover, the α and β values 
increased in response to γ-radiation treatment with increasing concentrations of DSF 
(Figure 26d). This indicated that DSF increased the proportion of γ-radiation-induced 
cytotoxicity caused by both single and multi-event DNA damage (Figure 26d). 
 
 Figure 26 The radiosensitising effect of DSF:Cu and DSF in SK
The clonogenic survival of SK
or in the presence of various concentrations of DSF:Cu (a) or DSF (c). The data were fitted to the linear
quadratic equation using GraphPad Prism version 6.0.1. Data are means ± SEM; n=3. The values 
DEF25, DEF50 and DEF75 
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4.4.2.4 The effect of DSF on the survival of UVW/NAT 
radiation treatment
UVW/NAT cells were also more resistant than SK
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Figure 27 The radiosensitising effect of DSF:Cu and DSF in UVW/NAT cells
The clonogenic survival of UVW/NAT cells was determined 24 
or in the presence of various concentrations of DSF:Cu (a) or DSF (c). The data were fitted with the linear
quadratic equation using GraphPad Prism version 6.0.1. The values 
calculated for DSF:Cu (b) or DSF (d) as explained in Section 
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4.4.2.5 Conclusions 
These data demonstrated that both DSF:Cu and DSF are radiosensitisers as indicated by 
the leftward shifts of their respective radiation survival curves. However, the peak plasma 
concentration after oral administration of a typical daily dose (250 mg) of DSF is 1 µM161. 
The radiosensitisation induced by DSF:Cu occurred at concentrations achievable in 
patients (0.1 to 0.3 µM) whereas the radiosensitisation induced by DSF occurred at 
concentrations greater than 5 µM. Thus, only the radiosensitisation induced by DSF:Cu is 
expected to be clinically applicable. 
 
The α and β values measure the proportion of radiation kill due to SSB and DSB, 
respectively. The observed variations in α and β values allow for the formulation of an 
hypothesis concerning the mechanism of radiosensitisation by DSF:Cu. The α value of the 
radiation kill was increased 12.2-fold and 3.9-fold when SK-N-BE(2c) and UVW/NAT 
cells, respectively, were irradiated in the presence of 0.3 µM DSF:Cu. This indicated that 
the radiosensitising mechanism of DSF:Cu is the increase of SSB incidence or the 
inhibition of repair of SSB. Furthermore, the proportion of SSB after radiation treatment in 
the presence of DSF:Cu was increased to a greater extent in SK-N-BE(2c) compared to 
UVW/NAT cells. The latter observation suggests that the SSB repair machinery was more 
efficient in UVW/NAT cells than in SK-N-BE(2c) cells. 
 
Similarly, the β value of the radiation kill was increased 4.8-fold when SK-N-BE(2c) cells 
were irradiated in the presence of 0.3 µM DSF:Cu compared with the 3-fold decrease of 
the β value observed in UVW/NAT cells. This indicates that UVW/NAT are also more 
efficient at repairing DSB than SK-N-BE(2c) cells. Furthermore, since UVW/NAT are 
more efficient at repairing SSB than SK-N-BE(2c) cells, as indicated by the smaller 
increase in the α value, fewer SSB will be converted into DSB during DNA replication. 
This is consistent with the absence of an increase in the β value after treatment of 
UVW/NAT cells with radiation in the presence of DSF:Cu. 
 
4.4.3 Determination of the nature of the radiosensitising effect of DSF:Cu and DSF 
The effect of a radiosensitiser on the response of cells to γ-radiation is the enhancement of 
γ-radiation kill compared with γ-radiation alone. DEF values are calculated as a measure of 
radiosensitisation. However, a comparison of DEF values does not enable the assignment 
of additive, supra-additive or infra-additive interactions between agents in a combination 
treatment. Moreover, the DEF values only quantify the potentiating effect of a drug on the 
 106
clonogenic cell kill of γ-radiation. The extent to which radiosensitisation results from an 
additive or a supra-additive interaction is investigated by isobologram and combination 
index methods of synergy analysis. These procedures enable the determination of the effect 
of DSF:Cu or DSF on radiation cell kill and the effect of γ-radiation on cytotoxicity 
induced by DSF:Cu or DSF. 
 
4.4.3.1 Isobologram analysis 
4.4.3.1.1 Isobologram analysis of DSF:Cu or DSF in combination with γ-radiation in 
SK-N-BE(2c) cells 
The effect of γ-radiation and DSF:Cu on the survival of SK-N-BE(2c) clonogens is shown 
in Figure 28a. The corresponding median effect plot and the parameters of the median 
effect equations are shown in Figure 28b and Figure 28c. Similarly, the effect of γ-
radiation and DSF on the clonogenic survival of SK-N-BE(2c) is shown in Figure 28d. The 
corresponding median effect plot and the parameters of the median effect equations are 
shown in Figure 28e and Figure 28f. The isobologram analysis of the combination of 
DSF:Cu or DSF with γ-radiation at 25%, 50% and 75% toxicity levels are shown in Figure 
29. 
 
At the 25% level of toxicity, one isoeffect point plotted above the envelope of additivity 
whereas the second isoeffect point plotted below, indicating synergistic or antagonistic 
interactions between DSF:Cu and γ-radiation depending on the relative contribution of 
each agent (Figure 29a). That is, when γ-radiation made a minor contribution to kill of 25% 
of clonogens, the interaction with DSF:Cu was antagonistic whereas the interaction 
between DSF:Cu and γ-radiation was synergistic when DSF:Cu made a minor contribution 
to kill of 25% (Figure 29a). At the 50% and 75% levels of toxicity, the isoeffect points, 
with one exception (Figure 29b), plotted below or within the envelope of additivity, 
demonstrating respectively supra-additive and additive interactions between DSF:Cu and 
γ-radiation depending on the relative dose of each agent (Figure 29b and Figure 29c). The 
combination of a large dose of γ-radiation with a small dose of DSF:Cu resulted in additive 
interactions. Likewise, the same result was observed following combinations of a small 
dose of γ-radiation with a large dose of DSF:Cu. 
 
 Figure 28 Median effect analysis of the combination of DSF:Cu or
BE(2c) cells 
The clonogenic survival of SK
or in the presence of various concentrations of DSF:Cu (a) or DSF (d). The corresponding median effect 
plots and parameters are shown in (b, c) and (e, f). A linear regression of the median effect equation was 
carried out as explained in Section 
the dose required to kill 50% of the clonogen
± SEM; n=3. 
 
The isobologram analysis of the combination of DSF with 
cells demonstrated an additive effect at the 25% and 50% toxicity levels, as indicated by 6 
out of 8 isoeffect points plotting within the envelope of additivity (
At the 75% level of toxicity, 5 isoeffect points out of 6 plotted below the envelope of 
additivity, demonstrating synergism (
isoeffect point corresponding to a high dose of 
concentration of DSF, lay above the envelope of additivity, demonstrating antagonism i
this particular condition.
 
 DSF with 
-N-BE(2c) cells was determined 24 h after γ-radiation treatment in the absence 
4.3.7 in order to calculate the parameters m, the y
s (IC50) and the coefficient of determination
γ-radiation in SK
Figure 29f). At the 75% level of toxicity, one 
γ-radiation combined with a low 
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γ-radiation in SK-N-
-axis intercept (y-int), 
 R2. Data are means 
-N-BE(2c) 
Figure 29d, Figure 29e). 
n 
 Figure 29 Isobologram analysis of the combination of DSF:Cu or DSF with 
cells 
The isobologram charts for the combination of DSF:Cu and 
and 75% (c) levels of toxicity. Similarly, the isobologram charts for the combination of DSF and 
are shown at the 25% (d), 50% (e) and 75% (f) levels of toxicity. If the isoeffect points lie below and to the 
left of the envelope of additivity, the combination is synergistic; if the isoeffect points lie above and to the 
right of the envelope of additivity, the combination is antagonistic; and if the isoeffect points lie within the 
envelope of additivity, the combination is additive.
 
The trend toward decreased synergy following combination treatment comprising a small 
dose of one agent with a high dose of the second agent may be explained as follows. The 
example considers an isobologram constructed at the 50% toxicity level (
design of such an experiment, the dose D1 of agent A may be selected so that the toxic 
effect of agent A alone is significantly less than 50%.
doses of agent B which could produce synergy as indicated by the red arrow (
As the selected concent
doses of agent B which could produce synergy in combination decreases as indicated by 
the blue arrow (Figure 
markedly exceeds the contribution of the second agent in a combination treatment. This 
phenomenon may have biological relevance. As the concentration of one age
γ-radiation are shown at the 25% (a),
 
 In this case, there is a wide range of 
ration of agent A is increased toward its IC
30). There is less scope for synergy as the contribution of one agent 
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γ-radiation in SK-N-BE(2c) 
 50% (b) 
γ-radiation 
Figure 30). In the 
Figure 30). 
50 value, the range of 
nt of the 
 combination increases, the dose of the second agent required to produce a combined 50% 
kill decreases. 
 
Figure 30 The effect of imbalance in the contribution of two agents on synergistic interaction
An idealised isobologram constructed at the 50% toxicity level is shown for the combination of agent A with 
agent B. Two hypothetical doses of agent A, D1 and D2, are selected such that D1 < D2 < IC
blue arrows illustrate the range of doses of agent B wh
doses D1 and D2 of agent A, respectively.
 
The doses of therapeutic agents in combination were selected so that the majority of the 
survival curves encompassed the 50% toxicity level. This design also provi
information for the determination of the corresponding combination effects at the 75% 
toxicity level. However, the selected doses were less informative at the 25% toxicity level. 
Only two or three of the resulting survival curves intersect
resulting in the construction of IC
only.  
 
4.4.3.1.2 Isobologram analysis of DSF:Cu and DSF in combination with 
in UVW/NAT cells 
The effect of γ-radiation and DSF:Cu on t
Figure 31a. The corresponding median effect plot and the parameters of the median effect 
equations are shown in 
DSF on the clonogenic survival of UVW/NAT is shown in 
median effect plot and the parameters of the median effect equations are shown in 
 
ich could produce synergy in combination with the 
 
ed the 25% toxicity level, 
25 isobologram charts with two or three isoeffect points 
he survival of UVW/NAT clonogens is shown in 
Figure 31b and Figure 31c. Similarly, the effect of 
Figure 
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50. The red and 
ded satisfactory 
γ-radiation 
γ-radiation and 
31d. The corresponding 
Figure 
 31e and Figure 31f. The isobologram analyses of the combination of DSF:Cu or DSF with 
γ-radiation at 25%, 50% and 75% toxicity levels are shown in 
 
Figure 31 Median effect analysis of the combination of DSF:Cu or DSF with 
cells 
The clonogenic survival of UVW/NAT cells was determined 24 
or in the presence of various concentrations of DSF:Cu (a) or DSF (d). The corresponding median effect 
plots are shown in (b, c) and (e, f). A linear r
explained in Section 4.3.7
required to kill 50% of the clonogens (IC
n=3. 
 
At the 25% level of toxicity, the isoeffect points lay above the envelope of additivity, 
demonstrating an antagonistic 
However, 11 isoeffect points out of 12 plotted within the envelope of additivity at the 50% 
and 75% levels of toxicity, demonstrating a predominantly additive interaction between 
DSF:Cu and γ-radiation (
 
The isobologram analysis of the combination of DSF and 
demonstrated antagonism at the 25% level of toxicity, as indicated by all isoef
lying above the envelope of additivity (
plotted below or within the envelope of additivity at 50% and 75% levels of toxicity, 
Figure 
h after γ-radiation treatments in the absence 
egression of the median effect equation was carried out as 
 in order to calculate the parameters m, the y-axis intercept 
50) and the coefficient of determination
interaction between DSF:Cu and γ-radiation (
Figure 32b and Figure 32c). 
γ-radiation in UVW/NAT cells 
Figure 32d). However, 9 out of 12 isoeffect points 
110
32. 
 
γ-radiation in UVW/NAT 
(y-int), the dose 
 R2. Data are means ± SEM; 
Figure 32a). 
fect points 
 demonstrating the mainly additive nature of the combination of DSF and 
UVW/NAT cells. 
 
Figure 32 Isobologram analysis of the combination of DSF:Cu or DSF with 
cells 
The isobologram charts for the combination of DSF:Cu and 
and 75% (c) level of toxicity. Sim
are shown at the 25% (d), 50% (e) and 75% (f) level of toxicity. If the isoeffect points lie below and to the 
left of the envelope of additivity, the combination is synergistic; if t
right of the envelope of additivity, the combination is antagonistic; and if the isoeffect points lie within the 
envelope of additivity, the combination is additive.
 
4.4.3.2 Combination index analysis
4.4.3.2.1 Combination index ana
SK-N-BE(2c) cells 
The toxicity of DSF:Cu, 
Figure 33a, Figure 33
shown in Figure 33d and the parameters of the median
33e. The CI values are shown in 
level of toxicity to 0.61 at 95% level of toxicity. Since
and 1.1 indicates additivity and a CI value less than 0.9 indicates synergism according 
γ-radiation are shown at the 25% (a), 50% (b) 
ilarly, the isobologram charts for the combination of DSF and 
he isoeffect points lie above and to the 
 
 
lysis of DSF:Cu in combination with 
γ-radiation or their combination to SK-N-
b and Figure 33c, respectively. The resultant median effect plot is 
 effect equation are given in 
Figure 33f. The CI values decreased from 1.07 at a 5% 
 a CI value comprised between 0.9 
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γ-radiation in 
 
γ-radiation in UVW/NAT 
γ-radiation 
γ-radiation in 
BE(2c) cells is shown in 
Figure 
to 
 the criteria of Chou and Talalay (
between DSF:Cu and 
additivity at toxicity levels of 15% and higher (
 
Figure 33 The combination index analysis of the combinatio
BE(2c) cells 
The clonogenic survival of SK
γ-radiation treatment (b) or 24 
Gy to 0.3 µM (c). Data are means ± SEM; n=3. The median effect plot of the single agents and the 
combination is shown in (d) and the parameters m, the y
of the clonogens (IC50) and the
combination index (CI) and intensity of treatment (level of toxicity) is shown in (f). CI values less than 0.90 
indicate synergism; CI values greater than 1.10 indicate ant
indicate additivity. 
 
4.4.3.2.2 The combination index analysis of DSF in combination with 
SK-N-BE(2c) cells  
The toxicity of DSF, 
Figure 34a, Figure 34
shown in Figure 34d and the parameters of the median effect equations are given in 
34e. The CI values are shown in 
toxicity level to 0.76 at 95% toxicity level. These data indicated antagonism between DSF 
Table 5)214, these data indicated an additive effect 
γ-radiation at toxicity levels less than 15% and increasing supr
Figure 33f). 
n of DSF:Cu with 
-N-BE(2c) cells was determined 24 h after exposure to DSF:Cu (a), 24 
h after treatment with various intensities of both 
-axis intercept (y-int), the dose required to kill 50% 
 coefficient of determination R2 are shown in (e). The relationship between 
agonism; and CI values between 0.90 and 1.10 
γ-radiation or their combination to SK-N-BE(2c) cells is shown in 
b and Figure 34c, respectively. The resultant median effect plot is 
Figure 34f. The CI values decreased from 1.20 at 5% 
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γ-radiation in SK-N-
h after 
agents in a constant ratio of 3 
γ-radiation in 
Figure 
 and γ-radiation at toxicity levels less t
15% and 60% and increasing supra
34f). 
 
Figure 34 The combination index analysis of the combination of DSF with 
cells 
The clonogenic survival of SK
radiation treatment (b) or 24 
3 Gy to 15 µM (c). Data are means ± SEM; n=3. The median effect plot of the single agents a
combination is shown in (d) and the parameters m, the y
of the clonogens (IC50) and the
combination index (CI) and intensity of treatment (level of toxicity) is shown in (f). CI values less than 0.90 
indicate synergism; CI values greater than 1.10 indicate antagonism; and CI values between 0.90 and 
indicate additivity. 
 
4.4.3.2.3 The combination index analysis of DSF:Cu in combination with 
in UVW/NAT cells  
The toxicity of DSF:Cu, 
Figure 35a, Figure 35
shown in Figure 35d and the parameters of the median effect equations are given in 
35e. The CI values are shown in 
toxicity level to 0.27 at 95% toxicity level. These data indicated antagonism bet
han 15%, additive effect at toxicity levels between 
-additivity at toxicity levels of 60% and higher (
γ
-N-BE(2c) cells was determined 24 h after exposure to DSF (a), 24 
h after treatment with various intensities of both modalities in a constant ratio of 
-axis intercept (y-int), the dose required to kill 50% 
 coefficient of determination R2 are shown in (e). The relationship between 
γ-radiation or their combination to UVW/NAT cells is shown in 
b and Figure 35c, respectively. The resultant median effect plot is 
Figure 35f. The CI values decreased from 2.78 at 5% 
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Figure 
 
-radiation in SK-N-BE(2c) 
h after γ-
nd the 
1.10 
γ-radiation 
Figure 
ween 
 DSF:Cu and γ-radiation at toxicity levels less than 25%, additivity at toxicity levels 
between 25% and 35% and increasing supra
(Figure 35f). 
 
Figure 35 The combination index analysis of the combination of DSF:Cu with 
UVW/NAT cells 
The clonogenic survival of UVW/NAT cells was determined 24 
radiation treatment (b) or 24 
3 Gy to 0.3 µM (c). Data are means ± SEM; n=3. The median effect plot of the single agents and th
combination is shown in (d) and the parameters m, the y
of the clonogens (IC50) and the
combination index (CI) and intensity 
indicate synergism; CI values greater than 1.10 indicate antagonism; and CI values between 0.90 and 1.10 
indicate additivity. 
 
4.4.3.2.4 The combination index analysis of DSF in combination w
UVW/NAT cells 
The toxicity of DSF, 
Figure 36a, Figure 36
Figure 16d and the parameters of the median effect equations are given in 
CI values are shown in 
to 0.93 at 95% toxicity level. These data indicated antagonism between DSF and 
-additivity at toxicity levels of 35% and higher 
h after exposure to DSF:Cu (a), 24 
h after treatment with various intensities of both modalities in a constant ratio of 
-axis intercept (y-int), the dose required to kill 50% 
 coefficient of determination R2 are shown in (e). The relationship between 
of treatment (level of toxicity) is shown in (f). CI values less than 0.90 
γ-radiation or their combination to UVW/NAT cells is shown in 
b and Figure 36c, respectively. The median effect plot is shown in 
Figure 36f. The CI values decreased from 1.93 at 5% toxicity level 
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γ-radiation in 
h after γ-
e 
ith γ-radiation in 
Figure 36e. The 
γ-
 radiation at toxicity levels less than 70% and an additive effect at toxicity levels of 70% 
and higher (Figure 36
 
Figure 36 The combination index analysis of the combination of DSF with 
cells 
The clonogenic survival of UVW/NAT cells was determined 24 
radiation treatment (b) or 24 
3 Gy to 24 µM ratio (c). The combination dose is the dimensionless sum of the dose of 
concentration of DSF. Data
combination is shown in (d) and the parameters m, the y
of the clonogens (IC50) and the
combination index (CI) and intensity of treatment (level of toxicity) is shown in (f). CI values less than 0.90 
indicate synergism; CI values greater than 1.10 indicate antagonism; and CI values between 0.90 and 
indicate additivity. 
 
4.4.3.3 Conclusions
The data from the isobologram analyses demonstrate the supra
combination of DSF:Cu and 
levels. Similarly, DSF without Cu supplementation 
toxicity levels. UVW/NAT cells were more resistant than SK
radiosensitising effect of DSF:Cu or DSF. In UVW/NAT cells, the combination of DSF:Cu 
or DSF with γ-radiation sterilised clonogens in an
toxicity levels. 
f). 
γ
h after exposure to DSF (a), 24 
h after treatment with various intensities of both modalities in a constant ratio of 
 are means ± SEM; n=3. The median effect plot of the single agents and the 
-axis intercept (y-int), the dose required to kill 50% 
 coefficient of determination R2 are shown in (e). The relationship between 
 
-additive nature of the 
γ-radiation in SK-N-BE(2c) cells at 50% and 75% toxicity 
synergised with 
-N-BE(2c) cells to the 
 additive fashion 
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-radiation in UVW/NAT 
h after γ-
γ-radiation and the 
1.10 
γ-radiation at the 75% 
at 50% and 75% 
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The results from the combination index analyses demonstrated that supra-additivity 
between DSF:Cu and γ-radiation occurred at toxicity levels greater than 15% and 35% in 
SK-N-BE(2c) and UVW/NAT cells, respectively. Combinations of DSF with γ-radiation 
were less effective than those of DSF:Cu with γ-radiation, as indicated by CI values, in the 
presence of DSF, greater than those obtained in the presence of DSF:Cu at similar levels of 
toxicity. Overall, UVW/NAT cells were more resistant than SK-N-BE(2c) cells, manifest 
by greater CI values, to the combination of either DSF:Cu or DSF with γ-radiation. 
 
4.5 Discussion 
It was demonstrated that DSF:Cu and DSF are both radiosensitisers, as indicated by the 
leftward shift of the radiation survival curve in the presence of DSF:Cu or DSF compared 
to the radiation curve after radiation treatment alone (Figure 26 and Figure 27). Moreover, 
DSF:Cu and DSF increased the cytotoxicity of γ-radiation in a dose-dependent manner. For 
instance, the DEF50 values were 1.18, 2.76 and 4.24 following treatment of SK-N-BE(2c) 
with γ-radiation in the presence of 0.1, 0.2 and 0.3 µM DSF:Cu, respectively (Figure 26b). 
Following treatment of SK-N-BE(2c) cells with γ-radiation in the presence of 5, 10 and 15 
µM DSF, the DEF50 values were 1.35, 2.59 and 3.72, respectively (Figure 26d). Similarly, 
the DEF50 values were 1.00, 1.38 and 2.00 following treatment of UVW/NAT with γ-
radiation in the presence of 0.1, 0.2 and 0.3 µM DSF:Cu, respectively (Figure 27b). 
Following treatment of UVW/NAT cells with γ-radiation in the presence of 8, 16 and 24 
µM DSF, the DEF50 values were 1.38, 1.90 and 2.17, respectively (Figure 27d). Similar 
increases in the DEF values were obtained at the 25% and 75% kill in both cell lines and 
for both DSF:Cu and DSF (Figure 26 and Figure 27). The classical method of displaying 
the effect of radiation modifiers (linear-quadratic evaluation of γ-radiation survival curves 
in the absence and in the presence of a drug) is not complete because it only measures the 
effect of a drug on the radiation survival curve. The reciprocal effect, the effect of radiation 
on the cytotoxicity of the drug, is ignored. The cytotoxic effect of a combination results 
from the mutual interaction of both agents which may be infra-additive, additive or supra-
additive. The interaction of two agents in combination is more thoroughly examined by the 
isobologram and combination index methods of synergy analysis rather than by the 
quantification of the leftward shift of the radiation survival curve. With respect to 
therapeutic application, the demonstration of supra-additivity over additivity has 
implications for the control of side-effects and normal tissue toxicity. The administration 
of DSF has been associated with vomiting, drowsiness, loss of coordination and loss of 
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consciousness173 whereas radiotherapy may have side effects such as fatigue, skin changes, 
diarrhoea, xerostomia and haematotoxicity. Therefore, synergistic interaction between DSF 
and radiotherapy is expected to result in the delivery of reduced dose with concomitant 
improvement of the quality of life of cancer patients. 
 
The isobologram and combination index methods of synergy analyses have been 
developed to determine supra- or infra-additivity when both agents of the combination 
have an effect of their own214. In these methods, the effect (potency and the shape of the 
dose-response curve) of each single agent is measured and taken into account in order to 
construct the theoretical additive effect of the combination (the envelope of additivity in 
the case of the isobologram and CI = 1 in the case of the combination index analysis). The 
observed experimental effect of the combination is then compared with the theoretical 
additive effect. Both methods were used to analyse the interaction between DSF:Cu or 
DSF with γ-radiation. There was an overall agreement between the two methods: both 
demonstrated greater synergism between γ-radiation and DSF:Cu or DSF at increasing 
intensity of treatment. Specifically, the CI values decreased with increasing levels of 
toxicity and the isobologram showed a trend from infra-additive or additive interaction at 
the 25% level of toxicity to additive or supra-additive interaction at the 75% level of 
toxicity (Table 7). Furthermore, both the isobologram and the combination index analyses 
indicated that the combinations of DSF:Cu or DSF with γ-radiation were more effective in 
SK-N-BE(2c) than UVW/NAT cells. The CI values were on average higher for 
UVW/NAT than for SK-N-BE(2c) cell and the isobologram analysis demonstrated that 
either DSF:Cu or DSF in combination with γ-radiation induced additive responses in 
UVW/NAT cells at toxicity levels which corresponded to supra-additivity in SK-N-BE(2c) 
cells (Table 7). 
 
 Table 7 Comparison between DEF, isobologram analysis and combination index analysis for the 
evaluation of the interaction between DSF:Cu or DSF with 
This table summarises the data from 
γ-radiation dose that can be applied, in the presence of 0.3 
radiation alone. In the case of isobologram analysis, if the majority of isoeffect points 
of additivity, the combination was considered additive. Similarly, if the majority of isoeffect points lay to the 
left and below or to the right and above the envelope of additivity, the combination was considered supra
infra-additive, respectively. The combination index (CI) is reported as mean ± SEM; n=3.
 
The linear-quadratic evaluation of the effect of DSF:Cu or DSF on the radiation survival 
curve suggested that UVW/NAT cells were also more resistant to the combination 
treatment due to the less appreciable increase of the quadratic component (
cell kill than observed in the case of SK
radiation kill induced by a radiosensitiser may be due to the increase in the i
DSB or to the inhibition of their repair. The ability of SK
to repair DSB has previously been
radiopharmaceutical [
topotecan92. It was shown that more DSB were produced by topotecan alone, [
alone or the combination of both in UVW/NAT cells compared 
immediately after the treatment
24 h after treatments with topotecan alone, [
combination of both agents compared with only
cells92. This study demonstrated the greater ability of UVW/NAT cells to repair DSB 
compared to SK-N-BE(2c) cells, which was consistent with the increase in the 
SK-N-BE(2c) cells but not in UVW/NAT cells after irradiation in the presence of DSF:Cu.
 
γ-radiation 
Figure 26 to Figure 36. The DEF values signify the fold decrease of the 
µM DSF:Cu, to achieve the same kill as 
-N-BE(2c) cells. An increase in the 
-N-BE(2c) and UVW/NAT cells 
 investigated by comet assay after treatment with the 
131I]mIBG alone or in combination with the topois
with
92
. However, UVW/NAT cells repaired 100% of the DSB 
131I]mIBG alone or the simultaneous 
 70-90% of DSB repaired in SK
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Although both the isobologram and the combination methods of synergy analysis indicated 
a more synergistic interaction between γ-radiation and DSF:Cu or DSF at increasing levels 
of toxicity, the DEF values decreased with increasing levels of toxicity (Table 7). This 
contradictory result may be explained as follows. The DEF values are calculated based on 
the linear-quadratic equation which describes the leftward shift of the radiation curve 
provoked by the addition of a radiosensitiser. The effect of a radiosensitiser is likely to be 
due to an increase in the linear (α) or quadratic (β) components of radiation cell killing or 
both. 
 
Firstly, we consider that the effect of a radiosensitiser is solely to increase the linear 
component of the radiation cell killing while the quadratic component remains constant 
(Figure 37a). Treatment with such a radiosensitiser would increase and straighten the 
initial slope of the radiation survival curve, with resulting higher DEF values at the initial 
levels of kill. Since the contribution of the quadratic component is greater than the linear 
component in response to radiation alone than in response to combination treatment, it 
follows that, with increasing radiation dose, the survival curve of radiation treatment alone 
starts bending at lower radiation dose than in the survival curve of the combination. This 
results in lower DEF values at higher levels of kill. An increase in the α value, with a 
constant β value, resulted in radiosensitisation, manifest by the DEF values greater than 1 
(Figure 37a). Furthermore, DEF values decreased with increasing toxicity levels (Figure 
37a). For instance, in the radiation survival curve obtained in the presence of a 
radiosensitiser characterised by α = 0.95 and β = 0.04, the DEF values were 7.12, 5.06 and 
3.84 at the 25%, 50% and 75% level of toxicity, respectively (Figure 37a). 
 
Secondly, we consider that the effect of an alternative radiosensitiser is solely an increase 
of the quadratic component of radiation cell killing, while the linear component remains 
constant (Figure 37b). Treatment with such a radiosensitiser increases the curvature of the 
radiation survival curve. The result is that the radiosensitiser plus radiation curve departs 
more from the radiation alone curve with increasing radiation dose. Therefore the DEF 
values increase with increasing toxicity levels. The increase of the β value, with a constant 
α value, showed a radiosensitising effect as indicated by DEF values greater than 1 (Figure 
37b). Moreover, DEF values increased with increasing toxicity levels (Figure 37b). For 
instance, in the radiation survival curve obtained in the presence of a radiosensitiser 
characterised by α = 0.05 and β = 0.24, the DEF values were 2.14, 2.24 and 2.30 at the 
25%, 50% and 75% level of toxicity, respectively (Figure 37b). 
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The linear component of the radiation cell kill was increased by DSF:Cu and DSF to a 
greater extent than the quadratic component (Figure 26 and Figure 27). For instance, 0.3 
µM DSF:Cu induced a 12.2- and 3.9-fold increase in the α value in SK-N-BE(2c) (Figure 
26b) and UVW/NAT cells (Figure 27b), respectively. In contrast, the β values were only 
increased 4.8-fold in SK-N-BE(2c) cells (Figure 26b) and decreased 3-fold in UVW/NAT 
cells (Figure 27b). The greater increase in the α values compared to the β values by 
DSF:Cu may account for the decreasing DEF values at increasing toxicity levels despite 
the demonstration of increased additivity at greater toxicity levels, as demonstrated by the 
isobologram and the combination index methods of synergy analysis. This discrepancy was 
explained by the strong reliance of the calculations of the DEF values on the shape of the 
linear-quadratic curve. The relative contributions of the linear (α) and quadratic (β) 
components of radiation cell kill, which may be differentially affected by different 
radiosensitisers, introduced a bias for the determination of radiosensitising potentials at 
different toxicity levels. These data demonstrated that the degree of radiosensitisation 
(additivity or supra-additivity) cannot be reliably assessed by the calculation of DEF 
values. Instead, the isobologram and the combination index methods of synergy analysis 
are particularly suited to this purpose. 
 
 Figure 37 The effect of the modification of the linear (
cell killing on the survival curve
The surviving fraction SF of radiation survival curves were calculated by computing radiation doses (D), 
and β values into the linear
kill was increased from 0.05 to 1.25 Gy
kill was kept constant at 0.04 Gy
75% kill, respectively. (b) The quadratic component (
Gy-1 by 0.05 increments. The linear component (
DER25, DER50 and DER75
 
The dataset also showed a discrepancy between the isobologram and the combination 
index analysis for the UVW/NAT cell line. The isobologram method indicated an additive 
interaction between DSF:Cu and 
combination index analysis indicated synergism at these levels of toxicity (
However, the isoeffect points corr
radiation at the 75% level of toxicity plotted at the border between additivity and supra
additivity (Fig. 12). Moreover, in the case of combinations of DSF and 
isobologram analysis revealed 
index analysis disclosed an infra
between the isobologram and the combination index analyses may derive from the 
differences in drug treatment used in the two methods. In combination index analysis, a 
α) or the quadratic (β
 
-quadratic equation SF = e(-αD-βD). (a) The linear component (
-1
 by 0.3 increments. The quadratic component (
-1
. The DER25, DER50 and DER75 values were calculated at the 25, 50 and 
β) of radiation cell kill was increased from 0.04 to 0.24 
α) of radiation cell kill was kept constant at 0.05 Gy
 values were calculated at the 25, 50 and 75% kill, respectively.
γ-radiation at the 50% and 75% levels of toxicity whereas 
esponding to the combination of DSF:Cu with 
additivity at the 50% level of toxicity whereas combination 
-additive interaction (Table 7d). The observed 
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fixed ratio of drug concentration to γ-radiation dose was used. In contrast, for isobologram 
analysis, the doses of drug and γ-radiation were both variable. Therefore, it is possible that 
the incongruities observed between the isobologram and combination index analyses may 
be due to differences in the relative contributions of each agent to the effectiveness of the 
combination. That is, variable ratios of dose of the two modalities are applied in the 
isobologram procedure whereas a fixed ratio of dose of the two treatments is used in the 
combination index analysis. 
 
DSF without Cu was also found to be a radiosensitiser, as indicated by DEF values greater 
than 1 (Table 7b and Table 7d). However, the concentrations of DSF between 5 and 24 µM 
examined in this study cannot be achieved in human plasma. It was shown that the peak 
plasma concentration measured after oral administration of a 250 mg DSF tablet was 1 
µM161. Therefore, radiosensitisation of a tumour using DSF is impossible. These results 
demonstrated that DSF-induced enhancement of γ-radiation treatment only occurred when 
the DSF concentration was high enough to induce cytotoxic effects as a single agent. 
 
Since it has been argued that DSF acts as a Cu ionophore, and that Cu alone exerts 
cytotoxic effects114, it could be hypothesised that Cu itself is a radiosensitiser. The results 
demonstrating radiosensitisation of SK-N-BE(2c) and UVW/NAT cells were obtained in 
physiological conditions, namely 5% CO2, 20% O2 and 75% N2. It has previously been 
shown that CuCl2 radiosensitises the bacterial strain Shigella Flexneri Y6R in hypoxic 
conditions but not in aerated cultures237. Furthermore, it has been hypothesised that the 
radiosensitising effect of Cu is due to the radiation-induced conversion of Cu2+ into the 
highly toxic Cu+ in hypoxia. In aerated cultures, O2 was able to convert Cu+ back to the 
less toxic Cu2+ resulting in the loss of the radiosensitising effect238. These two reports 
suggest that Cu is not a radiosensitiser in aerobic conditions. Therefore, the hypothetical 
radiosensitising effect of Cu alone in the experiments carried out in aerobic conditions in 
this chapter is unlikely. 
 
Isobologram analysis demonstrated that combination treatment was less effective when the 
contribution of one agent became greater than the contribution of the second agent (Figure 
29 and Figure 32). In patients, the distribution of a drug within the tumour is uneven 
because all parts of the tumour are not homogeneously vascularised239,240. Therefore 
differential distribution of DSF:Cu within a tumour due to uneven vascularisation may 
result in sub-optimal additive or supra-additive effects. Preclinical evaluation should be 
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conducted to determine the optimal doses of DSF:Cu which must be administered in order 
to avoid this complication. 
 
Together, these data demonstrated the benefit of using the isobologram and the 
combination index methods of synergy analysis over the calculation of the leftward shift of 
radiation curves for the determination of the degree and type of interaction (additivity or 
supra-additivity) between therapeutic modalities. These data also demonstrated that 
DSF:Cu sensitised monolayers of cancer cells to external beam γ-radiation treatment in a 
supra-additive fashion at toxicity levels greater than 50%. The evaluation of the 
radiosensitising effect of DSF:Cu using the linear-quadratic model unearthed an hypothesis 
regarding the mechanism of radiosensitisation. That is the greater increase of α values 
compared with the increase in β value following irradiation in the presence of DSF:Cu 
suggested that DSF:Cu increased the amount of SSB following radiation treatment. The 
DSF:Cu-mediated increase in SSB following radiation treatment might be due to the 
abrogation of the cell cycle delay by DSF:Cu or to the inhibition of the SSB DNA repair 
machinery. In the next chapter, the former hypothesis will be tested. 
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5 A hypothesised mechanism for the radiosensitisation induced 
by DSF:Cu 
5.1 Introduction 
The study described in chapter 4 has demonstrated the radiosensitising capacity of 
DSF:Cu. However, its mechanism of radiosensitisation remains unknown. The results of 
the analysis of the radiosensitising effect of DSF:Cu by the linear-quadratic model predict 
that DSF:Cu may increase the proportion of SSB to a greater extent than DSB after 
radiation treatment, as indicated by the greater increase in the α than the β values (Section 
4.4.2). The increase in SSB and DSB following irradiation in the presence of DSF:Cu 
could be due to the inhibition of DNA repair by DSF:Cu or to the abrogation of cell cycle 
checkpoints which does not allow enough time for the repair of SSB and DSB. Since cell 
cycle arrest at the G2 checkpoint, which controls entry to mitosis, is considered a hallmark 
of the cellular response to γ-radiation241, it is hypothesised that DSF:Cu may inhibit G2 
arrest following irradiation. 
 
Serum starvation has been shown to arrest cancer cells in the G1 phase of the cell cycle242. 
It has also been reported that serum starvation arrests the cell cycle in G2, especially in the 
case of a deficient G1 checkpoint243. In such studies cells were serum-starved for at least 
24 h before the observation of cell cycle arrest242-245. The treatment of cells with DSF:Cu 
requires serum-free conditions in order to study the effect of Cu. It was anticipated that 
serum starvation may influence the cell cycle response to radiation at a timepoint earlier 
than 24 h - used for the determination of clonogenic cell kill (Figure 26). 
 
The accumulation of cells in G2 following γ-radiation treatment in the presence and in the 
absence of DSF:Cu will be carried out in this chapter by FACS analysis of PI-stained cells. 
It will be shown that DSF:Cu abrogates the γ-radiation-induced G2 arrest in LNCaP, SK-
N-BE(2c), UVW/NAT, HCT116 p53+/+ and HCT116 p53-/- cells. 
 
5.2 Aims 
The aims of this chapter were: 
- determination of the time after radiation treatment required for maximal cell cycle 
arrest in G2 
- determination of the effect of serum starvation on the distribution of cells 
throughout the phases of the cell cycle 
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- determination of the effect of DSF:Cu on cell cycle arrest in G2 following radiation 
treatment 
 
5.3 Materials and methods 
5.3.1 Tissue culture 
LNCaP, SK-N-BE(2c) and UVW/NAT cells were maintained in culture as described in 
Section 3.3.1. HCT116 p53+/+ (parent) and HCT116 p53-/- cells were generously gifted 
by Dr Jane Plumb. The two alleles of the p53 gene were sequentially disrupted in the 
parent HCT116 cell line by homologous recombination. The p53 sequence was replaced by 
a geneticin resistance sequence246. Both cell lines were grown in Dulbecco’s modified 
essential medium (MEM) supplemented with 10% (v/v) FCS (Autogen Bioclear) and 2 
mM L-glutamine. All media and supplements were obtained from Invitrogen (Paisley, 
UK). HCT116 p53-/- cells were maintained in culture medium containing 1 mg/ml 
geneticin for the selection of p53-/- mutants246. 
 
5.3.2 γ-radiation treatment 
Section 4.3.2. 
 
5.3.3 Serum starvation 
SK-N-BE(2c) and UVW/NAT cells were washed in PBS three times and incubated in fresh 
serum-complemented culture medium or serum-free culture medium for 2, 4, 8, 12 and 24 
h. At the end of the incubation period, the cells were washed in PBS and fixed in 70% 
ethanol at -20°C. 
 
5.3.4 DSF:Cu treatment in combination with γ-radiation 
LNCaP, SK-N-BE(2c) and UVW/NAT cells were exposed to 0.3 or 1 µM DSF:Cu in 
serum-free culture medium. The cells were irradiated with 5 Gy γ-radiation immediately 
after exposure to DSF:Cu. All treatments were carried out in serum-free conditions 
(untreated controls, radiation, DSF:Cu and the combination of both). The cells were fixed 
in 70% ethanol at -20°C, 12 h after irradiation. The choice of this timepoint was based on 
results presented in Section 5.4.2. 
 
5.3.5 Cell cycle analysis 
See Section 3.3.8. 
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5.3.6 Statistical analysis 
See Section 3.3.9. 
 
5.4 Results 
5.4.1 The effect of serum starvation on cell cycle distribution 
SK-N-BE(2c) and UVW/NAT cells were cultured in serum-free culture medium for 2, 4, 8, 
12 or 24 h. In UVW/NAT cells, there was no accumulation of cells in the G2/M nor in the 
G0/G1 phase of the cell cycle up to 24 h exposure to serum-complemented culture medium 
(Figure 38a). Similarly, there was no redistribution of cells throughout the phases of the 
cell cycle after exposure to serum-free conditions for 24 h (Figure 38b). 
 
In SK-N-BE(2c) cells, there was no accumulation of cells in the G2/M nor in the G0/G1 
phase of the cell cycle after exposure to serum-complemented culture medium for 24 h 
(Figure 38c). Although serum starvation appeared to reduce the percentage of cells in the S 
phase of the cell cycle with a concomitant increase in the proportion of cells in the G2/M 
phase of the cell cycle, these modifications were not statistically significant (p > 0.05) 
(Figure 38d). A true G2/M arrest would result in an increased G2/M associated with a 
decreased G0/G1 population. These features were not observed in Figure 38d. Therefore, 
these data indicated that serum-starvation for up to 24 h did not influence the distribution 
of UVW/NAT or SK-N-BE(2c) cells throughout the phases of the cell cycle. Nevertheless, 
in the following experiments, all treatments (untreated controls, radiation, DSF:Cu and 
combination treatments) were conducted in serum-free conditions whether DSF:Cu was 
present or not. 
 
 Figure 38 Absence of an effect of serum starvation on the distribution of SK
cells throughout the phases of the cell cycle
UVW/NAT (a and b) and SK
and c) or to serum-free culture medium (b and d) for 2, 4, 8, 12 and 
start of the exposure to the different culture media, the cells were trypsini
20°C. FACS analysis of PI
the phases of the cell cycle. The software FlowJo was used to quantify the proportion cells in each phase of 
the cell cycle. Data are mean ± SEM; n=3.
 
5.4.2 Cell cycle arrest in response to 
In all three cell lines, there was a time
after irradiation, followed by a decrease of the G2/M population from 12
irradiation (Figure 39
statistically significant in 
39). The accumulation of cells in the G2/M phase of the cell cycle was accompanied by a 
 
-N-BE(2c) (c and d) were exposed to serum-complemented culture medium (a 
24 h. At the indicated timepoint after the 
sed and fixed in 70% ethanol at 
-stained cells was then carried out to determine the distribution of cells throughout 
 
γ-radiation treatment 
-dependent increase in the G2/M population
). The accumulation of cells in G2/M at 12 h
all three cell lines compared with non-irradiated controls (
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-N-BE(2c) and UVW/NAT 
-
 12 h 
 to 24 h after 
 after irradiation was 
Figure 
 decrease in the proportion of cells in G1, demonstrating that irradiated cells were unable to 
exit G2, progress through mitosis and enter the G1 phase of the cell cycle.
 
These data indicated that LNCaP, SK
arrest in G2 following irradiation. The maximal G2/M proportion of cells was observed 12 
h after irradiation (Figure 
investigation of the effect of DSF:Cu on radiation
the impact of the p53 status on the effect of DSF:Cu on radiation
was investigated by comparison of the HCT116 p53+/+ cells with the HCT116 p53
cells. 
 
Figure 39 Time-dependency of G2 arrest after 
LNCaP (a), SK-N-BE(2c) (b) and UVW/NAT cells (c) were fixed in 70% ethanol at 
timepoints after γ-radiation treatment. The cell cycle profiles were obtained by FACS
cells. The quantification of th
carried out using FlowJo software
Independent samples t-test was used to compare the mean percentage of irradiated 
unirradiated controls. One symbol indicates p < 0.05, two symbols indicate p < 0.01 and three symbols 
indicate p < 0.001. 
 
5.4.3 The effect of DSF:Cu on G2 arrest following 
The effect of DSF:Cu on the cell cycle respon
treatment is shown in 
increase in the G2/M population after 
controls (p < 0.05) (Figure 
population following 
-N-BE(2c) and UVW/NAT cells were all able to 
39). Accordingly this timepoint was selected for the 
-induced cell cycle arrest. Furthermore, 
-induced cell cycle arrest 
γ-radiation treatment 
e percentage of cells in each phase of the cell cycle (G0/G1, S, G2/M) was 
 (BD Biosciences, Mountain View, CA). Data are means +/
γ-radiation treatment
se of SK-N-BE(2c) cells to 
Figure 40. In these experiments, there was a statistically significant 
γ-radiation treatment compared with untreated 
40a). There was a statistically significant reduction in
γ-radiation treatment in the presence of 1 µM DSF:Cu, but not 0.3 
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 µM DSF:Cu, compared with the G2/M population after 
0.05). The percentages of cells in G2/M were 53.7% and 23.1% following 
treatment alone and after 
respectively (Figure 40
 
Figure 40 The effect of DSF:Cu on the redistribution of SK
the cell cycle following γ
SK-N-BE(2c) cells were fixed in 70% ethanol at 
the presence of 0.3 (a) or 1 
stained cells. The quantification of the percentage of cells in each phase of the cell cycle (G0/G1, S, G2/M) 
was carried out using FlowJo software
One symbol indicates p < 0.05.
 
The effect of DSF:Cu on the cell cycle response of UVW/NAT cells to 
shown in Figure 41. There was a statistically significant increase in the G2/M population 
after γ-radiation treatment compared with untreated controls (p < 0.001) (
There was a statistically significant reduction in the G2/M population following 
treatment in the presence of 0.3 or 1 
after γ-radiation treatment alone (p < 0.01). The percentages of cells in G2/M were 56.2% 
and 38.3% after γ-radiation treatment alone and 
µM DSF:Cu, respectively (
 
The effect of DSF:Cu on the cell cycle response of LNCaP cells to 
Figure 42. There was a statistically significant increase in the G2/M population after 
radiation treatment compared with untreated controls (p < 0. 01) (
statistically significant reduction of the G2/M population following 
γ-radiation treatment alone (p < 
γ-radiation treatment in the presence of 1 
b). 
-N-BE(2c) cells throughout the phases of 
-radiation treatment 
-20°C, 12 h after γ-radiation treatment in the absence or in 
µM DSF:Cu (b). The cell cycle profile was obtained by FACS analysis of 
 (BD Biosciences, Mountain View, CA). Data are mean ± SEM; n=3. 
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Figure 41 The effect of DSF:Cu on the redistribution of UVW/NAT cells throughout the phases of the 
cell cycle following γ-radiation treatment
UVW/NAT cells were fixed in 70% ethanol at 
presence of 0.3 (a) or 1 µM DSF:Cu (b). The cell
cells. The quantification of the percentage of cells in each phase of the cell cycle (G0/G1, S, G2/M) was 
carried out using FlowJo software
symbols indicate p < 0.01 and three symb
 
The effect of DSF:Cu on the cell cycle response of HCT116 p53+/+ cells to 
shown in Figure 43. There was a stat
after γ-radiation treatment compared with untreated controls (p < 0. 001) (
There was a statistically significant reduction in the G2/M population following 
treatment in the presence of 0.3 (p < 0.01) or 1 
G2/M population after 
57.27% and 41.87% after 
presence of 1 µM DSF:Cu, respectively (
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γ-radiation treatment alone. T
γ-radiation treatment alone and 
µM DSF:Cu, respectively (
 
-20°C, 12 h after γ-radiation treatment in the absence or in the 
 cycle profile was obtained by 
 (BD Biosciences, Mountain View, CA). Data are mean ± SEM; n=3. Two 
ols indicate p < 0.001. 
istically significant increase in the G2/M population 
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Figure 43b). 
130
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Figure 42b). 
 
FACS analysis of PI-stained 
γ-radiation is 
Figure 43a). 
γ-radiation 
/M were 
 Figure 42 The effect of DSF:Cu on the redistribution of LNCaP cells throughout the phases of the cell 
cycle following γ-radiation treatment
LNCaP cells were fixed in 70% ethanol at 
presence of 0.3 (a) or 1 µM DSF:Cu (b). The cell cycle profile was obtained by FACS analysis of 
cells. The quantification of the percentage of cells in each phase of the cell cycle (G0/G1, S, G2/M) was 
carried out using FlowJo software
symbols indicate p < 0.01.
 
Figure 43 The effect of DSF:Cu on the redistribution of HCT116 p53+/+ cells throughout the phases of 
the cell cycle following γ
HCT116 p53+/+ cells were fixed in 70% ethanol at 
in the presence of 0.3 (a) or 1 
stained cells. The quantification of the percentage of cells in each phase of the cell cycle (G0/G1, S, G2/M) 
was carried out using Flow
Two symbols indicate p < 0.01 and three symbols indicate p < 0.001.
 
The effect of DSF:Cu on the cell cycle response of HCT116 p53
shown in Figure 44. There was a statistically significant increase in the G2/M population 
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of 0.3 µM DSF:Cu (Figure 
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Figure 44 The effect of DSF:Cu
the cell cycle following γ
HCT116 p53-/- cells were fixed in 70% ethanol at 
the presence of 0.3 (a) or 1 
stained cells. The quantification of the percentage of cells in each phase of the cell cycle (G0/G1, S, G2/M) 
was carried out using FlowJo software
Two symbols indicate p < 0.01.
 
These data demonstrated that DSF:Cu 
treatment in LNCaP, SK
absence of functional p53 did not affect the inhibition of the G2 arrest by DSF:Cu in 
HCT116 cells, as indicated by the 
arrest by DSF:Cu in HCT116 p53+/+ and 
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they are converted into DSB during DNA replication in the S phase. DSB are strong 
signals for apoptosis248. The inappropriate entry of cells into mitosis in the presence of 
DNA damage leads to mitotic catastrophe. Mitotic catastrophe is not clearly defined. It is a 
cell death mechanism which results from aberrant mitotic activity of cells which have been 
damaged by chemotherapeutic drugs or radiation treatment249. Therefore, cells must 
undergo cell cycle arrest in order to avoid entry to mitosis (G2 arrest) or to the S phase (G1 
arrest) if their DNA has been damaged. In the experiments presented in this chapter, 
DSF:Cu inhibited γ-radiation-induced G2/M arrest in a variety of cell lines (Figure 40 to 
Figure 44), resulting in progression to mitosis in the presence of DNA damage. Therefore 
the suggested radiosensitising mechanism of DSF:Cu is increased cell death, through 
mitotic catastrophe, following exit from the G2/M phase of the cell cycle after the 
inefficient repair of γ-radiation-induced damage of DNA. 
 
Radiosensitisation by DSF:Cu in combination with γ-radiation treatment was demonstrated 
in SK-N-BE(2c) and UVW/NAT cells (Section 4.4.2). In these experiments, the cells were 
irradiated and then incubated with DSF:Cu for 24 h before clonogenic assay. At 24 h after 
irradiation, all SK-N-BE(2c) cells had undergone G2 arrest, progressed to mitosis and 
entered G1 (Figure 39b). This indicated that 24 h after irradiation, the majority of cells had 
re-entered the cell cycle following G2 arrest. In the radiosensitisation experiments using 
SK-N-BE(2c) cells (Section 4.4.2), DSF:Cu was present in the culture medium for 24 h 
following irradiation. Thus, the majority of cells which would otherwise have arrested in 
G2 in order to repair their DNA, were prevented from doing so by DSF:Cu. These cells 
then entered mitosis carrying the burden of unrepaired DNA resulting in mitotic 
catastrophe. 
 
However, the percentage of UVW/NAT cells in G2/M 24 h after irradiation was 45% 
versus 25% for the control, indicating the presence of a population of UVW/NAT cells still 
arrested in G2 24 h after irradiation (Figure 39c). This observation was consistent with the 
finding that the β value was lower in UVW/NAT cells following treatment with γ-radiation 
compared with SK-N-BE(2c) cells. The greater ability of UVW/NAT cells than SK-N-
BE(2c) cells to repair DSB, indicated by the lower β value (Section 4.4.2), may be a result 
of the longer cell cycle delay in G2. UVW/NAT cells benefit from more time to repair 
DNA damage following radiation. This could explain lower radiosensitivity of UVW/NAT 
cells compared with SK-N-BE(2c) cells. 
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The inhibition of G2 arrest following γ-radiation treatment occurred regardless of the p53 
status of the cell line, as indicated by the comparable abrogation of G2 arrest in HCT116 
p53+/+ cells (Figure 43) and HCT116 p53-/- cells (Figure 44). Also, the inhibition of G2 
arrest following γ-radiation treatment occurred regardless of the duration of the G2 arrest 
produced by γ-radiation treatment. For instance, all SK-N-BE(2c) cells had re-entered the 
cell cycle 24 h after irradiation (Figure 39b) whereas 20% of UVW/NAT (Figure 39c) cells 
were still arrested in G2 24 h following irradiation. For instance, DSF:Cu abrogated G2 
arrest following γ-radiation treatment in both SK-N-BE(2c) and UVW/NAT cells. These 
observations may indicate the generality of the inhibitory effect of DSF:Cu on G2 arrest 
after irradiation. Thus it may be hypothesised that the mechanism by which DSF:Cu 
inhibits G2 arrest is not through the specific regulation of the phosphorylation of key 
effectors of the G2 arrest. Instead, it may be due to a more general effect on the level of 
expression of proteins involved in cell cycle regulation. Experiments are currently being 
performed to elucidate the mechanism of DSF:Cu radiosensitisation via inhibition of the 
G2 arrest machinery. Furthermore, the consequence of the abrogation of the cell cycle 
arrest in G2 by DSF:Cu following irradiation should be an increase in SSB and DSB, as 
indicated by the increase in α and β values. Such conjectures are currently being tested. 
 
This series of experiments demonstrated the abrogation of G2 arrest following external 
beam radiation treatment by DSF:Cu which resulted in radiosensitisation of cells cultured 
as monolayers. However, two-dimensional monolayers are inadequately representative of 
tumours. The ensuing chapters will describe the characterisation of multicellular tumour 
spheroids as models for the study of the sensitisation of avascular metastases to targeted 
radiotherapy by DSF:Cu. 
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6 Characterisation of multicellular tumour spheroids (MTS) 
for the study of combination treatments 
6.1 Introduction 
6.1.1 Spheroids 
For the purpose of cancer research, malignant cells may be kept in their proliferating state 
attached to plastic surfaces as two-dimensional monolayers. Alternatively, they may be 
grown as multicellular tumour spheroids. These are spherical multicellular aggregates of 
malignant cells proliferating freely in suspension in culture medium. A range of spheroid 
models have been described to study many types of cancers such as breast cancer250, 
prostate cancer251, glioma252, colon cancer252 and lung cancer253. Spheroids bear greater 
similarity to tumours than monolayers because of their 3-dimensionnal morphology. For 
instance, the 3-D organisation of spheroids enables the investigation of the ability of a 
chemotherapeutic agent to penetrate the spheroid and target deeply located cells. 
Compounds with a high molecular weight or with low lipophilicity will penetrate less 
deeply inside a tumour than small lipophilic molecules thus resulting in lower toxicity to 
tumours. Such dependency cannot be evaluated in monolayers. 
 
Culture medium contains oxygen and nutrients essential for spheroid cells’ survival and 
proliferation. Upon attaining a diameter of approximately 300 µm, a decreasing gradient of 
nutrient and oxygen forms from the outer layer to the inner core254. The core of spheroids 
is accordingly hypoxic and exhibits low pH255,256. The cells in the outer layer of a spheroid 
are in a proliferating state because they are more adequately supplied with oxygen and 
nutrients. Although drug penetrability accounts for chemoresistance of spheroids, it has 
also been demonstrated that the proliferating status and the microenvironment (nutrient 
availability, hypoxia and pH) of the various layers within the spheroid influence sensitivity 
to treatment257. For instance, the proliferating outer layer is more sensitive to 
antimetabolites such as doxorubicin or FUra258. Moreover, the alkylating agent mitomycin 
is known to be more cytotoxic in hypoxic cells259. It was shown that mitomycin was more 
toxic to cells located within the core of spheroids, consistent with the hypoxia-specific 
cytotoxicity of mitomycin258. 
 
Furthermore, the indirect effect of radiation treatment was described in Section 1.1.5.1. 
ROS, formed by ionisation of oxygen-containing compounds, can damage DNA in the 
same way as its direct irradiation. The indirect effect of radiation relies on the presence of 
oxygen in the irradiated milieu. It follows that hypoxic regions are more resistant to 
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radiation than normoxic tissue260. This is supported by the demonstration that large 
spheroids are more resistant to radiation treatment than small spheroids due to the presence 
of a hypoxic core261,262. 
 
Tumour microenvironment plays an important role in the sensitivity to therapy. Therefore 
spheroids allow for a more accurate prediction of the outcome of chemotherapy and 
radiotherapy than monolayers. It was demonstrated that a human ovarian carcinoma cell 
line grown as xenografts and spheroids resembled tumours with respect to growth rate, 
necrotic region, hypoxia and radiation sensitivity263. However, there are differences 
between spheroids and tumours. For instance, decreasing gradients of nutrients and oxygen 
exist from the outside to the innermost regions of spheroids in a concentric layer fashion. 
This is in contrast to tumours where gradients of nutrients and oxygen form according to 
the blood supply within the tumour. Tumours could be represented by a “mosaic” of 
microenvironments whereas a spheroid could be represented as concentric circles of 
microenvironments. Furthermore, spheroids fail to represent the complete 
microenvironment in which the tumour is confined. Fibroblasts, endothelium and 
components of the immune system communicate with the tumour through secretion of 
growth factors and cytokines. Although spheroids lack these features, they do represent a 
useful alternative to xenografts in experimental animals by recreating in vitro the 
heterogeneity of microenvironments observed in a tumour264. 
 
6.1.2 Considerations for targeted radiotherapy 
Radiopharmaceuticals exert their cytotoxic effect by direct deposition of energy in targeted 
cells and by cross-fire to neighbouring cells. Thus, 3-D aggregates of cells such as 
spheroids, in which cross-fire occurs to a greater extent than in monolayers, constitute a 
better model to study therapeutic radiopharmaceuticals. 
 
Targeted radiotherapy is able to reach all malignant lesions expressing the specific 
molecular target regardless of the size or morphology of the target tissue. Spheroids are 
models of avascular micrometastases and have been used as models for the investigation of 
the effect of drugs or the penetration of agents within avascular malignant tissues265-268. 
Spheroids are perfectly suited for the investigation of radiopharmaceuticals in the context 
of targeted radiotherapy. 
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6.1.3 A mathematical approach to the quantification of spheroid growth delay 
One index of treatment-induced growth delay of spheroids is the time required for an x-
fold increase in volume (τx)269,270. Alternatively, the incorporation of fluorescent dyes may 
be used to measure cellular viability at a particular timepoint after treatment. However, the 
effect of a treatment may be the reduction of the growth rate of the spheroid or the increase 
of the growth delay before the proliferating phase of the spheroid. Thus, the measurement 
of cellular viability at a particular timepoint is not the optimal method of determining the 
effect of experimental therapy of spheroids. Instead, the kinetics of growth were measured 
over a period of 3 to 4 weeks which corresponded to the phase of exponential growth of 
LNCaP spheroids271.  
 
The mathematical equation for the dose-response relationship is given by the median effect 
principle. The median effect principle is based on the determination of a surviving fraction 
(unaffected by the treatment) and an affected fraction. Thus, in order to apply the median 
effect principle to the investigation of spheroid growth, it is necessary to derive the 
surviving fraction from growth delay experiments. In this chapter, the most appropriate 
index of the effect of a treatment that enables the calculation of surviving fraction - area 
under the volume-time curve or the time required for an x-fold increase in spheroid volume 
- will be evaluated. Furthermore, it will be assessed whether the median effect principle 
can be applied to spheroid growth delay experiments to determine the nature of the 
interaction between two agents in combination. 
 
6.2 Aims 
- investigation of the morphology of the spheroids during treatment and during their 
growth 
- determination of the growth characteristics of spheroids 
- the establishment of an analytical method to determine the dose-response 
relationship in spheroid growth delay experiments 
 
6.3 Materials and methods 
6.3.1 Spheroid initiation 
The prostate carcinoma cell line LNCaP, the glioma cell line UVW/NAT and the 
neuroblastoma cell line SK-N-BE(2c) were cultured as spheroids using the liquid overlay 
technique272. The monolayers were trypsinized and 3×106 cells were seeded into a 25cm² 
plastic flask coated with 1% agar. The agar solution was prepared by dissolving 1g of agar 
powder (Melford Laboratories Ltd, Ipswich) into 20 ml of distilled water and heated in a 
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microwave before the addition of 80 ml culture medium at 50°C. The cells were incubated 
for a period of 3 to 4 days in 95% air and 5% CO2 at 37ºC. At the end of this period, 
spheroids had formed and were used for treatment. 
 
6.3.2 DSF:Cu treatment 
After 3 to 4 days of incubation in 95% air and 5% CO2 at 37ºC, the spheroids were 
centrifuged at 300 rpm for 3 min and resuspended in 2 ml fresh serum-free culture medium 
containing DSF:Cu in universal tubes. Universal tubes were used in preference to agar-
coated flask used for initiation because it was anticipated that agar may interfere with the 
availability of drugs. Spheroids did not attach to the sides of the universal tube. At the end 
of the treatment period, the spheroids were washed three times in PBS. 
 
6.3.3 Spheroid volume measurement 
At the end of the treatment period, spheroids of approximately 100 µm in diameter were 
manually selected under a magnifying lamp and individually transferred into agar-coated 
wells of a 24-well plate (Fisher Scientific UK Ltd, Loughborough). The growth of 
individual spheroids was monitored twice per week using an inverted phase-contrast 
microscope connected to an image acquisition system. Two orthogonal diameters, dmax and 
dmin (µm), were measured using the image analysis software ImageJ and the volume, V 
(106 µm3), was calculated using the formula272: 
 
V = π × dmax × dmin² / 6,000,000 (17)  
 
Alternatively, the volume, V, of a single spheroid was divided by its initial volume V0 
(V/V0), to enable comparison between treatments. 
 
6.3.4 Calculation of the growth delay (τ2) and the doubling time (DT) 
Linear regression analysis between the logarithm of the fold increase of individual 
spheroid volume (logV/V0) and time t was performed using the method of least squares. 
The linear regression equation was fitted to the exponential part of the spheroid growth 
curve. The slope, b, and the y-intercept, a, of the linear regression equation logV/V0 = bt + 
a were used to calculate the time, τ2, required for an 2-fold increase in spheroid volume 
from day 0: 
 
τ2 = (log 2 – a) / b  (18) 
  
Alternatively, DT was d
exponential part of the spheroid growth curve
 
DT = log 2 / b  
 
The τ2 values represent a measure of the growth delay while the DT values repres
measure of the growth rate. Indeed, the effect of a treatment may be the delay of the start 
of the proliferating phase with a
untreated control. Alternatively, the effect of a treatment may be the 
growth rate (i.e. reduction of the slope of the log
shows the growth curves of an untreated spheroid (
treated with 3.7 MBq/ml of the radiopharmaceutical [
untreated spheroid is characterised by a 
Note that, in this particular example, the proliferating phase 
from day 0 without a lag phase (
3.7 MBq/ml [131I]MIP
DT value (3.31 days) (
[131I]MIP-1095 delay
This is consistent with a proportion of cells being killed by the treatment and the remaining 
cells able to proliferate at the same rate as the control. This example demonstrates the need 
to report both values in order to ass
 
Figure 45 Comparison between 
Two spheroids were evaluated: one untreated (a) and one treated with 3.7 MBq/ml [
logarithm of the V/V0 values was calculated in order to obtain a linear relationship between logV/V
time. The volume against time data were fitted by linear regression using the method of least squares. The 
efined as the time required for a 2-fold increase in volume 
. DT was calculated using equation (
(20) 
n ensuing proliferating phase parallel to that of the 
-transformed growth curve). 
Figure 45a) and that of a spheroid 
131I]MIP-1095 (
τ2 = 3.50 days and DT = 2
of the untreated spheroid 
Figure 45a). On the other hand, the spheroid treated with 
-1095 is characterised by an increased τ2 (8.77 days) but a similar 
Figure 45b). This indicates that this radioactivity concentration of 
s the start of the proliferating phase but does 
ess the effect of treatment on the growth of spheroids.
τ2 and DT values for the measure of spheroid growth
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in the 
20): 
ent a 
reduction of the 
Figure 45 
Figure 45b). The 
.82 days (Figure 45a). 
starts 
not alter the growth rate. 
 
 
 
131I]MIP-1095 (b). The 
0 and 
τ2 
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value was defined as the time required to achieve a 2-fold increase in spheroid volume from day 0 and the 
DT value was defined as the time required to achieve a 2-fold increase in spheroid volume during the 
exponential growth of the spheroid. The τ2 values are represented graphically by the red arrows whereas the 
DT values are represented graphically by the blue arrows. In both panels, the equation of the linear 
regression, the coefficient of determination R2, the τ2 and the DT values are reported. 
 
6.3.5 Calculation of the area under the curve (AUC) 
The area under the V/V0 versus time curve (AUClinear) was calculated for individual 
spheroids using trapezoidal approximation. Similarly, the area under the logV/V0 versus 
time curve (AUClog) was also calculated for individual spheroids using trapezoidal 
approximation. 
 
6.3.6 Statistical analysis 
The logarithmic transformation of the V/V0 values (logV/V0) linearises the growth curve, 
i.e. each timepoint is equally weighed in the calculation of AUClog. In contrast, the 
AUClinear value is relatively more dependent on the V/V0 values at the later timepoints than 
at the earlier timepoints because of the exponential increase in volume. Therefore, the 
AUClog values were chosen over the AUClinear values for the statistical analyses. 
 
The distributions of τ2, DT or AUClog values were not normal therefore non-parametric 
testing was performed using the statistical analysis software SPSS v.19 (IBM). The 
Kruskal-Wallis test was used to determine whether experimental data indicated a 
significant level of difference between the medians of the groups. If the p-value of the 
Kruskal-Wallis test was less than 0.05, the Mann-Whitney test was used for pairwise 
comparisons. The statistical analysis of the effect of increasing doses of a treatment was 
performed as follows. First, the median of the group treated with the highest concentration 
was compared with that of the control. If the p-value returned by the Mann-Whitney test 
was less than 0.05, the difference between the two groups was considered significant and 
the median of the group treated with the next highest concentration was then compared 
with that of the control. This stepwise procedure was applied to each drug concentration 
with 0.05 as the significance level until the median of a group was not significantly 
different from that of the control. When a comparison returned a p-value greater than 0.05, 
the effects of treatment with lower concentrations were considered not statistically 
significant. The assumption was made that increasing dose increases the effect, thus an 
observation of a more significant effect at a lower concentration was considered to be due 
to random variation. 
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6.3.7 Regression analysis 
The significance of the correlation between the parameters τ2, DT or AUClog and the initial 
spheroid volume at day 0 was determined using the statistical analysis software SPSS v.19 
(IBM). A linear regression equation was calculated by the software and an analysis of 
variance (ANOVA) was performed to determine whether the correlation was statistically 
significant. 
 
6.3.8 Immunocytochemistry 
Spheroids were stored at 4°C overnight in formalin and delicately processed into a wax 
block. Wax sections 4 µm thick were cut using a microtome (ThermoFisher Scientific, 
Hemel Hempstead, UK). These sections were placed onto poly-lysine coated slides and 
baked in an oven at 60°C for at least 1 h. Immunohistochemistry was performed using an 
automated staining platform. The sections were de-waxed in xylene and re-hydrated by 
successive immersions in 100% (v/v) alcohol, 75% (v/v) alcohol and distilled water. 
Endogenous peroxidase activity was quenched by incubation in 0.3% (v/v) H2O2 solution 
in methanol for 30 min. For epitopic exposure, heat-induced retrieval was performed in a 
10 mM sodium citrate, 0.05% (v/v) Tween 20, pH6 buffer using a pre-treatment module 
(DAKO, Cambridge, UK) set to 98°C for 25 minutes. The sections were then washed using 
Tris-buffered Tween before being exposed to anti-Ki67 (Thermo, 1:100) or anti-
phosphorylated caspase 3 (pCASP3) (Cell Signalling, 1:50). The anti-rabbit EnVision™ 
system (DAKO, Cambridge, UK) was used in conjunction with the 3, 3’-diaminobenzidine 
(DAB) substrate kit for peroxidase (Vector Laboratories, Burlingame, CA) to visualise 
epitope positivity. The spheroid sections were then counterstained with haematoxylin and 
immersed in Scotts tap water for 1 min in order to improve the contrast with eosin staining. 
Finally, the sections were dehydrated and rewaxed by successive immersions in 75% (v/v) 
ethanol, 100% (v/v) ethanol and xylene before application of DPX mountant (VWR, UK) 
and a glass coverslip. 
 
6.3.9 Pimonidazole treatment 
The hypoxic status of spheroids was determined using the hypoxyprobe™ kit 
(Hypoxyprobe Inc, Burlington, MA). Live spheroids were treated for 24 h with 200 µM 
pimonidazole in culture medium. Pimonidazole binds to thiol groups of proteins in the 
absence of or in the presence of low levels of oxygen273. Therefore, pimonidazole adducts 
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are markers of anoxia and hypoxia. After treatment with pimonidazole, the spheroids were 
fixed in formalin for 24 h before processing. 
 
6.3.10 Staining of pimonidazole adducts  
Spheroid sections were de-waxed and rehydrated by successive immersions in xylene, 
100% (v/v) ethanol, 75% (v/v) ethanol and distilled water. Firstly, endogenous peroxidase 
activity was quenched by incubation in 0.3% (v/v) H2O2 solution in methanol for 30 min. 
The sections were then blocked in 10% (v/v) goat serum in Tris-buffered EDTA (TBE) for 
30 min. Secondly, the sections were incubated in 10% (v/v) goat serum in TBE containing 
monoclonal mouse anti-pimonidazole adducts antibody (Hypoxyprobe, Inc, Burlington, 
MA, 1:5,000 or 1:1,000 dilutions as indicated) for 1 h. The spheroid sections were then 
incubated in 10% (v/v) goat serum in TBE containing a rabbit biotinylated polyclonal anti-
mouse secondary antibody (DAKO, Cambrifge, UK, 1:100) for 45 min. For visualisation 
of the pimonidazole adducts, the spheroid sections were incubated in TBE containing 
avidin and biotinylated horseradish peroxidase macromolecular complex (Vectastatin Elite 
ABC kit, Vector Laboratories, Burlingame, CA) for 30 min at room temperature followed 
by incubation in distilled water containing DAB (Vector Laboratories, Burlingame, CA) 
for 10 min at room temperature according to the manufacturer’s protocol. The spheroid 
sections were then counterstained with haematoxylin and immersed in Scotts tap water for 
1 min in order to improve the contrast with eosin staining. Finally, the sections were 
dehydrated and rewaxed by successive immersions in 75% (v/v) ethanol, 100% (v/v) 
ethanol and xylene before application of DPX mountant (VWR, UK) and a glass coverslip. 
 
6.3.11 Heamatoxylin and eosin 
Firstly, the sections were de-waxed in xylene and re-hydrated by successive immersions in 
100% (v/v) alcohol, 75% (v/v) alcohol and water. The staining procedure involved 
successive immersions in haematoxylin (Cell Path, UK, 7 min), 1% (v/v) acid alcohol, 
Scott’s tap water (1 min) and eosin (made in-house, 5 min) with intermediate washes in 
water. Finally, the stained sections were dehydrated in 75% (v/v) and 100% (v/v) alcohol 
solutions and immersed in xylene before application of DPX mountant (VWR, UK) and a 
glass coverslip. 
 
6.4 Results 
6.4.1 The morphology of spheroids is dependent on their size 
Spheroids were initiated using the liquid overlay technique for 3-4 days. Single spheroids 
were transferred into individual wells for monitoring of their size. The timepoint at which 
 the first spheroid image was captured was designa
average 100 µm in diameter whereas they were on average 500 
staining of spheroid sections was used to reveal their internal morphology. Day 0 LNCaP 
spheroids stained homogeneously for H&E. Many p
cytoplasm demonstrated a dense and homogeneous population of viable cells (
On the other hand, 21 day
outer layer was constituted of densely located nuclei surrounded by a cytoplasm 
reminiscent of the morphology of day 0 spheroids. The inner core was composed of areas 
of cells staining predominantly pi
layers. Both of these features were consistent with cell death in the core and an area of 
proliferating cells in the outer layer (
 
LNCaP spheroids were also stained for markers of proliferation (Ki67) and hypoxia 
(pimonidazole adducts). Day 0 LNCaP spheroids contained a sub
positive, proliferating cells scattered randomly throughout the spheroid (
Moreover, hypoxia was not evident (
showed heterogeneous staining for Ki67 and hypoxia. There was an outer layer of Ki67
positive proliferating cells and an inner population of hypoxic cells (
 
Figure 46 Hypoxic core and proliferative outer layer in LNCaP spheroids
ted day 0. At day 0, spheroids were on 
µm at day 21. The H&E 
urple nuclei surrounded by a pink 
s old LNCaP spheroids stained heterogeneously for H&E. The 
nk and possessing nuclei smaller than those in the outer 
Figure 46)274. 
-
Figure 46). In contrast, 21 days old LNCaP spheroids 
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Figure 46). 
population of Ki67-
Figure 46). 
-
Figure 46). 
 
 LNCaP spheroids of diameter 100
pimonidazole for 24 h then fixed in formalin and stained with an anti
(Hypoxiprobe™, 1:5,000) as described in Section 
regions within spheroids. Hematoxylin and eosin (H&E) staining was used to reveal the internal morphology 
of the spheroids. The bars indicate 150 
 
Day 0 SK-N-BE(2c) spheroids contained 
proliferative cells (Figure 
of a heterogeneous population of cells: a hypoxic core surrounded by a Ki67
proliferating outer layer (
numerous densely organised nuclei whereas the inner core contained fewer nuclei of 
chaotic morphology, indicative of a healthy outer layer surrounding a dying core (
47). 
 
Day 0 UVW/NAT spheroids showed a homogeneous, non
population of cells (Figure 
heterogeneous population of cells: there was a hypoxic core surrounded by an outer layer 
of Ki67-positive proliferating cells (
pCASP3, signifying apoptosis (
 
Figure 47 Hypoxic core and proliferative outer layer in SK
-150 µm (day 0) or 500 µm (day 21) were exposed to 200 
-pimonidazole adduct antibody 
6.3.10. Ki67 staining was used to reveal proliferating 
µm. 
a homogeneous population of normoxic and 
47). On the other hand, day 21 SK-N-BE(2c) spheroids consisted 
Figure 47). H&E staining revealed an outer layer comprisi
-hypoxic and proliferative 
48). On the other hand, day 21 UVW/NAT spheroids showed a 
Figure 48). The hypoxic core stained positively for 
Figure 48). 
-N-BE(2c) spheroids
144
µM of 
-positive 
ng 
Figure 
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SK-N-BE(2c) spheroids with a diameter of approximately 100 µm (day 0) or 500 µm (day 21) were exposed 
to 200 µM of pimonidazole for 24 h, then fixed in formalin and stained with anti-pimonidazole adduct 
(Hypoxiprobe™, 1:5,000) as described in Section 6.3.10. Ki67 staining was used to reveal the proliferative 
status of the spheroids. Hematoxylin and eosin (H&E) were used to reveal the internal morphology of the 
spheroids. The bars indicate 150 µm. 
 
A significant observation was the presence of a hypoxic ring of greater staining intensity 
located at the periphery of the hypoxic core and on the internal edge of the outer layer. 
This feature was present in LNCaP (Figure 46), SK-N-BE(2c) (Figure 47) and UVW/NAT 
spheroids (Figure 48). The greater intensity of staining for pimonidazole adducts at this 
location could not be due to lower oxygen tension since this would be contrary to the 
depth-dependent oxygen gradient. A proportion of cells located on the internal edge of the 
outer layer which was defined by the H&E staining as a densely organised viable 
population of cells also stained positive for pimonidazole adducts. The illusion of greater 
intensity arose from the pimonidazole adduct staining of the more densely packed 
population of the outer layer compared with that of the dying core. This suggested there 
was a population of cells deemed viable according to the H&E staining which was also 
hypoxic. Finally, the width of the Ki67-positive proliferating ring was thinner than that of 
the H&E-stained viable outer layer (Figure 48). The Ki67-positive proliferating ring did 
not overlap with the hypoxic ring on the internal edge of the H&E-stained viable outer 
layer (Figure 48). These observations suggested the presence of a non-dividing or 
quiescent population of live cells located within the spheroids. The latter conclusion is 
speculative because a similarly hypoxic yet viable region was less apparent in LNCaP 
(Figure 46) or SK-N-BE(2c) spheroids (Figure 47). 
 
 Figure 48 Hypoxic core and proliferative outer layer in UVW/NAT spheroids
UVW/NAT spheroids with a diameter of approximately 100 
200 µM of pimonidazole for 24 
(Hypoxiprobe™, 1:1,000) as described in Section 
status of the spheroids. Hematoxylin and eosin (H&E) were used to reveal the morphology of the spheroids. 
Apoptosis was detected using an antibody directed against the phosphorylated form of caspase 3 (pCASP3). 
The segments determine the width of the outer layer of viable cells as defined by the H&E staining. The bars 
indicate 150 µm. 
 
6.4.2 Spheroid growth rate is dependent on initial size
The τ2, DT and AUClog
spheroids were compared with their initial diameter. The correlation between each of these 
parameters and initial volume was investigated
 
6.4.2.1 LNCaP 
Growth curves were constructed for three size classes of LNCaP spheroids
diameter ≤ 200 µm, those of diameter 200 to 300 
(Figure 49). Analysis of the growth curves indicated that the bigger the initial volume, the 
slower the growth (Figure 
between τ2, DT, AUC
displayed in Figure 49
 
τ2 = 0.04 V0 + 3.10 
 
µm (day 0) or 500 
h, then fixed in formalin and stained with anti-pimonidazole adduct 
6.3.10. Ki67 staining was used to reveal the proliferative 
 
 values of untreated LNCaP, UVW/NAT and SK
 by regression analysis
µm and those of diameter 
49a and Figure 49b). A regression analysis of the correlation 
log and initial volume (V0) was carried out. Acc
c, τ2 values can be defined as follows:  
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µm (day 21) were exposed to 
-N-BE(2c) 
.  
: those of 
≥ 300 µm 
ording to the data 
 The growth delay increased by 0.04 days for 
The R2 value was 10%, indicating that 10% of the variability of 
variability of V0 (n = 66) (
49d, DT values can be defined as follows: 
 
DT = 0.08 V0 + 3.54 
 
The doubling time increased by 0.08 days for every 1×10
The R2 value was 37%, indicating that 37%
variability of V0 (n = 66) (
49e, AUClog values can be define
 
AUClog = - 0.03 V0 + 2.70
 
The area under the logV/V
volume) for every 1×10
that 75% of the variability of AUC
(Figure 49e). 
 
Figure 49 The effect of the initial volume (V
Spheroids were sorted according to their initial diameter d
to demonstrate the difference between the initial volumes (a). The V/V
every 1×106 µm3 increase of V
τ2
Figure 49c). Similarly, according to the data
 
6
 µm3 increase of V
 of the variability of DT was explained by the 
Figure 49d). Finally, according to the data displayed in 
d as follows: 
 
0 versus time curve decreased by 0.03 AU (AU = time * 
6
 µm3 increase of V0 (p < 0.001). The R2 value was 75%, indicating 
log values was explained by the variability of V
0) on the growth rate of LNCaP spheroids
max at day 0. Spheroid volumes are plotted in order 
0 values are plotted to demonstrate the 
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0 (p = 0.008). 
 was explained by the 
 displayed in Figure 
0 (p < 0.001). 
Figure 
0 (n = 27) 
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inverse correlation between initial volume and growth rate (b). τ2 values are plotted against initial volume (c). 
DT values are plotted against initial volume (d). AUClog values are plotted against initial volume (e). The 
correlations between τ2, DT, AUClog and the initial volume were statistically evaluated using SPSS; the 
regression equation, the coefficient of determination R2, the number of spheroid N and the p-value are given 
for each parameter. 
 
6.4.2.2 SK-N-BE(2c) 
Growth curves were constructed for three size classes of SK-N-BE(2c) spheroids: those of 
diameter ≤ 100 µm, those of diameter 100 to 200 µm and those of diameter ≥ 200 µm 
(Figure 50). Analysis of the growth curves indicated that the bigger the initial volume, the 
slower the growth (Figure 50a and Figure 50b). A regression analysis of the correlation 
between τ2, DT, AUClog and V0 was carried out. According to the data displayed in Figure 
50c, τ2 values can be defined as follows: 
 
τ2 = 0.17 V0 + 1.96 
 
The growth delay increased by 0.17 days for every 1×106 µm3 increase of V0 but the 
correlation was not statistically significant (p = 0.162) (Figure 50c). Similarly, according to 
the data displayed in Figure 50d, DT values can be defined as follows:  
 
DT = 0.19 V0 + 1.96 
 
The growth rate increased by 0.19 days for every 1×106 µm3 increase of V0 (p < 0.001). 
The R2 value was 71%, indicating that 71% of the variability of DT was explained by the 
variability of V0 (n = 21) (Figure 50d). Finally, according to the data displayed in Figure 
50e, AUClog values can be defined as follows: 
 
AUClog = - 0.39 V0 + 5.46 
 
The area under the logV/V0 versus time curve decreased by 0.39 AU (AU = time * 
volume) for every 1×106 µm3 increase of V0 (p < 0.001). The R2 value was 67%, indicating 
that 67% of the variability of AUClog was explained by the variability of V0 (n = 21) 
(Figure 50e). 
 
 Figure 50 The effect of the initial volume (V
Spheroids were sorted according to their
to demonstrate the difference between the initial volumes (a). The V/V
inverse correlation between initial volume and growth rate (b). The 
volume (c). DT values are
(e). The correlation between 
the regression equation, the
given for each parameter.
 
6.4.2.3 UVW/NAT 
Growth curves were constructed for three size classes of UVW/NAT spheroids (i) those of 
diameter ≤ 100 µm, (ii) those of diameter 100 and 200 
µm (Figure 51). Analysis of the growth curves indicated that the bigger the
the slower the growth (
τ2, DT, AUClog and V
Figure 51c, τ2 values can be defined as follows:
 
τ2 = 0.48 V0 + 0.87 
 
The growth delay increased by 0.48 days for every 1×10
The R2 value was 60%, indicating that 60% of the variability of 
variability of V0 (n = 40) (
displayed in Figure 51
0) on the growth rate of SK-N-BE(2c) spheroids
 initial diameter dmax at day 0. Spheroid volumes are plotted in order 
0 values are plotted to demonstrate the 
τ2 values are
 plotted against initial volume (d). AUClog values are 
τ2, DT, AUClog and the initial volume was statistically evaluated using SPSS; 
 coefficient of determination R2, the number of spheroid N and the p
 
µm and (iii) those of diameter 
Figure 51a and Figure 51b). The analysis of the correlation between 
0 was carried out. According to the growth delay data displayed in 
 
6
 µm3 increase of V
τ2
Figure 51c). Similarly, according to the doubling time data 
d, DT values can be defined as follows:  
149
 
 
 plotted against initial 
plotted against initial volume 
-value are 
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 initial volume, 
0 (p < 0.001). 
 was explained by the 
  
DT = 0.26 V0 + 2.17 
 
The growth rate increased by 0.26 days for every 1×10
The R2 value was 51%, indicating that 51% of the variability of DT was explained by the 
variability of V0 (n = 40) (
displayed in Figure 51
 
AUClog = - 0.33 V0 + 3.99
 
The area under the logV/V
volume) for every 1×10
that 40% of the variability of AUC
(Figure 51e). 
 
Figure 51 The effect of the initial volume (V
Spheroids were sorted according to their initial diameter d
to demonstrate the difference between the initial volumes (a). The V/V
inverse correlation between initial volume and growth rat
DT values are plotted against initial volume (d). AUC
correlation between τ2, DT, AUC
regression equation, the coefficient of determination
for each parameter. 
6
 µm3 increase of V
Figure 51d). Finally, according to the ar
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0 versus time curve decreased by 0.33 AU (AU = time * 
6
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These data demonstrate the statistically significant correlation between the three 
parameters τ2, DT and AUClog and the initial volume of LNCaP, SK-N-BE(2c) and 
UVW/NAT spheroids. Based on these results, all subsequent growth delay experiments 
have been carried out with spheroids of similar initial sizes in order to minimise the 
variation of the growth rate due to variation in initial size. 
 
6.4.3 Determination of the dose-response relationship using the spheroid model  
Our goal is to evaluate the radiosensitising potential of a drug in combination with targeted 
radiotherapy. For this purpose, spheroid growth curves must be analysed to determine the 
dose-response relationship. Furthermore, the dose-response relationship must conform to 
the median effect principle in order to calculate a combination index for the determination 
of supra- or infra-additive kill. 
 
In order to transform spheroid growth delay data into a dose-response relationship, the 
growth curve of a particular treatment must be reduced to a single value, which would 
represent the measure of the effect of a particular treatment. Several parameters have been 
described previously: τ2, DT, AUClog and AUClinear. Alternatively, the V/V0 value at a 
particular timepoint could be used as a measure of the effect of a treatment. 
 
The median effect principle requires the surviving fraction to decrease with increasing 
doses. Thus, τ2 and DT values, which both increase with increasing treatment dose, are not 
suitable for the application of the median effect principle. On the other hand, the AUClog, 
AUClinear or the V/V0 values at a particular timepoint decrease with increasing doses. Thus 
these three parameters were considered for the application of the median effect principle. 
 
An example will be used for the determination of the best parameter for the application of 
the median effect principle (Figure 52). The effect of various concentrations of the 
radiopharmaceutical [131I]MIP-1095 on the growth of LNCaP spheroids is shown on a 
linear scale (Figure 52a) and on a log scale (Figure 52b). The effect of a drug may be 
defined as the fractional reduction of the spheroid volume compared with that of the 
control, i.e. the affected fraction. The unaffected fraction, or surviving fraction, is given by 
1 minus this effect. The surviving fractions (1 minus the fractional reduction in V/V0) were 
calculated by dividing the V/V0 value after treatment by that of the untreated control at 
each timepoint. The resultant DSF:Cu dose-response relationship at each timepoint 
 demonstrated the variability of the surviving fractions 
The corresponding median eff
demonstrate the applicability of the median effect equation at 23 and 27 days, as indicated
by the R2 values greater than 0.9 (
confirmed the unreliability of the arbitrary choice of a p
application of the median effect principle (
 
Figure 52 The effect of the arbitrary choice of a timepoint on the variability of the surviving fractions
The effect of [131I]MIP-1095 on the growth of LNCaP spheroids is shown on a linear scale (a) or on a log 
scale (b). At each timepoint, the V/V
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effect, i.e. the growth curve resulting from such an effect should be equidistant between the 
growth curve of the untreated control and that of the maximal effect. Sterilisation is 
manifest by a growth curve defined by V/V0 values of 1. Therefore, the theoretical growth 
curve obtained in response to treatment with the IC50 dose of [131I]MIP-1095 can be 
obtained by plotting the volumes at each timepoint according to: 
 
V/V0 IC50 = (V/V0 control - 1) / 2  (20) 
 
The growth curve of the theoretical median effect is shown in Figure 53c. It plotted 
between the growth curves resulting from treatment with 0.37 and 1 MBq/ml [131I]MIP-
1095, indicating an IC50 value situated within this range (Figure 53c). Since the IC50 
concentration calculated using the AUClinear values was 1.04 MBq/ml, it was concluded 
that the AUClinear values were more suited than AUClog values for the application of the 
median effect principle. This observation was made in several other experiments not 
reported here. 
 
6.4.4 The influence of spheroid size on DSF:Cu cytotoxicity  
It has previously been shown that the size of spheroids as well as the presence of a non-
dividing and hypoxic population within spheroids influenced the response to drug 
treatment258. Therefore, the effect of spheroid size on the cytotoxicity of DSF:Cu was 
investigated (Figure 54). Non-hypoxic spheroids (average of 111 µm in diameter) were 
exposed to various concentrations of DSF:Cu. A concentration-effect relationship was 
observed for the growth delay but not for the doubling time. The τ2 values were 3.66 ± 
0.45, 4.21 ± 0.48, 6.43 ± 1.28 (p < 0.05) and 11.95 ± 1.55 (p < 0.001) days for the 
untreated controls, 1 µM, 3.37 µM and 10 µM DSF:Cu respectively. LNCaP spheroids 
were sterilised after exposure to 33.7 µM as indicated by the sub-zero AUClog value (p < 
0.001) (Figure 54a and Table 8a). Interestingly, the DT values did not significantly 
increase with DSF:Cu concentrations up to 10 µM (Table 8a). This indicated that DSF:Cu 
killed a sub-population of cells within the spheroid, the affected fraction, whereas the 
unaffected fraction was responsible for the subsequent growth at the same rate as the 
untreated controls (Table 8a). 
 
 Figure 54 The effect of spheroid size on DSF:Cu
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 acidic pH in the core of the spheroid and/or penetration within the spheroid may influence 
DSF:Cu cytotoxicity.
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confluence, density limitation is a signal for cessation or reduction of proliferation. In non-
perfused cell cultures, the lack of nutrients, the accumulation of harmful waste and the 
acidification of the culture medium also cause cessation or reduction of the growth 
fraction275. Cellular monolayers in the plateau phase of their growth have been used as an 
in vitro model for the investigation of the effect of chemotherapeutic drugs in conditions 
found in the core of tumours, but without the penetration problems encountered in 3-D 
aggregates such as spheroids277,278. LNCaP cells in the plateau phase of their growth are 
used to determine whether proliferating status influences DSF:Cu cytotoxicity. 
 
The MTT assay was used to assess the viability of LNCaP cells in various phases of 
growth. LNCaP cells seeded at 2,500 cells/cm2 grew at a constant rate over 10 days, as 
indicated by the increase in A570 (Figure 55a). In contrast, LNCaP cells seeded at 6,500 or 
13,000 cells/cm2 attained maximal formazan formation at day 7 and day 5 after seeding, 
respectively (Figure 55a). The maximal A570 value was 0.85, which was indicative of a 
plateau phase rather than the upper detection limit of formazan. Indeed, formazan 
absorbance increased linearly with cell number up to an A570 value of 1.2 (Figure 55b). 
Furthermore, daily microscopic examination of the monolayers confirmed that cell 
numbers increased until the cultures became confluent. 
 
Three days after initiating LNCaP monolayers, the cells seeded at 2,500, 6,500 or 13,000 
cells/cm2 started to proliferate (Figure 55a). Treatment of the cultures at this time point 
with 1 µM DSF:Cu significantly reduced the viability of LNCaP cells by 80-95% 
regardless of the number of cells seeded (Figure 55c). At day 5, LNCaP cells seeded at 
2,500 or 6,500 cells/cm2 were proliferating and 1 µM DSF:Cu significantly reduced their 
viability by 80-95% (Figure 55d). In contrast, LNCaP cells seeded at 13,000 cells/cm2 
reached the plateau phase at day 5. In this case, the viability was reduced by only 30% 
following treatment with 1 µM DSF:Cu (Figure 55d). This indicated that DSF:Cu was 
more toxic to proliferating cells. At day 7, LNCaP cells seeded at 2,500 cells/cm2 were 
proliferating, whereas those seeded at 6,500 or 13,000 cells/cm2 reached the plateau phase 
(Figure 55a). At this timepoint, treatment with 1 µM DSF:Cu reduced the viability of 
LNCaP cells by 20-40%, regardless of the proliferative status of the cells (Figure 55e). 
This indicated that the proliferating state of LNCaP cells was not the sole determinant of 
DSF:Cu cytotoxicity since LNCaP cells seeded at 2,500 cells/cm2 were proliferating at day 
7 but those seeded at 6,500 and 13,000 cells/cm2 were not (Figure 55a). The culture 
medium of LNCaP cells was deliberately not replaced by fresh medium over the course of 
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the experiment in order to recreate the accumulation of harmful waste and the acidification 
of the culture medium encountered in the core of hypoxic spheroids or in non-vascularised 
regions of tumours. Therefore, it was hypothesised that acidification of the culture medium 
could also be a determinant responsible for the loss of sensitivity to DSF:Cu treatments 
encountered after 7 days in culture (Figure 55e). 
 
Most cells grow well at pH 7.4, though some cell types have shown preferences for pH in 
the range 5.5 – 7.7275. In an investigation of the effect of pH (range 6 to 7.2) on the 
cytotoxicity of l-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU), it has been observed 
that pH 6 reduced the plating efficiency of mouse mammary cells EMT6 by 70%278. The 
pH of the culture medium used for LNCaP cells is 7.2. Hydrochloric acid was added until 
pH 6.0 was reached. Alternatively, sodium hydroxide was added until pH 8.1 was 
obtained. Firstly, LNCaP cells seeded at 2,500, 6,500 or 13,000 cells/cm2 were exposed to 
culture media at pH 6.0, 7.2 or 8.1 and the viability was measured (Figure 56a). Secondly, 
LNCaP cells seeded at 2,500, 6,500 or 13,000 cells/cm2 were used for the investigation of 
the effect of pH on DSF:Cu cytotoxicity (Figure 56b, Figure 56c and Figure 56d). 
Exposure to DSF:Cu was carried out 5 days after seeding so that the results were 
comparable to those presented in Figure 56d. 
 
The decrease of pH from 7.2 to 6.0 reduced the viability of LNCaP cells seeded at 2,500, 
6,500 or 13,000 cells/cm2 by 75% (p < 0.001), 60% (p < 0.001) or 40% (p < 0.01), 
respectively (Figure 56a). There was a statistically significant correlation between 
increasing cell density and decreased toxicity at pH 6.0 (r = 0.97, p < 0.001), indicating 
that increasing seeding density conferred upon LNCaP monolayers resistance to acidic pH. 
After 5 days in culture, LNCaP cells seeded at 2,500 or 6,500 cells/cm2 were proliferating 
whereas those seeded at 13,000 cells/cm2 were in plateau phase (Figure 55a). Thus, it 
could be hypothesised that a slower proliferating rate conferred upon LNCaP cells 
resistance to acidic pH. 
 
 Figure 55 The effect of confluency o
(a) LNCaP cells were seeded in 96
LNCaP cells was assessed by formazan absorbance (at 570 nm) measurements 3, 4, 5, 7 and 10 days
seeding. The culture medium was not replaced by fresh culture medium at any time throughout the course of 
the experiment. (b) The relationship 
analysis was applied to the linear 
equation of the linear regression and the
viability of LNCaP cells seeded at 2,500, 6,500 or 13,000 cells/cm
was assessed by formazan absorbance measurements 3, 5 and 7 days after seeding. The 
DSF:Cu-treated groups were normalised to the mean absorbance value of the untreated groups for each 
seeding density. Data are mean ± SEM; n=3. The independent sample t
formazan absorbance values of the DSF:Cu treated groups with that of their respective controls at every 
seeding density. One symbol indicates p < 0.05 and two symbols indicate p 
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Figure 56 The effect of pH on DSF:Cu cytotoxicity in LNCaP monolayers
LNCaP cells were seeded in 96
was assessed by formazan absorbance measurements 5 days after seeding. The pH of the culture medium was 
adjusted to 6.0 by incremental additions of hydrochlori
hydroxide. (a) The effect of pH on untreated LNCaP cells was assessed by formazan absorbance 
measurements. Data are mean ± SEM; n=3. 
seeded at 2,500, 6,500 and 13,000 cells/cm
formazan absorbance measurements 5 days after seeding. For every pH and seeding density, the mean 
formazan absorbance value of the DSF:Cu
the untreated control. Data are mean ± SEM; n=3. For every pH and seeding density condition, the 
independent sample t-test was used to compare the mean formazan absorbance value of the DSF:Cu
groups with that of the untreated control. Two symbols indicate p < 0.01 and three symbols indicate p < 0.01.
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(Figure 56c). Again, there was no significant difference in the cytotoxicity of DSF:Cu 
resulting from altered pH (p > 0.05). Finally, although statistical significance was not 
reached, the viability of LNCaP cells seeded at 13,000 cells/cm2 was reduced by 15% or 
30% after treatment with 1 µM DSF:Cu at pH 6.0 or 8.1, respectively (Figure 56d). These 
results indicated that DSF:Cu cytotoxicity was not dependent on the pH of the culture 
medium. 
 
These results suggest that DSF:Cu is more efficient at killing cells within small spheroids 
which have not developed an organised internal morphology (Figure 54, Table 8). Studies 
using plateau phase cells have indicated that non-dividing cells or cells dividing at a slower 
rate than those in the proliferating phase were more resistant to DSF:Cu treatments (Figure 
55). Since plateau phase cells did not receive fresh medium in the course of these 
experiments, it was possible that the accumulation of harmful waste, such as lactic acid, 
which also causes acidification of the culture medium, conferred upon LNCaP cells 
resistance to DSF:Cu treatments. However, pH variations within the range 6.0 to 8.1 did 
not affect DSF:Cu cytotoxicity. This suggested that the proliferating state of the cells but 
not the pH of the culture medium affected DSF:Cu cytotoxicity. That is, fast growing cells 
are more sensitive to DSF:Cu treatment than slow-growing cells. 
 
The effect of the hypoxic status on DSF:Cu cytotoxicity and the capacity of DSF:Cu to 
penetrate large spheroids are discussed in Section 6.5. 
 
6.5 Discussion/summary of the results 
Firstly, this chapter was concerned with the characterisation of the cellular aggregates 
obtained after seeding single cells onto agar-coated surfaces with respect to their 
morphology at a juvenile and at a more advanced stage of their growth. It has long been 
known that these cellular aggregates differentiate from a homogeneous to a heterogeneous 
mass of cells comprising a hypoxic and apoptotic core surrounded by a layer of 
proliferating cells254. These are called spheroids. The finding that these morphological 
changes occurred with increasing size (Table 9) demonstrated that the small cellular 
aggregates were indeed spheroids, the cell culture tool previously described as an in vitro 
model of avascular micrometastases265-268. 
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 Marker 
Staining 
Inner core Outer layer 
Day 0 spheroids 
(100-150 µm in 
diameter) 
Ki67 
(proliferation) 
yes 
Pimonidazole 
adducts (hypoxia) 
yes 
Day 21 spheroids 
(500-600 µm in 
diameter) 
Ki67 
(proliferation) 
no yes 
Pimonidazole 
adducts (hypoxia) 
yes no 
pCASP3 
(apoptosis) 
yes no 
Table 9 Summary of the metabolic characteristics of spheroids at day 0 and at day 21 
 
Spheroid initiation involves the seeding of single cells onto an agar-coated surface. The 
doubling time of LNCaP cells in vitro is approximately 60 h279, thus the clonal expansion 
from a single cell could only form an aggregate comprising between 2 and 4 cells after the 
initiation period which lasted 3 to 4 days. Therefore, it is likely that the majority of the 
spheroids were formed by aggregation rather than by clonal expansion. 
 
In conditions designed to keep constant the nutrient and oxygen concentrations in the 
culture medium, the depth to which each molecule of the culture medium can penetrate 
into the spheroid is dependent on its physico-chemical properties such as lipophilicity and 
the molecular weight280. The result is the formation of gradients of pH, oxygen and 
nutrients within spheroids254. As the spheroids grow, the oxygen, nutrients and pH 
gradients are responsible for the increase in acidity and the decrease in concentrations of 
oxygen and nutrients at the deepest locations within the spheroid. Thus, a layer forms at 
the surface of the spheroid within which the pH and the concentrations of oxygen and 
nutrients are suitable to sustain cellular growth (Figure 46, Figure 47 and Figure 48). The 
depth of this layer is directly dependent on the concentration of nutrients and oxygen in the 
culture medium but also on their penetrability. It follows that, in conditions designed to 
keep constant the nutrient and oxygen concentrations in the culture medium, the depth of 
the layer capable of sustaining cellular proliferation remains constant. Therefore, the 
relative proportion of proliferative cells within the whole of the spheroid decreases as the 
spheroid grows in size, leading to an apparent decreasing growth rate. This phenomenon 
was particularly prominent in SK-N-BE(2c) (Figure 50) and UVW/NAT spheroids (Figure 
51). It also explains why bigger spheroids grow more slowly than smaller spheroids 
(Figure 49, Figure 50 and Figure 51). 
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The demonstration that DSF:Cu was more cytotoxic in day 0 spheroids (100-150 µm in 
diameter) than in day 21 spheroids (500-600 µm in diameter) may be due to penetration 
issues, the presence of hypoxic region, the presence of a non-dividing population of cells 
or the presence of a region with acidic pH. It is improbable that resistance of LNCaP 
spheroids to DSF:Cu treatment (Figure 54, Table 8) was due to a poor penetrability 
because of the very small size (360 g/mol) and the lipophilic character of the DSF:Cu 
complex. Furthermore, it was previously demonstrated in Section 3.4.3 of this thesis that 
DSF:Cu entered the intracellular space without the assistance of a permeabilising agent 
(Figure 14). Therefore it was more likely that the oxygen status, the pH or the proliferative 
status of the cells within day 21 spheroids influenced DSF:Cu cytotoxicity. The effect of 
hypoxia on DSF:Cu cytotoxicity was assessed in monolayers but the results were 
inconclusive and not reported in this thesis. Indeed, as a positive control, monolayers were 
irradiated in hypoxic conditions and the clonogenic kill compared with that of cells 
irradiated in normoxic conditions. There was no prevention of the clonogenic kill in 
hypoxia compared with normoxia. The results of this experiment were not conclusive since 
hypoxic conditions were not achieved.  
 
The use of plateau phase monolayers suggested that DSF:Cu was more cytotoxic to fast-
growing cells compared with slow-growing cells or quiescent cells (Figure 55). The 
response to DSF:Cu treatment of plateau phase cells indicated that the pH did not affect the 
cytotoxicity of DSF:Cu (Figure 56). The demonstration of the increased DSF:Cu 
cytotoxicity in proliferating compared with non-proliferating LNCaP cells suggested that a 
quiescent sub-population of cells within day 21 spheroids which had undergone 
morphological reorganisation resisted DSF:Cu treatment and was able to recover and grow 
at a rate similar to that of untreated controls (Figure 54). Evidence of such a sub-population 
was found in UVW/NAT spheroids (Figure 48), but was not as obvious in LNCaP (Figure 
46) or SK-N-BE(2c) spheroids (Figure 47). Indeed, within UVW/NAT spheroids, there 
was a hypoxic ring of cells deemed viable by H&E staining yet not proliferating as 
indicated by the absence of Ki-67 staining (Figure 48). These results suggested that, in 
patients, DSF:Cu may be more cytotoxic to proliferating tumour cells than to non-
proliferating healthy tissues. 
 
The resistance to DSF:Cu treatment of day 21 spheroids which have undergone internal 
morphological changes has implications for the optimal application of this compound for 
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the treatment of cancer. It suggested that DSF:Cu should be especially effective for the 
elimination of undetectable, micrometastatic malignant deposits which have not developed 
oxic heterogeneity. It is unlikely that DSF:Cu as a single agent treatment will eliminate 
larger metastases which have undergone internal morphological changes since a 
concentration of more than 33.7 µM would be required (Figure 54). This concentration is 
100 times greater than the peak plasma concentration of DSF resulting from the 
administration of a 250 mg oral dose161. 
 
The assessment of the interaction between the agents of a combination treatment (additive, 
supra- or infra-additive) requires the use of the combination index or the isobologram 
method of synergy analysis. Synergy analysis is based on the median effect principle 
which mathematically relates the surviving fraction to the dose. In order to apply such an 
analysis to a spheroid growth delay experiment, the growth curves must be converted into 
a single parameter describing the effect of the treatment in terms of a surviving fraction. 
The results of this chapter showed that AUClinear values were amenable to the calculation 
of a surviving fraction. The surviving fraction after a particular treatment was defined as 1 
minus the fractional reduction of the AUClinear value compared with that of the control. 
This analytical method will be used in chapter 5 for the assessment of the effect of the 
combination of DSF:Cu with γ-radiation or with radiopharmaceuticals in spheroids which 
have not yet undergone internal morphological changes. 
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7 The enhancement of the effect of radiopharmaceuticals by 
DSF:Cu 
7.1 Introduction 
Targeted radiotherapy was introduced in Section 1.1.3. Targeted radiotherapy uses tumour-
seeking radiopharmaceuticals for the systemic delivery of radiation specifically to 
malignant lesions while limiting the toxicity to normal tissues. It has been used 
successfully for the palliation of bone metastases (Section 1.1.4.2) and is a curative 
treatment of thyroid carcinoma (Section 1.1.4.1)281,282. However, the treatment of other 
diseases such as neuroblastoma by targeted radiotherapy as a single modality is limited by 
haematological toxicity and cure rates remain low (Section 1.1.4).  
 
The results of Section 4.4.3 demonstrated the synergistic interaction between DSF:Cu and 
γ-radiation treatments which resulted in radiosensitisation. Thus, the putative synergistic 
interaction between radiopharmaceuticals and DSF:Cu could increase the tumouricidal 
effect of targeted radiotherapy, and improve patient outcome, without increasing radiation 
doses to levels detrimental to the patient. Furthermore, since a radiation dose is delivered 
specifically to the malignant lesions, the putative synergistic effect would only occur in the 
tumour while sparing normal tissue. The combination of DSF:Cu with targeted 
radiotherapy is not expected to result in a synergistic increase in normal tissue toxicity. 
The combination of DSF:Cu with radiopharmaceuticals will be investigated in order to 
determine whether a synergistic interaction similar to that of the combination with external 
beam radiotherapy occurs between DSF:Cu and radiopharmaceuticals. 
 
The radiopharmaceuticals [131I]mIBG and [131I]MIP-1095 were described previously in 
Sections 1.1.4.5 and 1.1.4.6. Briefly, mIBG is a radiopharmaceutical taken up by cells 
expressing the noradrenaline transporter (NAT). [123I]mIBG has been successfully used for 
the imaging of neuroblastoma. Clinical trials investigating the therapeutic potential of 
[131I]mIBG have yielded overall response rates between 30% and 58%33-40. [131I]MIP-1095 
has been developed to target PSMA65, which is overexpressed in malignant metastatic 
PCa60. CRPC is associated with a poor prognosis despite intensive hormonal and 
chemotherapeutic treatments. The median survival of patients with metastatic CRPC is 1 to 
2 years50-52. Thus alternative strategies need to be developed to improve the outcome of 
this subset of patients. 
 
 166
7.1.1 Study model 
The enhancement of the radiation kill was defined as the rightward and/or downward 
displacement of the spheroid growth curve obtained by combination treatment compared 
with that achieved by radiation treatment alone. τ2, DT and AUClog were used to quantify 
potentiation of radiation kill. 
 
The study of the combination of DSF:Cu with [131I]mIBG was carried out in spheroids 
derived from the neuroblastoma cell line SK-N-BE(2c), which endogenously expresses 
NAT, and in spheroids derived from the NAT-transfected glioma cell line UVW/NAT. The 
evaluation of the combination of DSF:Cu and [131I]MIP-1095 was performed in spheroids 
derived from the prostate carcinoma cell line LNCaP, which expresses the target PSMA. 
LNCaP cells do not form colonies so that the analysis of the combination of DSF:Cu with 
γ-radiation using the clonogenic assay could not be performed in chapter 4. Therefore, the 
evaluation of the effect of DSF:Cu in combination with γ-radiation in LNCaP cells was 
conducted using spheroids. 
 
The term “radiosensitisation” will not be used to refer to the enhancement of the cytotoxic 
effect of radiopharmaceuticals for the following reason. A “true radiosensitiser” was 
defined previously as “[…] a chemical which increases the cell-killing effect of a given 
dose of radiation. This is achieved either by increased formation of longer-lived toxic 
radiation-induced radicals or modification of vulnerable, critical targets in cells, or by 
interference with mechanisms of repair of sublethal radiation damage”82. In assessing the 
effect of a combination of a drug with a radiopharmaceutical in spheroids, the 
enhancement of the effect of the radiopharmaceutical may be due to the increase in its 
penetrability within tissues or to the increased binding to its target, the increased 
expression of transporter genes, as well as radiosensitising properties per se. Such effects 
on penetrability and/or binding of a radiopharmaceutical are independent of the 
enhancement of the kill due to the absorption of a radiation dose by a cell. Therefore, the 
term “radiosensitisation” will be replaced by enhancement or potentiation of the growth 
delay induced by radiopharmaceuticals. 
 
7.2 Aims 
- to evaluate the effect of DSF:Cu on the growth delay induced by γ-radiation in 
LNCaP spheroids 
 167
- to evaluate the effect of DSF:Cu on the growth delay induced by [131I]mIBG in SK-
N-BE(2c) and UVW/NAT spheroids 
- to evaluate the effect of DSF:Cu on the growth delay induced by [131I]MIP-1095 in 
LNCaP spheroids 
 
7.3 Materials and methods 
7.3.1 Spheroid initiation 
See Section 6.3.1. 
 
7.3.2 Spheroid treatments 
As a preliminary study, and in order to simplify analysis of treatment interaction with 
hypoxia, acidic pH and heterogeneous proliferation status, small spheroids, approximately 
150 µm diameter, which had not yet undergone internal morphological changes were used 
to assess the toxicity of DSF :Cu in combination with radiopharmaceuticals. Such 
spheroids provide a 3-dimensionnal structure wherein cross-fire radiation from 
radiopharmaceutical-bound radionuclide will make a contribution to growth inhibition. 
 
7.3.2.1 DSF:Cu treatment 
See Section 6.3.2. 
 
7.3.2.2 γ-radiation treatment 
See Section 4.3.2. 
 
7.3.2.3 Radiopharmaceutical treatment 
After 3 to 4 days of incubation at 37ºC and 5% CO2, spheroids were centrifuged at 300 
rpm for 3 minutes and resuspended in 2 ml fresh culture medium. Based on previous 
studies demonstrating optimal [131I]mIBG uptake after 2 h of exposure283, spheroid growth 
delay experiments using spheroids grown from SK-N-BE(2c) and UVW/NAT cell lines 
were exposed to [131I]mIBG for 2 h at 37°C and 5% CO2. At the end of the incubation 
period, [131I]mIBG that had not been taken up by the cells was removed by washing three 
times in PBS. 
 
Similarly, after 3 to 4 days of incubation at 37ºC and 5% CO2, the spheroids were 
centrifuged at 300 rpm for 3 minutes and resuspended in 2 ml fresh culture medium. The 
optimal duration of exposure of LNCaP spheroids to [131I]MIP-1095 was determined 
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experimentally. This is described in Section 7.4.2. At the end of the incubation period, 
excess [131I]MIP-1095 that had not been taken up by the cells was removed by washing 
three times in culture medium. Culture medium was used for the washes instead of PBS 
because Molecular Insight Pharmaceuticals, Inc observed that PBS, but not culture 
medium, inhibited the binding of [131I]MIP-1095 to PSMA (Dr S. Hillier, personal 
communication). 
 
7.3.2.4 Combination treatment 
In the case of combination treatment consisting of DSF:Cu and γ-radiation, spheroids were 
exposed to DSF:Cu in serum-free culture medium immediately followed by irradiation. 
Spheroids were then incubated at 37°C and 5% CO2 for 24 h before removal of excess 
DSF:Cu and the start of the monitoring of the size of individual spheroids. In the case of 
combination treatment consisting of DSF:Cu and a radiopharmaceutical, spheroids were 
treated with DSF:Cu and radiopharmaceutical simultaneously and incubated at 37°C and 
5% CO2 for 2 h. Thereafter excess radiopharmaceutical was washed off. The spheroids 
were re-incubated at 37°C and 5% CO2 for 22 h in the presence of DSF:Cu before removal 
of the excess DSF:Cu by washing three times and the start of the monitoring of the size of 
individual spheroids. 
 
7.3.3 [131I]MIP-1095 uptake 
LNCaP spheroids were treated with various concentrations of [131I]MIP-1095 for 0.25, 0.5, 
1, 2 and 8 h at 37°C and 5% CO2. Alternatively, LNCaP spheroids were equilibrated at 4°C 
for 30 min prior to treatment with [131I]MIP-1095 at 4°C and 5% CO2. At the end of the 
treatment, LNCaP spheroids were washed three times in culture medium, centrifuged and 
the pellets were resuspended in 1 ml fresh culture medium. A γ-counter (Canberra Packard, 
Berkshire) was used to measure the radioactivity (in count per minute [CPM]) retained in 
the pellet. The protein content of the pellet was measured according to Section 7.3.4 and 
the uptake value was expressed as CPM per mg of protein. 
 
7.3.4 Protein extraction and quantification 
Protein extracts of the spheroid pellets were obtained by incubation in 100 µl lysis buffer 
[protease inhibitor (Calbiochem), 1.19 g Hepes, 1.46 g NaCl and 0.5 ml Nonidet P-40 in 
100 ml distilled water, pH 7] for 45 min on ice. The extracts were centrifuged at 16,000 g 
for 5 min and the protein content of the supernatants was quantified using the Bradford 
assay284. Protein extracts and bovine serum albumin (BSA) standards (0, 0.2, 0.4, 0.6, 0.8, 
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1 mg/ml) were mixed in equal ratios with the Bradford reagent (Bio-Rad) in dH2O and the 
absorbance was measured at 595 nm (A595). The absorbance values (A595) and the protein 
concentrations of the BSA standards in mg/ml [BSA] were used to determine the 
relationship between absorbance and protein content according to equation (21): 
 
A595 = b*[BSA] + a  (21) 
 
Linear regression analysis of equation (21) by the method of the least squares allowed the 
calculation of the slope b and the y-intercept a. The amount of proteins in each spheroid 
pellet extract [extract] in mg was calculated using equation (22): 
 
[extract] = 0.1 * (A595 extract – a) / b  (22) 
 
7.3.5 Spheroid measurement 
See Section 6.3.3. 
 
7.3.6 Calculation of τ2 and DT values 
See Section 6.3.4. 
 
7.3.7 Calculation of AUC values 
See Section 6.3.5 
 
7.3.8 Statistical analyses 
Because the distribution of τ2, DT and AUClog values were non-normally distributed, non-
parametric testing (the Kruskal-Wallis test followed by the Mann-Whitney test) was 
carried out using SPSS (IBM). 
 
7.3.8.1 Statistical analysis of single agent dose-response effects 
This procedure was described in more details in Section 6.3.6. Briefly, the medians of τ2, 
DT and AUClog values of the group treated with the highest treatment intensity were 
compared with those of the untreated control by non-parametric testing (Kruskal-Wallis 
test followed by the Mann-Whitney test). If a significant difference was obtained (p < 
0.05), the medians of τ2, DT and AUClog values of the next highest treatment intensity 
were compared with those of the untreated controls. This procedure was carried out until a 
pairwise comparison returned a non-significant p-value (greater than 0.05).  
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7.3.8.2 Statistical analysis of the effect of 2-(phosphonomethyl)pentanedioic acid 
(PMPA) on the spheroid growth delay induced by [131I]MIP-1095 
The statistical analysis of the effect of the PSMA-specific binding inhibitor PMPA on the 
spheroid growth delay induced by [131I]MIP-1095 was carried out as follows. The groups 
treated with 0.37, 1, 3.7 or 10 MBq/ml [131I]MIP-1095 in the absence of PMPA, in the 
presence of 10 µM PMPA or in the presence of 100 µM PMPA were considered a family. 
Each family was analysed separately. Firstly, the medians of τ2, DT and AUClog values of 
the group treated with [131I]MIP-1095 in the presence of 100 µM PMPA was compared 
with that of the group treated with [131I]MIP-1095 alone. If the p-value returned by the 
Mann-Whitney test was higher than 0.05, there was no further testing of this family. Any 
significant difference between the medians of the group treated with [131I]MIP-1095 in the 
presence of 10 µM PMPA and that of the group treated with [131I]MIP-1095 alone was 
considered random variation if there was no significant difference between the medians of 
the group treated with [131I]MIP-1095 in the presence of 100 µM PMPA and that of the 
group treated with [131I]MIP-1095 alone. 
 
On the other hand, if the p-value of the comparison between the medians of the group 
treated with [131I]MIP-1095 in the presence of 100 µl PMPA and that of the group treated 
with [131I]MIP-1095 alone was lower than 0.05, then the median of the group treated with 
[131I]MIP-1095 and 10 µM PMPA was compared with that of the group treated with 
[131I]MIP-1095 alone with a significance level of 0.05. This stepwise analysis was repeated 
independently for each family, i.e. for each radioactivity concentration of [131I]MIP-1095. 
 
7.3.8.3 Statistical analysis of the potentiation of radiation kill 
In order to demonstrate the enhancement of the radiation-induced growth delay, the 
observed effect in response to a combination treatment of a drug with radiation must be 
greater than that induced by radiation alone. Moreover, the effect in response to the 
combination treatment must be greater than that of the drug alone. Even though the effect 
of the combination is greater than that induced by radiation alone, if there is no significant 
difference between the drug-induced effect and the combination-induced effect, then the 
effect of the combination could only be due to that of the drug alone. Secondly, the 
absence of the enhancement of radiation-induced growth delay could be due to either the 
intrinsic inability of the drug to potentiate the effect of radiation or to the use of a dose of 
the drug too low to have any effect at all. Therefore, the effect of the single agents 
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compared with the untreated control must also be examined. Thus, the determination of the 
presence or the absence of potentiation of the effect of radiation involves a family of four 
pairwise comparisons: 
1- Drug versus untreated control 
2- Radiation versus untreated control 
3- Drug + radiation versus drug  
4- Drug + radiation versus radiation 
 
The multiple pairwise comparisons (four) required for the investigation of the 
enhancement of the growth delay induced by radiation are susceptible to the family-wise 
error. Indeed, the p-value is the probability to find a difference between two groups 
assuming there is none. If the significance level of a particular test is set at 5%, it follows 
from the definition of the p-value that in a family of comparisons, there is a 5% chance of 
finding a significant result assuming there is none. This is known as the family-wise error. 
The Bonferroni correction was used to overcome this issue. In order to keep the overall 
level of significance of 0.05, the level of significance of each pairwise comparison was set 
to 0.05 divided by the number of comparison, i.e. the significance level α was set at 0.0125 
(0.05/4 = 0.0125). 
 
7.3.9 Calculation of the combination index CI 
7.3.9.1 Calculation of IC50 and m parameters 
The surviving fraction of a treatment group was calculated as one minus the fractional 
reduction of the AUClinear value compared with that of the control. The median effect 
principle was applied to the surviving fraction values in order to calculate the parameters m 
and IC50 as described in Sections 3.3.5. 
 
7.3.9.2 Calculation of the CI value 
Knowing the values of the IC50 and m parameters, the median effect principle allows the 
calculation of a dose D that produces a particular effect (fa/fu) as described in Section 
4.3.5 by equation (12): 
 
D = IC50 × (fa/fu)1/m (12) 
 
The calculation of the CI values was performed at the toxicity level obtained following 
combination treatment. For instance, if the combination treatment consisting of agent A 
and agent B produced 95% reduction of the control AUClinear value, the CI value was 
 calculated at the 95% toxicity level. The doses of 
combination were selected, hence known. The doses of 
induce a 95% effect as single agents 
 
Secondly, the dose reduction index 
of this agent within the combination by the dose of this agent that induce
as a single treatment according to equation (15)
 
DRI = dose within the combination / dose as single agent
 
Finally, the CI value was calculated as
combination according to equation (16)
 
CI = DRIagentA + DRI
 
7.4 Results 
7.4.1 The radiosensitising effect of DSF:Cu in combination with 
treatment in LNCaP spheroids 
Prior to the study of the combination of DSF:Cu and 
radiation as single agent on the growth of LNCaP spheroids was investigated. The effect of 
DSF:Cu on the growth of LNCaP spheroids was described in Section 
the IC50 value of DSF:Cu was 1.82 
 
Figure 57 The effect of DSF:Cu on the growth of LNCaP spheroids
agent A and agent B
agent A and 
were calculated using equation (
DRI of one agent were calculated by dividing the dose 
: 
 (15) 
 the sum of the DRI values of each agent of the 
: 
agentB (16) 
 
γ-radiation treatment, the effect of 
µM (Figure 57d). 
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LNCaP spheroids were treated with various concentrations of DSF:Cu for 24 h. The V/V0 values are 
displayed on a linear scale (a) and on a logarithmic scale (b). Data are mean ± SEM. (c) τ2, DT and AUClog 
values were calculated according to Section 6.3.4 and 6.3.5. ∞ indicates that there was not a 2-fold increase 
in spheroid volume. Data are mean ± SEM. The statistical significance of the differences in τ2, DT and 
AUClog values between groups was determined by non-parametric testing (Kruskal-Wallis followed by 
Mann-Whitney tests) using SPSS. The medians of τ2, DT and AUClog values of DSF:Cu-treated groups were 
compared with those of the untreated control (*). One symbol indicates p < 0.05, two symbols indicate p < 
0.01 and three symbols indicate p < 0.001. (d) The surviving fraction (SF) was calculated using the AUClinear 
values. The median effect principle was applied to the SF values in order to calculate m and the IC50 of the 
effect of DSF:Cu according to Section 3.3.5. The coefficient of determination (R2) is a measure of the 
goodness of the fit of the linear regression of the median effect plot. 
 
Treatment with γ-radiation alone increased both the growth delay and the doubling time of 
the spheroids in a dose-dependent manner (Figure 58). The τ2 values were 3.06 ± 0.18, 
4.21 ± 0.57 (p < 0.001), 5.34 ± 0.28 (p < 0.001), 8.36 ± 0.65 (p < 0.001) and 11.55 ± 0.85 
(p < 0.001) days for untreated controls and the groups treated with 2, 4, 6 and 10 Gy, 
respectively (Figure 58c). The DT values were 2.80 ± 0.12, 3.41 ± 0.47 (p < 0.001), 5.37 ± 
0.25 (p < 0.001), 11.40 ± 0.98 (p < 0.001) and 15.24 ± 0.95 (p < 0.001) days for untreated 
controls and the groups treated with 2, 4, 6 and 10 Gy, respectively (Figure 58c). The IC50 
value for γ-radiation was 1.69 Gy (Figure 58d). The growth delay after γ-radiation 
treatment was due to a reduction in the growth rate. This effect is consistent with all the 
cells within the spheroids being affected by γ-radiation. If only a sub-population was 
affected by γ-radiation, the unaffected population would grow at the same rate as the 
untreated controls, thus showing a growth delay followed by a parallel growth curve to that 
of the untreated control at the later timepoints. The lack of a growth delay (Figure 58b) 
indicated that all cells were affected by γ-radiation treatment. 
 
Knowing the effects of DSF:Cu and γ-radiation as single agents, the investigation of the 
combination of both was carried out in order to determine whether DSF:Cu also 
radiosensitised LNCaP spheroids (Figure 59). The statistically significant increase in τ2 
and DT values and the statistically significant decrease in AUClog values following 
treatment with the combination of DSF:Cu and γ-radiation compared with either DSF:Cu 
or γ-radiation alone demonstrated the enhancement of γ-radiation kill by DSF:Cu. For 
instance, the τ2 values were 3.21 ± 0.14, 5.21 ± 0.43 (p < 0.001), 4.44 ± 0.28 (p < 0.001) 
and 5.47 ± 0.51 (p < 0.001) days for the untreated controls and the groups treated with 3 
Gy, 1 µM DSF:Cu and 3.37 µM DSF:Cu, respectively (Figure 59c). In comparison, the τ2 
values were 8.02 ± 0.78 (p < 0.01) days for the combination of 1 µM DSF:Cu with 3 Gy 
 and 14.12 ± 1.59 (p < 0.001) days for the combination of 3.37 
(Figure 59c). However, the increase in 
statistical significance according to both the DT and AUC
indicated that 1 µM DSF:Cu enhanced 
treatment (τ2 = 8.02 ± 0.78 days) wherea
γ-radiation-treated group thereafter. All three parameters 
significant enhancement of 
combination indices were 1.21 and 0.56 for the combinations of 3 Gy with 1 
µM DSF:Cu, respectively (
DSF:Cu and γ-radiation treatment only in response to 3.37 
 
Figure 58 The effect of γ
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concentrations of [131I]MIP-1095; a tendency toward saturation was indicated at 10 
MBq/ml by the reduction of the slope (Figure 60b). There was a statistically significant 
reduction of the binding to PSMA in the presence of the binding inhibitor PMPA. At 0.1 
MBq/ml [131I]MIP-1095, 10 µM and 100 µM PMPA inhibited 85% (p < 0.001) and 90% (p 
< 0.001) of the [131I]MIP-1095 binding to PSMA, respectively (Figure 60b). At 1 MBq/ml 
[131I]MIP-1095, 10 µM and 100 µM PMPA inhibited 55% (p < 0.01) and 75% (p < 0.001) 
of the binding, respectively (Figure 60b). At 10 MBq/ml [131I]MIP-1095, 10 µM and 100 
µM PMPA inhibited 10% and 40% (p < 0.05) of the [131I]MIP-1095 binding, respectively 
(Figure 60b). These data indicated the competitive nature of the [131I]MIP-1095 binding to 
PSMA. 
 
Next, the internalisation of [131I]MIP-1095 into the intracellular space of LNCaP cells 
within the spheroids was investigated at 37°C. LNCaP spheroids were exposed to 0.1 
MBq/ml [131I]MIP-1095 for 2 h. There was a 75% decrease in uptake at 4°C compared 
with that at 37°C (p < 0.01) (Figure 60c). PMPA inhibited 95% of the uptake at 37°C (p < 
0.01), indicating that binding is required for internalisation (Figure 60c). Also, 3.37 µM 
DSF:Cu had no effect on the uptake of [131I]MIP-1095 by LNCaP spheroids (Figure 60c), 
suggesting that DSF:Cu is unlikely to decrease [131I]MIP-1095 efficacy. 
 
Potassium cyanide (KCN), an inhibitor of the adenosine triphosphate (ATP) production by 
the mitochondrial respiratory chain, inhibited 70% of the uptake of [131I]MIP-1095 at 37°C 
(p < 0.001) (Figure 60d). This reduction of the uptake by KCN was similar to that induced 
by exposure to [131I]MIP-1095 at 4°C (Figure 60d), suggesting that cellular metabolism 
and ATP was required for internalisation.  
 
Chloroquine (CHQ) is an inhibitor of lysosomal degradation and of the recycling of the 
endosomes back to the cell membrane. It was added simultaneously with [131I]MIP-1095 in 
order to determine the involvement of endocytosis in the internalisation process of 
[131I]MIP-1095. CHQ inhibited 50% of the uptake of [131I]MIP-1095 at 37°C (p < 0.001) 
(Figure 60d). However, there was a statistically significant increase in [131I]MIP-1095 
uptake when spheroids were exposed to [131I]MIP-1095 with CHQ at 37°C compared with 
that at 4°C (p < 0.001) (Figure 60d). This result may be explained as follows. CHQ was 
shown to reduce the uptake of antibodies by inhibition of the recycling of the endosomes to 
the cell membrane, but not by inhibition of the binding to the antigen285. Thus, CHQ allows 
a first round of binding and internalisation of [131I]MIP-1095 but prevents the recycling of 
 PSMA receptors back to the membrane, thereby inhibiting a second round of 
internalisation. This was consistent with the obse
[131I]MIP-1095 at 37°C compared with that at 4°C in the presence of CHQ (p < 0.001).
 
Figure 60 The binding and internalisation of [
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If KCN and CHQ were toxic to LNCaP cells, the decrease in [131I]MIP-1095 uptake 
observed after such treatment would be due to their cytotoxicity since it was shown that 
reduced metabolic activity at 4°C or the lack of ATP production reduced [131I]MIP-1095 
uptake. Thus, the viability of LNCaP monolayers was assessed using the MTT assay 
following treatment with KCN and CHQ for 2 h. There was no statistically significant 
decrease in viability when LNCaP monolayers were treated with KCN and CHQ for 2 h 
(Figure 60e), thus discounting KCN- and CHQ-induced cytotoxicity as the cause of 
reduced [131I]MIP-1095 uptake. 
 
These results demonstrated the requirement of ATP for the internalisation of [131I]MIP-
1095 by endocytosis. The duration of exposure for optimal [131I]MIP-1095 uptake was 2 h 
at 37°C. This duration was used in subsequent spheroid growth delay experiments. 
 
7.4.3 Determination of PSMA-specific [131I]MIP-1095-induced LNCaP spheroid 
growth delay 
In order to determine the PSMA-specificity of [131I]MIP-1095-induced delay of LNCaP 
spheroid growth, [131I]MIP-1095 was administered to LNCaP spheroids in the absence 
(Figure 61a) or in the presence of 10 µM (Figure 61b) or 100 µM PMPA (Figure 61c). 
There was a significant dose-dependent increase in τ2 values in response to 0.37, 1 and 3.7 
MBq/ml [131I]MIP-1095 (Table 10). Apart from the DT value of the group treated with 3.7 
MBq/ml, the DT values increased in a dose-dependent manner with increasing [131I]MIP-
1095 radioactivity concentrations (Table 10). Similarly, the AUClog values significantly 
decreased in a dose-dependent manner with increasing [131I]MIP-1095 concentrations up to 
3.7 MBq/ml (Table 10). The τ2 and AUClog values demonstrated the absence of a 
significantly increased growth delay when the radioactivity concentration of [131I]MIP-
1095 was increased from 3.7 to 10 MBq/ml (Table 10). This was consistent with the 
tendency toward a plateau with respect to binding of [131I]MIP-1095 at a radioactivity 
concentration greater than 1 MBq/ml (Figure 60b). 
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dose-dependent binding of [131I]MIP-1095 to PSMA (Figure 60b). Indeed, PMPA was less 
efficient at inhibiting the binding of 3.7 and 10 MBq/ml [131I]MIP-1095 to PSMA than the 
binding of [131I]MIP-1095 at radioactivity concentrations less than 3.7 MBq/ml (Figure 
60b). Based on these data, a radioactivity concentration of 0.37 MBq/ml was chosen for 
the investigation of the effect of DSF:Cu on the growth delay induced by [131I]MIP-1095 in 
LNCaP spheroids. This concentration corresponded to a PSMA-specific growth delay, 
indicative of targeted radiotherapy. 
 
It has been shown that [131I]MIP-1095 was a more potent inhibitor of the enzymatic 
activity of PSMA than PMPA: the Ki values in LNCaP cells were 0.24 nM and 2.1 nM, 
respectively65,286. Based on the greater potency of [131I]MIP-1095 compared with that of 
PMPA and assuming that the difference in Ki values reflected the differences in PSMA-
binding affinity between [131I]MIP-1095 and PMPA, it was anticipated that PMPA 
concentration at least 10 times greater than that of [131I]MIP-1095 would inhibit 50% of the 
binding of [131I]MIP-1095 to PSMA. The molar concentration of 10 MBq/ml [131I]MIP-
1095 was 638 nM. However, 10 µM PMPA, which corresponded to a 15-fold molar excess 
of PMPA compared with [131I]MIP-1095, only inhibited 15% of the binding of [131I]MIP-
1095 to PSMA (Figure 60b). Moreover, 100 µM PMPA, which corresponded to a 150-fold 
molar excess of PMPA, only inhibited 40% of the binding of [131I]MIP-1095 to PSMA 
(Figure 60b). This could be explained by a difference in binding affinity between 
[131I]MIP-1095 and PMPA greater than that implied by the Ki values. The Ki values were 
measured using LNCaP cells membranes65,286. Thus it was possible that the use of LNCaP 
spheroids introduced complicating factors such as lipophilicity and penetrability which 
affected PMPA to a greater extent than [131I]MIP-1095. 
 
7.4.4 The effect of DSF:Cu in combination with [131I]MIP-1095 in LNCaP spheroids 
The effects of the single agents DSF:Cu and [131I]MIP-1095 on the growth delay of LNCaP 
spheroids were described in Figure 57 and Figure 61, respectively. The effect of the 
combination is shown in Figure 62. The statistically significant increase in τ2 and DT 
values and the statistically significant decrease in AUClog values following treatment with 
DSF:Cu in combination with [131I]MIP-1095 compared with either [131I]MIP-1095 or 
DSF:Cu alone demonstrated the enhancement of [131I]MIP-1095 kill by DSF:Cu (Figure 
62c). For instance, the τ2 values were 2.82 ± 0.15, 5.62 ± 0.24 (p < 0.001), 4.13 ± 0.46 and 
7.14 ± 0.60 (p < 0.001) days for untreated controls and the groups treated with 0.37 
MBq/ml [131I]MIP-1095, 1 µM DSF:Cu and 3.37 µM DSF:Cu (Figure 62c). In contrast, 
 the τ2 values of the combination of 1 
[131I]MIP-1095 were 13.85 ± 2.41 (p < 0.001) and 12.37 ± 1.63 (p < 0.001) days (
62c). The CI values corresponding to the mixture of 1 
MBq/ml [131I]MIP-1095 were 0.05 or 0.25, respectively, indicating a supra
interaction between DSF:Cu
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spheroids was investigated (Figure 63). The simultaneous treatment of LNCaP spheroids 
with DSF:Cu and [131I]MIP-1095 resulted in a significant increase in τ2 and DT values and 
a significant decrease in AUClog values compared with those of the groups treated with 
DSF:Cu or [131I]MIP-1095 as single agents (Figure 63c). For instance, the τ2 values were 
2.10 ± 0.26, 5.08 ± 0.74 and 5.33 ± 0.43 days for untreated controls and the groups treated 
with 3.37 µM DSF:Cu and 0.37 MBq/ml [131I]MIP-1095, respectively. In contrast, the τ2 
value of the group treated with the combination of 3.37 µM DSF:Cu and 0.37 MBq/ml 
[131I]MIP-1095 was 14.91 ± 2.58 (Figure 63c), indicating enhancement of [131I]MIP-1095-
induced growth delay by DSF:Cu, as already reported in Figure 62. 
 
The alternative schedules consisting of pre-treatment of DSF:Cu followed by treatment 
with [131I]MIP-1095, or vice versa, also resulted in a significant increase in τ2 and DT 
values and a significant decrease in AUClog values compared with those of the groups 
treated with DSF:Cu or [131I]MIP-1095 as single agents (Figure 63c). Furthermore, there 
was no significant difference in the medians of τ2 and AUClog values between the three 
combination schedules. However, the median of DT values of the combination schedule 
consisting of pre-treatment with DSF:Cu was significantly smaller than that of the 
simultaneous combination treatment of DSF:Cu and [131I]MIP-1095 (p < 0.001). This may 
have indicated that pre-treatment with DSF:Cu did not potentiate [131I]MIP-1095-induced 
spheroid growth delay as efficiently as the simultaneous administration of both agents, 
which may have resulted in a quicker regrowth of the spheroids (Figure 63b). 
  
Figure 63 The effect of treatment schedules of DSF:Cu and [
spheroids 
LNCaP spheroids were treated with DSF:Cu in serum
for 2 h. In the first combination schedule examined, 3.37
co-administered simultaneously for 2 
culture medium and the spheroids were exposed to fresh culture medium containing DSF:Cu alone for a 
further 22 h. The second combination schedule consisted of a pre
24 h followed by treatment with 0.37 MBq/ml [
washing at the end of their respective incubation period. 
treatment with 0.37 MBq/ml [
24 h. Both drugs were removed by washing at the end of their respective incubation period. The V/V
are displayed on a linear scale (a) and on a log scale (b). Data are mean ± SEM. (c) 
were calculated according to Section 
the differences in τ2, DT and AUC
(Kruskal-Wallis followed by Mann
the groups treated with DSF:Cu or 
untreated controls (*). The medians of 
treatment with DSF:Cu were compared with those of 
drug treatment alone (†). Two symbols indicate p < 0.01 and three symbols indicate p < 0.001.
 
131I]MIP-1095 on the growth of LNCaP 
-free culture medium for 24 
 µM DSF:Cu and 0.37 MBq/ml [
h. Then unbound [131I]MIP-1095 was removed by three washes with 
-treatment with 3.37 
131I]MIP-1095 alone for 2 h. Both drugs were removed by 
The third combination schedule consisted of a pre
131I]MIP-1095 alone for 2 h followed by treatment with 3.37 
6.3.4 and 6.3.5. Data are mean ± SEM. The statistical significance of 
log values between groups was determined by non
-Whitney tests) using SPSS. The medians of 
[131I]MIP-1095 as single agents were compared with those of the 
τ2, DT and AUClog values of the combinations of 
[131I]MIP-1095 treatment alone (¶) and to those of the 
184
 
h or with [131I]MIP-1095 
131I]MIP-1095 were 
µM DSF:Cu alone for 
-
µM DSF:Cu for 
0 values 
τ2, DT and AUClog values 
-parametric testing 
τ2, DT and AUClog values of 
[131I]MIP-1095 
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Figure 64 The effect of DSF:Cu on the growth of SK
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Figure 65 The effect of DSF:Cu on the growth of UVW/NAT spheroids
UVW/NAT spheroids were treated with various concentrations of DSF:Cu for 24 h. The V/V
displayed on a linear scale (a) and on a logarithmic scale (b). Data are mean ± SEM. (c) 
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Figure 68 The effect of DSF:Cu on the growth delay induced by [
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Figure 69 The effect of DSF:Cu on the growth delay induced by [
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and AUClog values of the groups treated with a combination of [131I]mIBG with DSF:Cu were compared with 
those of the groups treated with [131I]mIBG alone (¶) and to those of the group treated with DSF:Cu alone 
(†). Three symbols indicate p < 0.001. (d) The CI values were calculated as explained in Section 7.3.9.2 
using the AUClinear values of the combination. The calculation was based on the parameters m and IC50 
calculated for the single agents (Figure 65d and Figure 67d). 
 
These results demonstrated the strong synergism between DSF:Cu and two 
radiopharmaceuticals ([131I]MIP-1095 and [131I]mIBG) in spheroids derived from three cell 
lines, confirming the synergistic interaction between DSF:Cu and γ-radiation described in 
Section 4.4.3. Moreover, the finding of a supra-additive interaction between DSF:Cu and 
two radiopharmaceuticals in spheroids supported the strategy of using DSF:Cu as an 
adjuvant of targeted radiotherapy. 
 
7.5 Discussion and summary of the results 
The effect of [131I]MIP-1095 on the growth of LNCaP spheroids was characterised prior to 
the investigation of the combination with DSF:Cu. It was shown than the maximal PSMA-
specific binding of [131I]MIP-1095 occurred at radioactivity concentrations less than 1 
MBq/ml within 2 h (Figure 60a and Figure 60b). Moreover, the internalisation of 
[131I]MIP-1095 by endocytosis was demonstrated by co-incubation with CHQ, an inhibitor 
of the recycling of endosomes to the cell membrane (Figure 60d). The internalisation of 
[131I]MIP-1095 within endosomes would indicate that the retention of the 
radiopharmaceutical would be of greater duration than if [131I]MIP-1095 only bound to the 
PSMA receptor but was not intracellularly concentrated. In turn, prolonged intracellular 
retention should result in an increased absorbed radiation dose. Secondly, since [131I]MIP-
1095 is trapped in the intracellular space of the targeted cells, thus reducing leakage, 
improved imaging of prostate carcinoma is expected. Accordingly, it has been shown that 
[123I]MIP-1072 and [123I]MIP-1095 were successfully used as imaging agents of prostate 
carcinomas61. 
 
Moreover, it was also shown that internalisation was dependent on the metabolic status of 
the cells since KCN, an inhibitor of mitochondrial ATP production, inhibited intracellular 
concentration of [131I]MIP-1095 (Figure 60d). This result has therapeutic implications for 
the scheduling of [131I]MIP-1095 with radiosensitisers which may be cytotoxic in their own 
right. It is anticipated that a cytotoxic compound administered prior to [131I]MIP-1095 
would reduce the metabolic activity of the target cells, thus leading to sub-optimal 
internalisation of [131I]MIP-1095. However, it was shown that 3.37 µM DSF:Cu, which 
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was toxic to LNCaP spheroids (Figure 57, Figure 59 and Figure 62), did not inhibit the 
internalisation of [131I]MIP-1095 (Figure 60c). Although pre-treatment of LNCaP 
spheroids with DSF:Cu potentiated the growth delay induced by [131I]MIP-1095 (Figure 
63), the enhancement was not as efficient as that induced by the simultaneous 
administration of DSF:Cu and [131I]MIP-1095 (Figure 63c). This was indicated by the 
significantly smaller DT value compared with that of the combination schedule consisting 
of the simultaneous administration of DSF:Cu and [131I]MIP-1095. Since both τ2 and 
AUClog parameters did not significantly differ between the two schedules of 
administrations, the difference in DT value may have been an artefact due to the initial 
deep in the growth curve following the combination treatment consisting of pre-treatment 
with DSF:Cu followed by [131I]MIP-1095 (Figure 63c). Nevertheless, simultaneous 
administration of [131I]MIP-1095 and DSF:Cu induced a greater growth delay than the 
alternative schedules of delivery. After a single dose of disulfiram, maximal plasma 
concentration in patients is reached within 10 h161. Further investigation of the scheduling 
of administration of DSF:Cu with [131I]MIP-1095 is recommend in order to achieve 
optimal tumour concentration of both compounds at the same time. 
 
The pattern of growth of spheroids was dependent on the treatment administered. DSF:Cu 
induced an initial growth delay followed by a proliferating phase parallel to that of the 
untreated control. This was manifest by increasing τ2 values in response to increasing 
DSF:Cu concentrations while the DT values remained constant in LNCaP (Figure 57c), 
SK-N-BE(2c) (Figure 64c) and UVW/NAT spheroids (Figure 65c). This pattern is 
consistent with the initial killing of a sub-population of cells within spheroids whereas the 
unaffected cell fraction is responsible for the regrowth at later timepoints. In contrast, γ-
radiation treatment did not induce growth delay in LNCaP spheroids (Figure 58). Instead, 
the growth rate of the proliferating phase was reduced from day 0, as indicated by the 
concomitant increases in τ2 and DT values (Figure 58c). This pattern was consistent with 
the delivery of a dose of radiation to every cell of the spheroid. However, this experiment 
may represent a snapshot of the behaviour of the LNCaP cells soon after γ-radiation 
treatment; the spheroids may start to grow at a similar growth rate as the untreated control 
after 22 days (Figure 58). 
 
The spheroid growth pattern following radiation treatment was dependent on the cell line 
used. [131I]MIP-1095 decreased the growth rate of LNCaP spheroids from day 0 without 
sterilising the spheroids up to 10 MBq/ml (Figure 61). The effect of γ-radiation in LNCaP 
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spheroids produced similar growth curve patterns in which the growth rate was affected 
from day 0 (Figure 58a). The SK-N-BE(2c) and UVW/NAT spheroid growth patterns 
following [131I]mIBG treatment were different from that of LNCaP spheroids following 
[131I]MIP-1095 treatment. [131I]mIBG sterilised SK-N-BE(2c) spheroids one week 
following treatment (Figure 66) or sterilised UVW/NAT spheroids 3 days following 
treatment (Figure 67). In both SK-N-BE(2c) and UVW/NAT spheroids, a phase of 
spheroid growth preceded sterilisation. This growth pattern after treatment with [131I]mIBG 
was also observed after treatment of SK-N-BE(2c) and UVW/NAT spheroids with γ-
radiation (data not shown). The similarity of spheroid growth patterns between the two 
modes of radiation dose delivery (131I-labelled radiopharmaceutical or external beam γ-
radiation) in three cell lines indicated that dose rate had negligible influence on regrowth 
delay of spheroids. LNCaP spheroids are slow growing (mean DT = 2.75 days) compared 
with SK-N-BE(2c) (mean DT = 1.36 days) and UVW/NAT (mean DT = 2.05 days). 
Although parameters other than growth rate influence response to radiation, the slower 
growth rate of LNCaP spheroids may explain in part the absence of sterilisation by 10 
MBq/ml [131I]MIP-1095 compared with sterilisation after treatment of SK-N-BE(2c) and 
UVW/NAT spheroids with 5 MBq/ml [131I]mIBG287. 
 
A radiosensitiser in vitro is defined as an agent which enhances the cell killing of a 
particular radiation dose82. In chapter 4, this definition was applied to radiation survival 
curves, in which radiosensitisation was demonstrated when the surviving fraction after γ-
radiation treatment in the presence of DSF:Cu was lower than that after treatment with the 
same dose of γ-radiation alone. By extrapolation, in a spheroid growth delay experiment, 
radiosensitisation may be defined as the reduction of the area under the curve after 
radiation treatment in the presence of a radiosensitiser compared with the area under the 
curve after treatment with the same dose of radiation alone. A treatment may affect the 
growth of spheroids in various ways. A sub-population of cells within a spheroid may be 
especially susceptible or resistant to a treatment modality. For instance, a drug with poor 
penetrability would only be toxic to the external cellular layer of a spheroid, thus sparing 
more deeply located cells. This mode of action would lead to an initial delay in the growth 
of the treated spheroids compared with that of untreated spheroids with subsequent parallel 
growth curves. The parallelism of the growth curves of treated versus untreated spheroids 
at later timepoints results from the similar growth rate of the cells that have been 
unaffected by the treatment as that of the cells of untreated spheroids.  
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Alternatively, the totality of the cells within the spheroid may be affected by a treatment. If 
the treatment intensity is high enough, sterilisation occurs. Otherwise, the growth rate of all 
the cells in the spheroids is reduced, which results in the growth curve of treated spheroids 
deviating from that of the untreated control. Whether a treatment affects all or a smaller 
proportion of cells within a spheroid, the result is always the decrease in the area under the 
curve. The effect of DSF:Cu on the growth delay induced by radiation treatment was 
investigated in LNCaP, UVW/NAT and SK-N-BE(2c) spheroids using the following 
parameters: τ2, DT and AUClog. DSF:Cu potentiated the effect of γ-radiation, [131I]mIBG 
and [131I]MIP-1095 as indicated by a reduction in AUClog and an increase in τ2 and DT 
values compared with radiation treatment alone in LNCaP, SK-N-BE(2c) and UVW/NAT 
spheroids. 
 
Moreover, it is the purpose of the combination index and the isobologram methods of 
synergy analyses to quantify the effect of agent B upon A and, simultaneously, that of 
agent A upon B in the combination A+B. In all three cell lines, the CI values ranged from 
0.08 to 0.56 for treatments consisting of 3.37 µM DSF:Cu with external beam γ-radiation 
or targeted radiotherapy. This indicated supra-additivity regardless of the mode of radiation 
delivery or the cell line used (Figure 59, Figure 62, Figure 68 and Figure 69). In LNCaP 
spheroids, 1 µM and 3.37 µM DSF:Cu yielded CI values of 1.21 and 0.56, respectively, 
when given in combination with γ-radiation. This suggested that supra-additivity was more 
likely to occur at DSF:Cu concentrations higher than 1 µM. The tendency toward synergy 
associated with increased concentrations of DSF:Cu was also observed in the analysis of 
DSF:Cu-induced radiosensitisation in SK-N-BE(2c) and UVW/NAT monolayers (Table 
7). 
 
The concentration of DSF:Cu (1 µM), which is achievable in the plasma in patients161, 
affected the growth of LNCaP spheroids in a manner that was dependent on the mode of 
radiation delivery with which it was combined. The CI value was 1.21 when combined 
with external γ-radiation treatment (Figure 59), suggesting infra-additivity, whereas the CI 
value was 0.05 when combined with targeted radiotherapy in the form of [131I]MIP-1095, 
suggesting supra-additivity (Figure 62). In these experiments, the effect of 3 Gy of γ-
radiation and that of 0.37 MBq/ml [131I]MIP-1095 were similar with respect to 
cytotoxicity. SF values were 0.25 (Figure 59) and 0.26 (Figure 62), respectively. Thus, the 
effects of the combinations were comparable. These observations suggested that DSF:Cu 
was a better enhancer of the efficacy of targeted radiotherapy than that of external beam 
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radiotherapy. However, in a separate experiment determining the dose-response 
relationship of [131I]MIP-1095 in LNCaP spheroids (Figure 61), the SF value obtained 
following treatment with 0.37 MBq/ml [131I]MIP-1095 was 0.58, twice as much as in the 
combination experiment (Figure 62). This indicated that the effect of [131I]MIP-1095 as a 
single agent, depicted in the combination experiment (Figure 62), was greater than that 
observed in the evaluation of the dose-response relationship of [131I]MIP-1095 alone 
(Figure 61). The CI value is the sum of the ratios of the doses of each agent within the 
combination by their doses which induce the same effect as single agents. Since the CI 
value was calculated based on an effect of [131I]MIP-1095 as a single agent which was 
underestimated, the CI value of the combination of [131I]MIP-1095 with DSF:Cu was 
likely to be overestimated (Figure 62). 
 
The second discrepancy of this dataset was the surviving fraction obtained after treatment 
of UVW/NAT with [131I]mIBG. The determination of the dose-response relationship of 
[131I]mIBG (Figure 67) and the evaluation of the potentiating effect of DSF:Cu in 
combination with [131I]mIBG yielded different surviving fraction values (Figure 69). The 
surviving fractions obtained in response to treatment with 0.5 MBq/ml [131I]mIBG alone 
were 0.33 and 0.87 in Figure 67 and Figure 69, respectively. Since the CI value of the 
combination of DSF:Cu and [131I]mIBG was calculated based on an effect of [131I]mIBG as 
a single agent which was overestimated (Figure 67), the CI value was likely to be 
underestimated. Thus, the combination of 0.5 MBq/ml [131I]mIBG with 3.37 µM DSF:Cu 
should be even more supra-additive than indicated (Figure 69). 
 
Despite the discrepancies observed in the calculations of the surviving fractions based on 
the AUClinear values, generally there was agreement among experimental results. For 
instance, the surviving fractions in response to the treatment of LNCaP spheroids with 1 
µM DSF:Cu in the three separate experiments were 0.63, 0.68 and 0.74 (Figure 57d, Figure 
59d and Figure 62d). Similarly, the τ2 values of the untreated SK-N-BE(2c) spheroids were 
1.11, 0.93 and 1.15 days and the DT values were 1.93, 1.23 and 1.62 days (Figure 64c, 
Figure 66c and Figure 68c). Due to time constraint, every determination of spheroid 
response to specific therapy was embodied in a single experiment. A maximum of 24 
spheroids was evaluated in every treatment group. With the exception of the evaluation of 
the effect of DSF:Cu in combination with [131I]MIP-1095 on the growth of LNCaP 
spheroids (Figure 62), all other experimental determinations of potentiation of radiation-
induced growth delay constituted single experiments. Nonetheless, regardless of cell line 
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(LNCaP, SK-N-BE(2c) or UVW/NAT), regardless of mode of radiation delivery (external 
beam or radiopharmaceutical) and regardless of the tumour cell culture (spheroids or 
monolayers), DSF:Cu consistently enhanced the radiation kill in a supra-additive manner. 
 
The lack of reproducibility of the experiments resulted in the variability of the surviving 
fractions that was not suitable for the application of the median effect principle and the 
subsequent calculation of CI values. For instance, this was evident by the discrepancies 
between the surviving fraction calculated following treatment of UVW/NAT spheroids 
with 0.5 MBq/ml [131]mIBG (SF = 0.33 Figure 67c versus SF = 0.87 Figure 69c). Thus, the 
calculation of a CI value based on individual spheroid growth delay experiments is not an 
accurate assessment of the efficacy of a combination treatment. A faster alternative method 
which measures the potentiation of the radiation kill would be as follows. First, the 
spheroids would be treated with drug alone, radiation alone or combination of drug and 
radiation. Secondly, the spheroids would be enzymatically dissociated into single cells and 
clonogenic assay performed. The median effect principle and the calculation of CI values 
would be directly applicable to the surviving fractions derived from clonogenic assay. 
However, LNCaP cells do not form colonies, thus such a method is not suitable for the 
determination of modulation of the toxicity of [131I]MIP-1095. 
 
However, the determination of growth delay of spheroids is valuable in assessing subtle 
aspects of the efficacy of combination treatment. For instance, the comparison between the 
τ2 and the DT values was used to elucidate the existence of an anti-tumour effect which 
was not immediately apparent but was manifest several days after the initiation of drug or 
radiation treatment. Spheroids, rather than cellular monolayers, allowed an assessment of 
the potential efficacy of novel therapy of microscopic metastases – the type of malignant 
disease against which targeted radionuclide treatment is expected to be most effective. In 
the final chapter, the use of the spheroid model is described for the comparison of the 
ability of various drugs to potentiate radiation-induced spheroid growth delay. 
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8 Comparison of the ability of drugs to potentiate the growth 
delay induced by γ-radiation and [131I]MIP-1095 in spheroids 
8.1 Introduction 
A promising means of maximising the efficacy of targeted radiotherapy is by combination 
with radiosensitisers44,91. Clinical trials should be designed based on the in vitro 
assessment of the radiosensitising potential of chemotherapeutic agents. The latter studies 
should be carried out in spheroids which are representative of micrometastases in their 
prevascular stage of development. Moreover, these cellular aggregates are similar to the 
size class of malignant disease which is optimally sensitive to treatment with targeted 
radionuclides14. 
 
The results of the screening of five radiosensitisers in LNCaP spheroids in combination 
with γ-radiation treatment and in combination with the radiopharmaceutical [131I]MIP-1095 
will be presented. A description is provided of the variety of mechanisms underlying the 
radiosensitisation engendered by the series of drugs tested. Then, the modification of the 
growth delay induced by γ-radiation or [131I]MIP-1095 by each drug will be analysed by 
the τ2, DT and AUClog parameters as described in Section 6.3.4 and 6.3.5. In the last part of 
this chapter, an attempt is made to rank the enhancement of γ-radiation-induced and 
[131I]MIP-1095-induced spheroid growth delay by the drugs using the specific growth 
delay (SGD) value. 
 
8.1.1 Nutlin-3 
The small molecule nutlin-3 (FW 581.49 g/mol) is a cis-imidazoline analogue which 
inhibits the interaction between murine double minute 2 (MDM2) and the tumour 
suppressor protein p53288. Under unstressed conditions, the binding of MDM2 to the 
transactivation domain of p53 inhibits p53 transcriptional activity. Furthermore, MDM2 is 
an ubiquitin ligase which promotes proteasomal degradation of p53. In response to 
radiation, the phosphorylation of p53 results in its release from MDM2. In turn, p53 
triggers cell cycle arrest in G1 and promotes the repair of DNA damage. Alternatively, if 
the extent of DNA damage is greater than the capacity of the DNA repair machinery, 
radiation-induced p53 activation may result in apoptotic cell death289. Once activated, p53 
also stimulates the transcription of the MDM2 gene. The resulting negative feedback 
prevents aberrant p53-induced apoptosis. It has been shown that the inhibition of MDM2 
interaction with p53 by nutlin-3 radiosensitises tumour cells, presumably through increased 
apoptotic cell death290. 
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8.1.2 Olaparib 
Poly(ADP-ribose)polymerase 1 (PARP-1) is a sensor of SSB and a signaller to the DNA 
repair machinery. PARP-1 is recruited at the site of DNA damage where it catalyses the 
binding of poly(ADP-ribose) polymers to histones, a process that requires the reduction of 
nicotinamide adenine dinucleotide (NAD+) to NADH. The branching structure of the 
positively charged ADP-ribose polymer opens up the chromatin structure, thus allowing 
access of the DNA repair machinery to the damaged sites and preventing DNA 
replication88. The small molecule olaparib (FW 435.08 g/mol) has a moiety similar to 
nicotinamide which confers inhibitory properties against PARP-1 enzymatic activity. 
Olaparib’s Ki value is 5 nM291. Several studies have demonstrated the radiosensitising 
properties of olaparib in replicating cells, especially in those with a deficiency in the repair 
of DSB89,292. These studies suggest that the radiosensitising mechanism of olaparib was the 
increased rate of SSB conversion to DSB during DNA replication89,292. 
 
8.1.3 AZD7762 
The small molecule AZD7762 (FW 362.4 g/mol) is a thiophene carboxamide urea which 
inhibits the kinase activity of Chk1 with a Ki value of 3.6 nM293. Although data were not 
provided, the authors stated that AZD7762 inhibits Chk2 with the same potency as 
Chk1293. As a result of Chk1/2 inhibition, AZD7762 abrogates the G2 arrest machinery 
following treatment with gemcitabine293. AZD7762 has also been shown to radiosensitise a 
wide range of cell lines. In this report, the DEF values ranged from 1.05 to 1.2 in cell lines 
harbouring wild type p53 whereas the DEF values ranged from 1.21 to 1.7 in cell lines 
with a mutated version of p53294. The authors suggested that, due to the G2 arrest-
inhibitory property of AZD7762, cells lacking a functional G1 arrest machinery, such as 
p53 mutated cells, would be more readily radiosensitised by treatment with AZD7762. 
However, a second study reported the radiosensitising effect of AZD7762 in the p53 wild 
type cell line H460 (human large cell lung carcinoma) as indicated by a DEF value of 
1.5295. The observation of a DEF value of 1.5 in a p53 wild type cell line, which was in the 
same range as the DEF values obtained in p53 mutated cell lines (1.21 – 1.7) suggested 
that the p53 status of a cancer cell is not the only determinant of radiosensitisation induced 
by AZD7762. 
 
8.1.4 Topotecan 
The role of topoisomerase I is to alleviate the torsional stress generated as the replication 
fork advances during replication of DNA. Topoisomerase I cleaves one strand of DNA, 
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allowing the second strand to pass through the cleavage site, before re-sealing the nick. 
During this process, an intermediate state is created by the formation of a transient 
covalent bond between topoisomerase I and the cleaved strand of DNA, the so-called 
“cleavable complex”.  
 
The small molecule topotecan (FW 457.9 g/mol) is a derivative of camptothecin, an 
alkaloid extract of the tree Camptotheca acuminata with antitumour properties296. The fork 
collision model has been described to explain topotecan cytotoxicity297. Topotecan binds to 
and stabilises the normally transient cleavable complex consisting of topoisomerase I and 
cleaved DNA. As the replication fork advances, the collision with the stalled cleavable 
complex (consisting of topotecan, topoisomerase I and cleaved DNA) results in the 
formation of DSB, leading to cell cycle arrest and cell death. Furthermore, topotecan has 
recently been shown to be a radiosensitiser92,298. It has also been observed that 
topoisomerase I is involved in the recruitment of the DNA repair machinery to sites of 
DNA strand breakage299. Therefore the radiosensitising mechanism of topotecan may not 
only result from the generation of DSB during DNA replication but may also be due to the 
inhibition of DNA repair. 
 
8.1.5 Bortezomib  
The small molecule bortezomib (FW 384.24 g/mol) is a boron-based dipeptide with 
binding affinity for the 26S proteasome, the organelle responsible for the controlled 
enzymatic degradation of proteins. Bortezomib inhibits the catalytic activity of the 26S 
proteasome with a Ki value of 0.56 nM300. Many cellular pathways are regulated by the 
proteasome: inflammation, antigen presentation, cell cycle regulation and cell death. For 
instance, proteasomal degradation of IκB is required for the activation of the transcription 
factor NF-κB which is up-regulated in response to radiation treatment and is associated 
with radioresistance301. It has been demonstrated that bortezomib radiosensitisess cancer 
cells via the prevention of NF-κB activation302, which resulted in apoptosis, and also via 
the down-regulation of the DNA damage response303. 
 
8.1.6 Justification of the concentrations of the drugs examined 
The concentrations of the drugs used in the evaluation of the modulation of γ-radiation-
induced or [131I]MIP-1095-induced spheroid growth delay were based on published reports 
and on the drug concentrations achievable in the plasma of patients (Table 11). 
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Target 
Ki 
Lowest 
radiosensitising 
concentration tested 
Plasma concentration achieved 
Topotecan Topoisomerase I 10 nM 
7.21-17.03 nM304 
2.23-9.06 nM305 
24.8 - 108.9 nM306 
Olaparib 
PARP-1 
5.5 nM291 
1 µM 
0.23 - 2.3 nM307 
5.75 µM308 
11 µM309 
Bortezomib 
26S proteasome 
0.56 nM300 
7.5 nM 
205.60 nM310 
580 nM311 
Nutlin-3 
Mdm2-p53 
80.3 nM288 
10 µM clinical trial in progress 
AZD7762 
Chk1 
3.6 nM293 
Not radiosensitising at 
concentrations < 1 µM 
clinical trial in progress 
Table 11 The plasma concentrations of the evaluated drugs 
The Ki values, the reported peak plasma concentrations and the concentrations found to be radiosensitising in 
this chapter are presented. The lowest radiosensitising concentrations tested for every drug will be described 
in the respective results Sections. 
 
8.2 Aim 
- determination and comparison of the capacity of cytotoxic drugs to enhance the 
growth delay of multicellular tumour spheroids following treatment with γ-
radiation or [131I]MIP-1095 
 
8.3 Materials and methods 
8.3.1 Spheroid formation and analysis 
See sections 6.3.1, 6.3.3, 6.3.4 and 6.3.5. 
 
8.3.2 Combined treatments of drugs with γ-radiation or [131I]MIP-1095 
See sections 4.3.4.4 and 7.3.2.4. 
 
8.3.3 Calculation of specific growth delay SGD 
The growth rate of treated spheroids and untreated controls varied between experiments. 
Therefore, to enable comparison of the cytotoxicity of single-agent treatments between 
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separate experiments (drug alone or radiation alone), the specific growth delay resulting 
from single-agent treatment (SGDSA) was calculated using equation (23)269: 
 
SGDSA = (τ2 - τ2 control) / τ2 control (23) 
 
where the τ2 value is the time required for a 2-fold increase in volume after a particular 
treatment, as described in Section 6.3.4, and τ2 control is that of the respective untreated 
control. 
 
Similarly, the effect of radiation alone varied between experiments. Thus, to enable the 
comparison of the enhancement of γ-radiation-induced and [131I]MIP-1095-induced growth 
delay by various drugs, the specific growth delay of a combination treatment (SGDC) was 
compared with the effect of radiation or [131I]MIP-1095 treatment alone and calculated 
using equation (24): 
 
SGDC = (τ2 - τ2 radiation) / τ2 radiation (24) 
 
 
where the τ2 value is the time required for a 2-fold increase in volume after a particular 
combination treatment and τ2 radiation is the τ2 value of the γ-radiation or [131I]MIP-1095 
treatment alone. 
 
8.3.4 Statistical analysis of the drug-induced potentiation of γ-radiation or 
[131I]MIP-1095 
See section 7.3.8.3. 
 
8.3.5 Test for outlying results 
According to the Grubb’s test312, an outlier is defined as a value within a dataset which 
deviates from the mean to a significantly greater extent than the standard deviation of the 
dataset. The Z-score is calculated according to equation (25): 
 
Z-score = ABS (mean – value) / SD (25) 
 
where ABS is the absolute value and indicates that the Z-score is positive and SD is the 
standard deviation of the dataset containing the tested value. 
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Then, if the Z-score is greater than a critical Z value, the tested value is defined as an 
outlier. Examples of critical Z values are found in Table 12 and are depend on the number 
of observations (n) within the dataset and on the level of statistical significance. 
 
 
Table 12 Critical Z values at the 1%, 2.5% and 5% levels of significance for dataset containing n 
observations 
 
8.4 Results 
8.4.1 Enhancement of the growth delay induced by γ-radiation or [131I]MIP-1095 
8.4.1.1 Nutlin-3 
It has been reported that 5 and 10 µM nutlin-3 were required for the inhibition of the 
interaction of MDM2 with p53 which resulted in the increased expression of the p53-target 
gene p21 in LNCaP monolayers313. Secondly, the radiosensitising property of nutlin-3 has 
been demonstrated in monolayers using concentrations of 3 and 5 µM314-316. Based on 
these studies, the potentiation of the growth delay induced by γ-radiation or [131I]MIP-1095 
was carried out using nutlin-3 concentration of 10 µM (Figure 70). 
 
Increased growth delay by treatment with nutlin-3 was indicated by modification of τ2, DT 
and AUClog values. The toxicities of both γ-radiation (Figure 70a) and [131I]MIP-1095 
(Figure 70b) were enhanced by inclusion of 10 µM nutin-3 in combination treatments. The 
AUClog value of the combination of 10 µM nutlin-3 with 3 Gy γ-radiation was 3.96 ± 1.09 
compared with 15.58 ± 1.46 for 3 Gy γ-radiation alone (p < 0.001) and 21.57 ± 1.15 for 10 
µM nutlin-3 alone (p < 0.001) (Figure 70c). Similarly, the AUClog value of the 
combination of 10 µM nutlin-3 with 0.37 MBq/ml [131I]MIP-1095 was -3.25 ± 0.75 
compared with 12.86 ± 0.44 for 0.37 MBq/ml [131I]MIP-1095 alone (p < 0.001) and 19.20 
± 1.20 for 10 µM nutlin-3 alone (p < 0.001) (Figure 70d). These observations indicated 
 that nutlin-3 potentiated the growth delay induced by 
treatments. 
 
Figure 70 Spheroid growth delay induced by treatment with 
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induced growth delay by olaparib was investigated at concentrations ranging from 0.1 to 1 
µM (Figure 71). 
 
The τ2, DT and AUClog values of the groups treated with the combinations of 0.1, 0.5 or 1 
µM olaparib with 3 Gy γ-radiation were not significantly different from those of the group 
treated with 3 Gy γ-radiation alone (Figure 71b). For instance, the τ2 values of the 
combinations ranged from 4.43 ± 0.37 to 4.76 ± 0.33 days compared with 4.14 ± 0.43 days 
for 3 Gy γ-radiation alone (Figure 71b). This indicated that olaparib was not able to 
potentiate the toxicity induced by γ-radiation at concentrations less than 1 µM. 
 
Olaparib is an inhibitor of DNA damage repair. Therefore, in the absence of a DNA 
damaging agent such as radiation, olaparib as a single-agent treatment is unlikely to be 
cytotoxic (Figure 71). However, it was also possible that the absence of a growth delay in 
response to olaparib alone was due to insufficient concentration of drug. It has also been 
shown that the administration to patients of a single 400 mg dose of olaparib resulted in a 
peak plasma concentration of 11 µM and it was well tolerated309. Thus, the investigation of 
the combination of olaparib with [131I]MIP-1095 was carried out with concentrations of 
olaparib of 1 and 10 µM (Figure 72). 
 
 Figure 71 Absence of enhancement of 
treatment with olaparib
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0.001. The specific growth delay values corresponding to the single-agent treatments (SGDSA) and the 
specific growth delay of the combination treatments (SGDC) were calculated according to Section 8.3.3. 
 
8.4.1.3 AZD7762 
The radiosensitisation of monolayers has been demonstrated at AZD7762 concentration of 
100 nM295. Based on this report, the investigation of the modification of γ-radiation-
induced spheroid growth delay by AZD7762 was carried out at concentrations ranging 
from 1 nM to 1 µM (Figure 73). 
 
The τ2, DT and AUClog values of the groups treated with the combinations of 1 nM, 10 nM 
or 1 µM AZD7762 with 3 Gy γ-radiation were not significantly different from those of the 
group treated with 3 Gy γ-radiation alone (Figure 73b). For instance, the τ2 values of the 
combinations ranged from 4.05 ± 0.27 to 5.33 ± 0.52 days compared with 5.32 ± 0.45 days 
for 3 Gy γ-radiation alone (Figure 73b). This indicated that AZD7762 was not able to 
potentiate γ-radiation toxicity at concentrations less than 1 µM. 
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8.4.1.4 Topotecan 
Topotecan-induced radiosensitisation was demonstrated in monolayers at concentrations 
ranging from 5 to 100 nM319,320. However, concentrations of topotecan ranging from 10 
nM to 10 µM induced a modest reduction in the area under the V/V0 versus time curve of 
LNCaP spheroid growth. For instance, the AUClog value following treatment with 10 µM 
topotecan was 31.52 ± 4.49 days (p < 0.001) compared with that of the untreated control 
(39.57 ± 3.14 days) (Figure 75). Based on these observations, the effect of topotecan on the 
growth delay induced by γ-radiation was investigated at concentrations ranging from 10 
nM to 10 µM (Figure 75). 
 
The increase in τ2 values and the decrease in AUClog values following treatment with the 
combinations of 10 nM, 100 nM, 1 µM or 10 µM topotecan with 3 Gy γ-radiation were 
significant in comparison with the τ2, and AUClog values of the group treated with 3 Gy γ-
radiation alone and with those treated with topotecan alone (Figure 75b). For instance, the 
τ2 values of the combinations ranged from 4.51 ± 0.25 to 8.02 ± 1.51 days compared with 
3.46 ± 0.29 days for the group treated with 3 Gy γ-radiation alone (Figure 75b). This 
indicated that topotecan was able to potentiate the toxicity induced by γ-radiation at 
concentrations less than 10 µM in spheroids. 
 
The conclusion of the analysis of the DT values conflicted with that obtained by the 
analysis of the τ2 values. For instance, the DT values were 3.70 ± 0.17, 3.91 ± 0.23 and 
3.90 ± 0.39 days for the groups treated with the combinations of 3 Gy γ-radiation with 10 
nM topotecan, 100 nM topotecan or 1 µM topotecan, respectively (Figure 75b). The DT 
values of these combination were not significantly greater than that of the group treated 
with 3 Gy γ-radiation alone (3.49 ± 0.27 days) (Figure 75b), indicating the absence of the 
potentiation of γ-radiation toxicity by topotecan at concentrations less than 1 µM. This was 
in contrast to the enhancement of γ-radiation kill by topotecan at these concentrations as 
determined by analysis of the τ2 and AUClog values (Figure 75b). However, the 
combination of 10 µM topotecan with 3 Gy γ-radiation resulted in the statistically 
significant increase in DT values (6.64 ± 1.24 days) compared with that of the group 
treated with 3 Gy γ-radiation alone (3.49 ± 0.27 days) (p < 0.001) (Figure 75b). This 
indicated the potentiation of γ-radiation-induced growth delay at this level of topotecan 
toxicity (10 µM). 
 
 Figure 75 Spheroid growth delay induced by treatment with 
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(a) The potentiation of γ-radiation kill by topotecan was investigated. LNCaP spheroids were exposed to 10 
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are mean ± SEM. (b) τ2, DT and AUClog values were calculated according to Section 6.3.4 and 6.3.5. Data 
are mean ± SEM. The statistical significance of the differences in τ2, DT and AUClog values between groups 
was determined by non-parametric testing (Kruskal-Wallis followed by Mann-Whitney tests) using SPSS. 
The medians of τ2, DT and AUClog values of the groups treated with single agents were compared with those 
of the untreated control (*).The medians of τ2, DT and AUClog values of the combination treatment were 
compared with those of the group treated with radiation alone (¶) and with those of the group treated with 
bortezomib alone (†). Two symbols indicate p < 0.01 and three symbols indicate p < 0.001. The specific 
growth delay values corresponding to the single-agent treatments (SGDSA) and the specific growth delay of 
the combination treatments (SGDC) were calculated according to Section 8.3.3. 
 
No significant potentiation of γ-radiation toxicity by simultaneous treatment with 
bortezomib was indicated from the analysis of τ2, DT and AUClog values. The τ2 values 
were 9.55 ± 1.55 (p < 0.01), 3.26 ± 0.42 and 8.09 ± 1.04 days for the groups treated with 3 
Gy γ-radiation, 5 nM bortezomib and the combination of 3 Gy γ-radiation with 5 nM 
bortezomib, respectively (Figure 77b). Similarly, the τ2 value of the group treated with 10 
nM bortezomib in combination with 3 Gy γ-radiation (14.93 ± 4.54 days) was not 
significantly higher than that of the group treated with 3 Gy alone (Figure 77b). However, 
the growth delay induced by 3 Gy γ-radiation was unusually high in this particular 
experiment (τ2 = 9.55 ± 1.55 days); the average τ2 value following 3 Gy irradiation from 
Figure 70, Figure 71, Figure 73 and Figure 75 was 4.42 ± 0.40 days. Thus, any further 
reduction of the area under the curve induced by bortezomib would have been more 
difficult to discriminate from that induced by γ-radiation treatment alone. The Z-score, a 
measure of the deviation of a value from the mean in comparison with the standard 
deviation of the dataset (Section 8.3.5), was 1.712 which was higher than the critical Z-
score (1.71), thus demonstrating that the τ2 value following treatment with 3 Gy γ-radiation 
in this experiment was an outlying result at the 2.5% significance level312. Therefore, the 
observation of the absence of potentiation of the γ-radiation-induced growth delay by 
bortezomib is inconclusive. 
 
The effect of bortezomib on the growth delay induced by [131I]MIP-1095 is depicted in 
Figure 78. The spheroid growth delay induced by [131I]MIP-1095 was enhanced by 
treatment with 7.5 µM and 10 µM bortezomib (Figure 78a). This observation was manifest 
by the significant modification of τ2, DT and AUClog values following treatment with 7.5 
or 10 nM bortezomib in combination with [131I]MIP-1095 compared with those of the 
group treated with [131I]MIP-1095 alone (Figure 78b). For instance, the τ2 values were 3.08 
± 0.24 (p < 0.001), 4.31 ± 0.30 (p < 0.001) and 4.86 ± 0.28 (p < 0.001) following treatment 
 with 7.5 nM bortezomib, 10 nM bortezomib and 0.37 MBq/ml [
respectively (Figure 78
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and 7.39 ± 0.69 days 
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8.4.2 Comparison of enhancement of [131I]MIP-1095-induced and γ-radiation-
induced growth delay by drugs 
Olaparib is an inhibitor of DNA repair in response to radiation damage and AZD7762 
inhibits the radiation-induced cell cycle arrest in G2. Drugs such as olaparib and AZD7762 
which fall into the category of inhibitors of the cellular responses to radiation-induced 
damage exert cytotoxic effects only in combination with DNA damaging treatments such 
as radiation. Such drugs may be harmless as single agents at concentrations close to the Ki 
value corresponding to the inhibition of the target necessary for survival after radiation 
treatment (i.e. PARP-1 for olaparib and Chk1 for AZD7762). On the other hand, drugs 
may enhance radiation kill at concentrations which are toxic as single agents. For example, 
oxidising agents are toxic to cancer cells via the generation of oxidative stress which is 
also capable of enhancing radiation kill. Ideally, the comparison of the potentiation of 
radiation toxicity between two drugs should be performed at drug concentrations which 
induce an equivalent kill as single agents. However, the comparison of drugs which are 
cytotoxic as single agents with drug which are not cytotoxic as single agents demonstrates 
the difficulty of such a strategy. 
 
The specific growth delay of a combination treatment SGDC was used as a measure of the 
enhancement of γ-radiation- or [131I]MIP-1095-induced growth delay. The calculation of 
the SGDC value allowed for the variation of the effect of radiation treatment alone among 
experiments. The SGDC values of the combination treatments were calculated separately 
for every experiment. The graph presenting the SGDC values of the combination of the 
drugs with 3 Gy γ-radiation against the SGDSA values of each drug as single agent is 
shown in Figure 79a. Drugs, administered as single agents, that induce similar growth 
delays (similar SGDSA) can be ranked for radiosensitising potency at a given level of 
cytotoxicity. For instance, nutlin-3 and topotecan were equally toxic to LNCaP spheroids 
as indicated by the SGDSA value of 0.75 (Figure 79a). At the toxicity level defined by 
SGDSA = 0.75, the SGDC for nutlin-3 was 1.58 whereas that of topotecan was 0.43, thus 
indicating the superior potentiation of γ-radiation-induced growth delay by nutlin-3 than by 
topotecan (Figure 79a). Similarly, olaparib and topotecan were equally toxic to LNCaP 
spheroids as indicated by the SGDSA value of 0.1 (Figure 79b). At the toxicity level 
defined by SGDSA = 0.1, the SGDC for olaparib was 0.79 whereas that of topotecan was 
0.44, thus indicating the superior potentiation of γ-radiation-induced growth delay by 
olaparib than by topotecan (Figure 79b). 
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and 2.5 and 5 nM bortezomib (Figure 78) on the growth delay induced by [131I]MIP-1095. 
Accordingly, the lowest SGDC values were calculated for AZD7762 and 2.5 and 5 nM 
bortezomib (SGDC range 0.05 - 0.19) whereas the highest SGDC values were calculated for 
10 µM nutlin-3, 1 and 10 µM olaparib, 0.1 and 1 µM topotecan and 7.5 and 10 nM 
bortezomib (SGDC > 0.34) (Figure 70 to Figure 78). The agreement between the analysis 
of τ2 values and SGDC was expected since the calculation of SGDC values is based on τ2 
values. With the exception of topotecan given in combination with γ-radiation, the analysis 
of DT values yielded results similar to those derived from τ2 values with respect to the 
statistical significance of the potentiation of the growth delay induced by [131I]MIP-1095 
following combination with the drugs. The τ2 values are a measure of the early effect of 
the treatment since a doubling of the spheroid volume occurs within 3 to 4 days from the 
start of the monitoring period (3 to 4 weeks). DT values are a measure of the growth rate of 
the exponential growth of the spheroids over 3 to 4 weeks. Thus, the significant increase in 
DT values following combination treatment compared with single agent treatments 
demonstrated the persistence of the enhancement of the growth delay induced by 
[131I]MIP-1095 following combination with nutlin-3, olaparib and bortezomib. 
 
The enhancement of the γ-radiation-induced spheroid growth inhibition by 0.01, 0.1 and 1 
µM topotecan was only transient as indicated by the failure of the combination treatments 
to significantly increase the DT values (Figure 75). Upon increase of topotecan 
concentration to 10 µM, the analysis of the τ2 and DT values showed that the enhancement 
of the γ-radiation-induced spheroid growth inhibition persisted over the course of the 
experiment. This example illustrated the merit of analysing both the growth delay and the 
growth rate of the exponential phase of spheroid growth for the determination of the 
enhancement of radiation treatment in a spheroid growth delay experiment. 
 
Spheroids reaching a diameter of approximately 300 µm develop a non-proliferative, 
hypoxic and acidic core surrounded by a proliferative layer of cells254. These features of 
spheroids in an advanced stage of their growth have been shown to confer resistance to 
therapy258,261,262. In this chapter, LNCaP spheroids on average 100 µm diameter were 
treated with the drugs, γ-radiation or [131I]MIP-1095 as single agents or in combination. 
Therefore, the demonstration of the potentiation of the growth delay induced by γ-radiation 
or [131I]MIP-1095 was limited to spheroids which had not yet undergone internal 
morphological changes. Therefore, the clinical implications of the study reported in this 
chapter are that the drugs that enhanced the growth delay induced by [131I]MIP-1095 may 
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also retard the growth of juvenile malignant lesions which do not contain hypoxic and non-
proliferative regions. Alternatively, the combinations of drugs with [131I]MIP-1095 may be 
used as second-line treatments when malignant lesions have been reoxygenated following 
cytoreductive therapy. A follow-up study would be the evaluation of the potentiating effect 
of the drugs on the growth delay induced by [131I]MIP-1095 in spheroids which have 
developed a hypoxic core surrounded by a proliferating region of cells using an 
experimental design similar to that used in Figure 54. This analysis would evaluate the 
ability of these combinations to overcome the putative resistance to treatment conferred by 
non-proliferative and hypoxic regions. 
 
As explained in Sections 4.1.3, combination index and isobologram methods of synergy 
analysis enable the determination of supra-additive or infra-additive interaction between 
the components of combination therapy. The lack of time did not permit the repetition of 
these experiments. As explained in Section 7.5, repetitions are needed for the accurate 
application of the median effect principle and the subsequent calculation of CI values. 
Furthermore, the application of the combination index and isobologram methods requires 
the determination of a single-agent dose-response relationship for the two agents of the 
combination treatment. This is impossible in the case of drugs which do not have an effect 
on their own such as olaparib (PARP-1 inhibitor) or AZD7762 (Chk1 inhibitor). These two 
drugs are toxic only to cells which have experienced DNA damage since they specifically 
target DNA damage responses. Therefore, the combination index and isobologram 
methods of synergy analysis were not suitable for the comparison of the radiosensitising 
effects of these drugs. 
 
The purpose of the screening of the radiosensitising properties of drugs is the treatment of 
prostate carcinoma in combination with [131I]MIP-1095. Therefore, it is important that the 
drug concentrations achievable in the plasma of patients are shown to enhance the growth 
delay induced by [131I]MIP-1095. Clinical studies in which the plasma concentrations of 
the drugs were measured are listed in Table 11. Olaparib and bortezomib enhanced 
[131I]MIP-1095-induced LNCaP spheroid growth delay at concentrations which are 
achievable in the plasma of patients (Table 11). No clinical trial involving nutlin-3 or 
AZD7762 has been reported. The highest topotecan concentration achieved in the plasma 
of patients was 108.9 nM (Table 11). The lowest concentration of topotecan found to 
radiosensitise LNCaP spheroids was 10 nM, though the radiosensitising effect was no 
longer observed 2 to 3 weeks after the end of the treatment (Figure 75). The enhancement 
of the [131I]MIP-1095-induced growth delay by topotecan was observed at a topotecan 
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concentration of 100 nM (Figure 76). Topotecan concentration of 100 nM constitutes the 
top end of the range of topotecan plasma concentration (Table 11). The investigation of the 
radiosensitising effect of topotecan at concentrations less than 100 nM in combination with 
[131I]MIP-1095 constitutes a follow-up experiment to the dataset presented in Figure 76. 
 
Radiation delivered at a high dose rate (HDR) is more cytotoxic than radiation delivered at 
a low dose rate (LDR). The 60Co source of γ-radiation used in these experiments 
corresponded to HDR (1 Gy/min), whereas radiation delivered using [131I]MIP-1095 
corresponded to LDR (typically several Gy per hour322). The linear-quadratic equation 
which describes the effect of radiation on the survival of cells was described in Section 
4.1.2. Briefly, the initial slope of the radiation survival curve results from single hit events 
in DNA whereas the bend of the radiation survival curve at high radiation doses results 
from multiple hit events. HDR results in a higher density of ionisations of DNA compared 
with LDR. Thus HDR results in a greater proportion of lethal DSB formation323.  
 
Olaparib is an inhibitor of DNA repair of SSB via the abrogation of PARP-1 enzymatic 
activity. Since LDR radiation predominantly creates SSB, olaparib should be an efficient 
radiosensitiser when combined with LDR radiation such as radionuclide therapy. The 
observation that 1 µM olaparib sensitised LNCaP spheroids to [131I]MIP-1095 treatment 
(Figure 72) but not to γ-radiation (Figure 71) treatments was consistent with this 
conjecture. Recently, the PARP-1 inhibitor PJ34 was shown to be a radiosensitiser in 
combination with LDR in the form of [131I]mIBG324. 
 
However, it has been demonstrated that 0.5 µM olaparib sensitised Hela cells and mouse 
embryo fibroblasts (MEF) to HDR (7.5 Gy/min)292. The observation of the radiosensitising 
effect induced by olaparib in combination with HDR radiation in Hela and MEF 
monolayers is in contrast to the absence of a radiosensitising effect in combination with 
HDR in LNCaP spheroids in the present study. The concentrations of olaparib used were 
similar: 0.5 versus 1 µM. It is suggested that phenotypic differences between the cell lines 
arising from their respective genetic backgrounds and also from structural differences 
between monolayers and spheroids may explain this discrepancy. 
 
Cancer cells halt their progression through the cell cycle in response to radiation treatment 
at the two major cell cycle checkpoints: G1 and G2. Furthermore, the p53 gene is the most 
commonly mutated gene in cancer325. Since p53 controls G1 arrest, inhibitors of G2 arrest 
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were developed in the expectation that they would constitute efficient treatments of p53-
mutated tumours in combination with radiotherapy or other DNA damaging agents. 
Indeed, cancer cells with no functional checkpoint are more likely to carry DNA damage 
through S phase and mitosis than cells with only one functional checkpoint. Thus, cancer 
cells with no functional checkpoint should be more radiosensitive. Wild type p53 LNCaP 
spheroids were not radiosensitised by the Chk1 inhibitor AZD7762 regardless of the mode 
of delivery of radiation treatment (γ-radiation or [131I]MIP1095) (Figure 73 and Figure 74). 
This result was consistent with the observation of an increased radiosensitising effect by 
AZD7762 in p53-mutated cancer cells compared with p53 wild type cells295. However, it 
could be argued that the failure of radiosensitisation by AZD7762 could be due to 
inadequate concentration. The evaluated concentrations of AZD762 depicted in Figure 73 
and Figure 74 ranged from 1 nM to 1 µM. However, supplementary experiments using 10 
µM AZD7762 in combination with 3 Gy γ-radiation did not result in the potentiation of the 
radiation-induced growth delay of LNCaP spheroids (data not shown). Furthermore, it has 
been demonstrated that 100 nM AZD7762 radiosensitised p53 wild type cells294,295. 
Therefore, the concentrations of AZD7762 in Figure 73 and Figure 74 (1 nM to 1 µM) are 
similar to those previously examined. Moreover, the Ki value of Chk1 inhibition by 
AZD7762 is 3.6 nM293, suggesting that the concentration of AZD7762 used in the spheroid 
studies was sufficient for Chk1 inhibition. 
 
The G2 arrest inhibitor, AZD7762, may still be a useful compound for the treatment of p53 
wild type cancers but only in combination with inhibitors of the G1 arrest. For instance, 
nutlin-3, an inhibitor of the MDM2/p53 interaction, demonstrated a strong radiosensitising 
effect in LNCaP spheroids (Figure 70). The determination of the radiopotentiating effect of 
the perturbation of the G1 arrest mediated by nutlin-3 in combination with the inhibition of 
the G2 arrest mediated by AZD7762 is worthy of further investigation. 
 
These data demonstrated that the disruption of the cell cycle is an efficient enhancing 
mechanism of the growth delay induced by [131I]MIP-1095. Indeed, targeting the G2 
checkpoint by DSF:Cu (Chapter 4 and 5), targeting the G1 checkpoint by nutlin-3 or 
inhibiting DNA replication by topotecan, all enhanced the effect of γ-radiation or that of 
[131I]MIP-1095. The proteasome is involved in the degradation of proteins, such as cyclins, 
involved in cell cycle regulation. Thus, inhibition of the proteasome may also 
radiosensitise through disruption of cell cycle progression. In conclusion, there is a good 
prospect for the use of [131I]MIP-1095 in combination with radiosensitising drugs for the 
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treatment of metastatic PCa. The demonstration of potentiation of the effect of [131I]MIP-
1095 was the objective of the screening program. Further studies are required to quantify 
the enhancing effect of nutlin-3, topotecan and olaparib using a wider range of 
concentrations. 
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9 Summary and future work 
The focus of this thesis was the elucidation of the mechanisms of DSF cytotoxicity and its 
radiomodifying properties. Furthermore, we have demonstrated, in spheroids, improved 
efficacy of radiopharmaceuticals by combination with cytotoxic drugs such as DSF but 
also nutlin-3, olaparib, topotecan and bortezomib, which potentially constitutes a treatment 
strategy in metastatic neuroblastoma and PCa. 
 
The first part of the experimental work of this thesis evaluated the dependence on Cu of 
DSF cytotoxicity. It was shown that the biphasic response profile of DSF resulted from 
two different mechanisms of action (Figure 8). Equimolar concentrations of DSF and Cu 
(DSF:Cu) induced a hyperbolic dose-response relationship according to the median effect 
principle (Figure 15), which allowed the application of isobologram and combination index 
methods of synergy analysis in the ensuing chapters. Moreover, it was shown that DSF:Cu-
induced cytotoxicity did not result from proteasome inhibition because it occurred at 
concentrations less than 1 µM, which are clinically applicable, whereas proteasome 
inhibition occurred at concentrations greater than 1 µM (Figure 17). 
 
Secondly, the conflicting reports on the radiomodifying properties of DSF were explained 
by the wide range of DSF concentrations examined (0.1 µM to 3 mM) and the lack of 
consideration of the presence of Cu in the culture medium. It was demonstrated that 
DSF:Cu, at concentrations less than 1 µM, sensitised SK-N-BE(2c) and UVW/NAT cells 
to γ-radiation treatment delivered by external beam in a synergistic manner (Table 7). The 
hypothesised radiosensitising mechanism was the inhibition, by DSF:Cu, of DNA repair. 
This was suggested by the observation that DSF:Cu abrogated the G2 arrest following γ-
radiation treatment, thus reducing time for DNA repair (chapter 5).  
Furthermore, CDK1 is the most downstream molecular effector of G2 arrest. CDK1 
activity depends on its phosphorylation status. CDK1 phosphorylated at tyrosine 15 
(pCDK115) is a marker of G2 arrest. If the radiosensitising action of DSF:Cu is the 
impediment of G2 arrest, then pCDK115 activity should be reduced following irradiation in 
the presence of DSF:Cu compared with radiation treatment alone. We are currently 
investigating how DSF:Cu modulates total levels of CDK1 and pCDK115 following 
radiation treatment in unsynchronised and synchronised cells. If the levels of pCDK115 
appear to be modulated by DSF:Cu, the intention is to investigate the levels of the kinase 
Wee1 and phosphatase Cdc25C which control the phosphorylation status of CDK1. 
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Moreover, the application of the linear-quadratic model to γ-radiation survival curves 
allowed the formulation of the hypothesis that DSF:Cu increases the proportion of SSB but 
not DSB. To further investigate this conjecture, the analysis of the type of DNA damage 
produced by radiation in the presence of DSF:Cu could be carried out by comet assay in 
alkaline versus neutral conditions. Alkaline pH denatures DNA. Thus, in alkaline 
conditions, DNA molecules containing SSB (alkali-labile sites) give rise to the presence of 
DNA fragments of reduced size. In contrast, the comet assay performed in non-denaturing 
conditions at neutral pH measures the amount of DSB only because DNA molecules 
containing SSB do not result in DNA fragments of reduced size326. The observation of a 
“comet tail” in alkaline comet assay, indicative of the presence of SSB, but not in neutral 
comet assay, indicative of the absence of DSB, following irradiation in the presence of 
DSF:Cu would validate the conjecture formulated following the linear-quadratic evaluation 
of radiosensitisation by DSF:Cu. 
 
The third part of this thesis was the investigation of the enhancement of the efficacy of two 
radiopharmaceuticals, [131I]mIBG and [131I]MIP-1095, with specificity for neuroblastoma 
and PCa, respectively. This study was carried out in multicellular tumour spheroids, in 
vitro models of avascular micrometastases, which are optimally suited for the investigation 
of the efficacy of radiopharmaceuticals. It was shown that DSF:Cu potentiated the spheroid 
growth delay induced by [131I]mIBG or [131I]MIP-1095 in a synergistic manner (chapter 7). 
Furthermore, olaparib, nutlin-3, topotecan and bortezomib also enhanced the spheroid 
growth delay induced by [131I]MIP-1095 (chapter 8). 
 
Internal morphological changes in LNCaP spheroids at an advanced stage of development 
were more resistant to DSF:Cu treatment than juvenile spheroids (Figure 54). An important 
follow-up project to this thesis is the evaluation of the efficacy of combination treatments 
consisting of DSF:Cu with [131I]mIBG or [131I]MIP-1095 in developmentally advanced 
spheroids which had undergone internal morphological changes. This work is important to 
understand the impact of hypoxia, pH and heterogeneous proliferation status on the 
interaction of DSF:Cu with radiation. The putative demonstration of such a combination 
treatment able to sterilise spheroids at a more advanced stage of development would 
suggest that this combination may also target more advanced malignant lesions. 
 
In conclusion, DSF is a promising drug for inclusion in combination with [131I]mIBG or 
[131I]MIP-1095 for the treatment of metastatic neuroblastoma or PCa, respectively. There 
is also a good prospect for the treatment of metastatic PCa with [131I]MIP-1095 in 
 225
combination with olaparib, nutlin-3, topotecan or bortezomib. It was recently reported by 
us that DSF enhanced efficacy of [131I]mIBG treatment in mice bearing SK-N-BE(2c) and 
UVW/NAT xenografts219. In vitro studies, using monolayers and spheroids, as well as 
animal models have suggested the benefit of DSF:Cu adjunct to radiotherapy. Furthermore, 
since DSF has only been used in the treatment of addictive behaviours in teenagers and 
adults, future studies should also include evaluation of the safety of DSF in children before 
inclusion of DSF in combination with [131I]mIBG for the treatment of metastatic 
neuroblastoma. 
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